{
  "doc_id": "a30aa822e0b614e1da22d902e152915c",
  "source_id": "konstantinides2019",
  "total_pages": 61,
  "pages": [
    "2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC) Authors/Task Force Members: Stavros V. Konstantinides* (Chairperson) (Germany/ Greece), Guy Meyer* (Co-Chairperson) (France), Cecilia Becattini (Italy), He ´ctor Bueno (Spain), Geert-Jan Geersing (Netherlands), Veli-Pekka Harjola (Finland), Menno V. Huisman (Netherlands), Marc Humbert 1 (France), Catriona Sian Jennings (United Kingdom), David Jime ´ nez (Spain), Nils Kucher (Switzerland), Irene Marthe Lang (Austria), Mareike Lankeit (Germany), Roberto Lorusso (Netherlands), Lucia Mazzolai (Switzerland), Nicolas Meneveau (France), Fionnuala N \u0013 ı \u0013 Ainle (Ireland), Paolo Prandoni (Italy), Piotr Pruszczyk (Poland), Marc Righini (Switzerland), Adam Torbicki (Poland), Eric Van Belle (France), Jose ´ Luis Zamorano (Spain) * Corresponding authors: Stavros V. Konstantinides, Center for Thrombosis and Hemostasis, Johannes Gutenberg University Mainz, Building 403, Langenbeckstr. 1, 55131 Mainz, Germany. Tel: þ 49 613 117 6255, Fax: þ 49 613 117 3456, Email: stavros.konstantinides@unimedizin-mainz.de; and Department of Cardiology, Democritus University of Thrace, 68100 Alexandroupolis, Greece. Email: skonst@med.duth.gr. Guy Meyer, Respiratory Medicine Department, Ho ˆ pital Europe ´en Georges Pompidou, 20 Rue Leblanc, 75015 Paris, France. Tel: þ 33 156 093 461, Fax: þ 33 156 093 255, Email: guy.meyer@aphp.fr; and Universite ´ Paris Descartes, 15 rue de l’e ´cole de me ´decine 75006 Paris, France. Author/Task Force Member Affiliations: listed in the Appendix. ESC Committee for Practice Guidelines (CPG) and National Cardiac Societies document reviewers : listed in the Appendix. 1 Representing the ERS. ESC entities having participated in the development of this document: Associations : Acute Cardiovascular Care Association (ACCA), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular Imaging (EACVI), European Association of Percutaneous Cardiovascular Interventions (EAPCI), Heart Failure Association (HFA). Councils : Council on Cardiovascular Primary Care. Working Groups : Aorta and Peripheral Vascular Diseases, Cardiovascular Surgery, Pulmonary Circulation and Right Ventricular Function, Thrombosis. The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oxfordjournals.org). Disclaimer . The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other official recom- mendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encour- aged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accu- rate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription. V C The European Society of Cardiology 2019. All rights reserved. For permissions please email: journals.permissions@oup.com. European Heart Journal (2019) 00 , 1 \u0002 61 ESC GUIDELINES doi:10.1093/eurheartj/ehz405 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Document Reviewers: Nazzareno Galie ´ (CPG Review Coordinator) (Italy), J. Simon R. Gibbs (CPG Review Coordinator) (United Kingdom), Victor Aboyans (France), Walter Ageno (Italy), Stefan Agewall (Norway), Ana G. Almeida (Portugal), Felicita Andreotti (Italy), Emanuele Barbato (Italy), Johann Bauersachs (Germany), Andreas Baumbach (United Kingdom), Farzin Beygui (France), Jørn Carlsen (Denmark), Marco De Carlo (Italy), Marion Delcroix 1 (Belgium), Victoria Delgado (Netherlands), Pilar Escribano Subias (Spain), Donna Fitzsimons (United Kingdom), Sean Gaine 1 (Ireland), Samuel Z. Goldhaber (United States of America), Deepa Gopalan (United Kingdom), Gilbert Habib (France), Sigrun Halvorsen (Norway), David Jenkins (United Kingdom), Hugo A. Katus (Germany), Barbro Kjellstro ¨ m (Sweden), Mitja Lainscak (Slovenia), Patrizio Lancellotti (Belgium), Geraldine Lee (United Kingdom), Gre ´ goire Le Gal (Canada), Emmanuel Messas (France), Joao Morais (Portugal), Steffen E. Petersen (United Kingdom), Anna Sonia Petronio (Italy), Massimo Francesco Piepoli (Italy), Susanna Price (United Kingdom), Marco Roffi (Switzerland), Aldo Salvi (Italy), Olivier Sanchez 1 (France), Evgeny Shlyakhto (Russian Federation), Iain A. Simpson (United Kingdom), Stefan Stortecky (Switzerland), Matthias Thielmann (Germany), Anton Vonk Noordegraaf 1 (Netherlands) The disclosure forms of all experts involved in the development of these Guidelines are available on the ESC website www.escardio.org/guidelines For the Supplementary Data which include background information and detailed discussion of the data that have provided the basis for the Guidelines see https://academic.oup.com/eurheartj/article-lookup/doi/ 10.1093/eurheartj/ehz405#supplementary-data ................................................................................................................................................................................................... Keywords Guidelines • pulmonary embolism • venous thrombosis • shock • dyspnoea • heart failure • right ven- tricle • diagnosis • risk assessment • echocardiography • biomarkers • treatment • anticoagulation • thrombolysis • pregnancy • venous thromboembolism • embolectomy Table of contents Abbreviations and acronyms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 1 Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 2.1 Why do we need new Guidelines on the diagnosis and management of pulmonary embolism? . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 2.2 What is new in the 2019 Guidelines? . . . . . . . . . . . . . . . . . . . . . . . . . . 7 2.2.1 New/revised concepts in 2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 2.2.2 Changes in recommendations 2014 \u0002 19 . . . . . . . . . . . . . . . . . . 7 2.2.3 Main new recommendations 2019 . . . . . . . . . . . . . . . . . . . . . . . . 8 3 General considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 3.1 Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 3.2 Predisposing factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 3.3 Pathophysiology and determinants of outcome . . . . . . . . . . . . . . . 10 4 Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 4.1 Clinical presentation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 4.2 Assessment of clinical (pre-test) probability . . . . . . . . . . . . . . . . . . . 12 4.3 Avoiding overuse of diagnostic tests for pulmonary embolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 4.4 D-dimer testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 4.4.1 Age-adjusted D-dimer cut-offs . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 4.4.2 D-dimer cut-offs adapted to clinical probability . . . . . . . . . . . 13 4.4.3 Point-of-care D-dimer assays . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 4.5 Computed tomographic pulmonary angiography . . . . . . . . . . . . . . 13 4.6 Lung scintigraphy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 4.7 Pulmonary angiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 4.8 Magnetic resonance angiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 4.9 Echocardiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 4.10 Compression ultrasonography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 4.12 Computed tomography venography . . . . . . . . . . . . . . . . . . . . . . . . 18 5 Assessment of pulmonary embolism severity and the risk of early death . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 5.1 Clinical parameters of pulmonary embolism severity . . . . . . . . . . 18 5.2 Imaging of right ventricular size and function . . . . . . . . . . . . . . . . . . 18 5.2.1 Echocardiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 5.2.2 Computed tomographic pulmonary angiography . . . . . . . . . 19 5.3 Laboratory biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 5.3.1 Markers of myocardial injury . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 5.3.2 Markers of right ventricular dysfunction . . . . . . . . . . . . . . . . . . 19 5.3.3 Other laboratory biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 5.4 Combined parameters and scores for assessment of pulmonary embolism severity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 5.5 Integration of aggravating conditions and comorbidity into risk assessment of acute pulmonary embolism . . . . . . . . . . . . . . . 20 5.6 Prognostic assessment strategy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 6 Treatment in the acute phase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 6.1 Haemodynamic and respiratory support . . . . . . . . . . . . . . . . . . . . . . 22 6.1.1 Oxygen therapy and ventilation . . . . . . . . . . . . . . . . . . . . . . . . . . 22 2 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6.1.2 Pharmacological treatment of acute right ventricular failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 6.1.3 Mechanical circulatory support and oxygenation . . . . . . . . . . 23 6.1.4 Advanced life support in cardiac arrest . . . . . . . . . . . . . . . . . . . 23 6.2 Initial anticoagulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 6.2.1 Parenteral anticoagulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 6.2.2 Non-vitamin K antagonist oral anticoagulants . . . . . . . . . . . . . 24 6.2.3 Vitamin K antagonists . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 6.3 Reperfusion treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 6.3.1 Systemic thrombolysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 6.3.2 Percutaneous catheter-directed treatment . . . . . . . . . . . . . . . 25 6.3.3 Surgical embolectomy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 6.4 Multidisciplinary pulmonary embolism teams . . . . . . . . . . . . . . . . . 26 6.5 Vena cava filters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 7 Integrated risk-adapted diagnosis and management . . . . . . . . . . . . . . . . 28 7.1 Diagnostic strategies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28 7.1.1 Suspected pulmonary embolism with haemodynamic instability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29 7.1.2 Suspected pulmonary embolism without haemodynamic instability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30 7.1.2.1 Strategy based on computed tomographic pulmonary angiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30 7.1.2.2 Strategy based on ventilation/perfusion scintigraphy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30 7.2 Treatment strategies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30 7.2.1 Emergency treatment of high-risk pulmonary embolism . . . 30 7.2.2 Treatment of intermediate-risk pulmonary embolism . . . . . 30 7.2.3 Management of low-risk pulmonary embolism: triage for early discharge and home treatment . . . . . . . . . . . . . . . . . . . . . . . 30 8 Chronic treatment and prevention of recurrence . . . . . . . . . . . . . . . . . 32 8.1 Assessment of venous thromboembolism recurrence risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 8.2 Anticoagulant-related bleeding risk . . . . . . . . . . . . . . . . . . . . . . . . . . . 34 8.3 Regimens and treatment durations with non-vitamin K antagonist oral anticoagulants, and with other non-vitamin K antagonist antithrombotic drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34 8.5 Management of pulmonary embolism in patients with cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36 9 Pulmonary embolism and pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 9.1 Epidemiology and risk factors for pulmonary embolism in pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 9.2 Diagnosis of pulmonary embolism in pregnancy . . . . . . . . . . . . . . . 37 9.2.1 Clinical prediction rules and D-dimers . . . . . . . . . . . . . . . . . . . . 37 9.2.2 Imaging tests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 9.3 Treatment of pulmonary embolism in pregnancy . . . . . . . . . . . . . . 39 9.3.1 Role of a multidisciplinary pregnancy heart team . . . . . . . . . . 40 9.4 Amniotic fluid embolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 10 Long-term sequelae of pulmonary embolism . . . . . . . . . . . . . . . . . . . . . 41 10.1 Persisting symptoms and functional limitation after pulmonary embolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41 10.2 Chronic thromboembolic pulmonary hypertension . . . . . . . . . . 41 10.2.1 Epidemiology, pathophysiology, and natural history . . . . . . 41 10.2.2 Clinical presentation and diagnosis . . . . . . . . . . . . . . . . . . . . . . 42 10.2.3 Surgical treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42 10.2.4 Balloon pulmonary angioplasty . . . . . . . . . . . . . . . . . . . . . . . . . 43 10.2.5 Pharmacological treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43 10.3 Strategies for patient follow-up after pulmonary embolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44 11 Non-thrombotic pulmonary embolism . . . . . . . . . . . . . . . . . . . . . . . . . . 45 12 Key messages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45 13 Gaps in the evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46 14 ‘What to do’ and ‘what not to do’ messages from the Guidelines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 15 Supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48 16 Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48 17 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49 Recommendations 4.11 Recommendations for diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 5.7 Recommendations for prognostic assessment . . . . . . . . . . . . . . . . . . . 22 6.6 Recommendations for acute-phase treatment of high-risk pulmonary embolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 6.7 Recommendations for acute-phase treatment of intermediate- or low-risk pulmonary embolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 6.8 Recommendations for multidisciplinary pulmonary embolism teams . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 6.9 Recommendations for inferior vena cava filters . . . . . . . . . . . . . . . . . . 27 6.10 Recommendations for early discharge and home treatment . . . . . 27 8.4 Recommendations for the regimen and the duration of anticoagulation after pulmonary embolism in patients without cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 8.6 Recommendations for the regimen and the duration of anticoagulation after pulmonary embolism in patients with active cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 9.5 Recommendations for pulmonary embolism in pregnancy . . . . . . . 40 10.4 Recommendations for follow-up after acute pulmonary embolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45 List of tables Table 1 Classes of recommendation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 Table 2 Levels of evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 Table 3 Predisposing factors for venous thromboembolism . . . . . . . . . 10 Table 4 Definition of haemodynamic instability, which delineates acute high-risk pulmonary embolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Table 5 The revised Geneva clinical prediction rule for pulmonary embolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Table 6 Imaging tests for diagnosis of pulmonary embolism . . . . . . . . . . 14 Table 7 Original and simplified Pulmonary Embolism Severity Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Table 8 Classification of pulmonary embolism severity and the risk of early (in-hospital or 30-day) death . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 ESC Guidelines 3 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Table 9 Treatment of right ventricular failure in acute high-risk pulmonary embolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 Table 10 Thrombolytic regimens, doses, and contra indications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Table 11 Categorization of risk factors for venous thromboembolism based on the risk of recurrence over the long-term . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 Table 12 Estimated radiation absorbed in procedures used for diagnosing pulmonary embolism (based on various references) . . . . . . 39 Table 13 Risk factors and predisposing conditions for Chronic throm- boembolic pulmonary hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42 List of figures Figure 1 Trends in annual incidence rates and case fatality rates of pulmonary embolism around the world, based on data retrieved from various references . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Figure 2 Key factors contributing to haemodynamic collapse and death in acute pulmonary embolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Figure 3 Graphic representation of transthoracic echocardiographic parameters in the assessment of right ventricular pressure overload . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Figure 4 Diagnostic algorithm for patients with suspected high-risk pulmonary embolism, presenting with haemodynamic instability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28 Figure 5 Diagnostic algorithm for patients with suspected pulmonary embolism without haemodynamic instability . . . . . . . . . . . . . 29 Figure 6 Risk-adjusted management strategy for acute pulmonary embolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31 Figure 7 Diagnostic workup for suspected pulmonary embolism during pregnancy and up to 6 weeks post-partum . . . . . . . . . 38 Figure 8 Follow-up strategy and diagnostic workup for long-term sequelae of pulmonary embolism . . . . . . . . . . . . . . . . . . . . . . . . 44 Abbreviations and acronyms AcT Right ventricular outflow Doppler acceleration time AFE Amniotic fluid embolism ALT Alanine aminotransferase AMPLIFY Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-line Therapy ASPIRE Aspirin to Prevent Recurrent Venous Thromboembolism trial AV Arteriovenous b.i.d Bis in die (twice a day) BNP B-type natriuretic peptide BP Blood pressure BPA Balloon pulmonary angioplasty b.p.m Beats per minute CI Confidence interval CO Cardiac output CPET Cardiopulmonary exercise testing CPG Committee for Practice Guidelines CrCl Creatinine clearance CRNM Clinically relevant non-major (bleeding) CT Computed tomogram/tomographic/tomography CTED Chronic thromboembolic disease CTEPH Chronic thromboembolic pulmonary hypertension CTPA Computed tomography pulmonary angiography/ angiogram CUS Compression ultrasonography CYP3A4 Cytochrome 3A4 DAMOVES D-dimer, Age, Mutation, Obesity, Varicose veins, Eight [coagulation factor VIII], Sex DASH D-dimer, Age, Sex, Hormonal therapy DVT Deep vein thrombosis ECMO Extracorporeal membrane oxygenation ELISA Enzyme-linked immunosorbent assay EMA European Medicines Agency ERS European Respiratory Society ESC European Society of Cardiology FAST H-FABP, Syncope, Tachycardia (prognostic score) FDA US Food and Drug Administration GUSTO Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries HAS-BLED Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol concomitantly HERDOO2 Hyperpigmentation, Edema, or Redness in either leg; D-dimer level > _250 l g/L; Obesity with body mass index > _30 kg/m 2 ; or Older age, > _65 years H-FABP Heart-type fatty acid-binding protein HIV Human immunodeficiency virus HR Hazard ratio INR International normalized ratio IU International units i.v Intravenous IVC Inferior vena cava LA Left atrium LMWH Low-molecular weight heparin(s) LV Left ventricle/ventricular MRA Magnetic resonance angiography NCT National clinical trial NOAC(s) Non-vitamin K antagonist oral anticoagulant(s) NT-proBNP N-terminal pro B-type natriuretic peptide NYHA New York Heart Association OBRI Outpatient Bleeding Risk Index o.d Omni die (once a day) OR Odds ratio PAH Pulmonary arterial hypertension PAP Pulmonary artery pressure PE Pulmonary embolism PEA Pulmonary endarterectomy PEITHO Pulmonary Embolism Thrombolysis trial PERC Pulmonary Embolism Rule-out Criteria PERT Pulmonary Embolism Response Team PESI Pulmonary Embolism Severity Index 4 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-gp P-glycoprotein PH Pulmonary hypertension PIOPED Prospective Investigation On Pulmonary Embolism Diagnosis PISAPED Prospective Investigative Study of Acute Pulmonary Embolism Diagnosis PREPIC Prevention of Recurrent Pulmonary Embolism by Vena Cava Interruption PVR Pulmonary vascular resistance RA Right atrium/atrial RCT Randomized controlled trial RIETE Registro Informatizado de la Enfermedad Thromboembolica venosa RR Relative risk rtPA Recombinant tissue-type plasminogen activator RV Right ventricle/ventricular SaO 2 Arterial oxygen saturation SPECT Single-photon emission computed tomography sPESI Simplified Pulmonary Embolism Severity Index SURVET Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis study TAPSE Tricuspid annular plane systolic excursion TOE Transoesophageal echocardiography/ echocardiogram TTE Transthoracic echocardiography/echocardiogram TV Tricuspid valve U Unit UFH Unfractionated heparin VKA(s) Vitamin K antagonist(s) V/Q Ventilation/perfusion (lung scintigraphy) VTE Venous thromboembolism VTE-BLEED ActiVe cancer, male with uncontrolled hyperTension at baseline, anaEmia, history of BLeeding, agE > _60 years, rEnal Dysfunction WARFASA Warfarin and Aspirin study 1 Preamble Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final deci- sions concerning an individual patient must be made by the responsi- ble health professional(s) in consultation with the patient and caregiver as appropriate. A great number of guidelines have been issued in recent years by the European Society of Cardiology (ESC), as well as by other soci- eties and organisations. Because of their impact on clinical practice, quality criteria for the development of guidelines have been estab- lished in order to make all decisions transparent to the user. The rec- ommendations for formulating and issuing ESC Guidelines can be found on the ESC website (http://www.escardio.org/Guidelines-&- Education/Clinical-Practice-Guidelines/Guidelines-development/Wri ting-ESC-Guidelines). The ESC Guidelines represent the official posi- tion of the ESC on a given topic and are regularly updated. The ESC carries out a number of registries which are essential to assess, diagnostic/therapeutic processes, use of resources and adher- ence to Guidelines. These registries aim at providing a better under- standing of medical practice in Europe and around the world, based on data collected during routine clinical practice. The guidelines are developed together with derivative educational material addressing the cultural and professional needs for cardiolo- gists and allied professionals. Collecting high-quality observational data, at appropriate time interval following the release of ESC Guidelines, will help evaluate the level of implementation of the Guidelines, checking in priority the key end points defined with the ESC Guidelines and Education Committees and Task Force members in charge. The Members of this Task Force were selected by the ESC, includ- ing representation from its relevant ESC sub-specialty groups, in order to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management of a given condition according to ESC Committee for Practice Guidelines (CPG) policy. A critical evaluation of diagnostic and thera- peutic procedures was performed, including assessment of the risk \u0002 benefit ratio. The level of evidence and the strength of the rec- ommendation of particular management options were weighed and graded according to predefined scales, as outlined in Tables 1 and 2 . The experts of the writing and reviewing panels provided declara- tion of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. These forms were compiled into one file and can be found on the ESC website (http:// www.escardio.org/guidelines). Any changes in declarations of interest that arise during the writing period were notified to the ESC and updated. The Task Force received its entire financial support from the ESC without any involvement from the healthcare industry. The ESC CPG supervises and coordinates the preparation of new Guidelines. The Committee is also responsible for the endorsement process of these Guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions the Guidelines are approved by all the experts involved in the Task Force. The finalized document is approved by the CPG for publica- tion in the European Heart Journal. The Guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating. The task of developing ESC Guidelines also includes the crea- tion of educational tools and implementation programmes for the recommendations including condensed pocket guideline versions, summary slides, booklets with essential messages, summary cards for non-specialists and an electronic version for digital applications (smartphones, etc.). These versions are abridged and thus, for more detailed information, the user should always access to the full text version of the Guidelines, which is freely available via the ESC website and hosted on the EHJ website. The National Societies of the ESC are encouraged to endorse, translate and implement all ESC Guidelines. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clini- cal recommendations. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the ESC Guidelines 5 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . determination and the implementation of preventive, diagnostic or ther- apeutic medical strategies. However, the ESC Guidelines do not over- ride in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in considera- tion of each patient’s health condition and in consultation with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regu- lations applicable in each country to drugs and devices at the time of prescription. 2 Introduction 2.1 Why do we need new Guidelines on the diagnosis and management of pulmonary embolism? This document follows the previous ESC Guidelines focusing on the clinical management of pulmonary embolism (PE), published in 2000, 2008, and 2014. Many recommendations have been retained or their validity has been reinforced; however, new data have extended or Table 2 Levels of evidence ©ESC 2019 Level of evidence A Data derived from multiple randomized clinical trials or meta-analyses. Level of evidence B Data derived from a single randomized clinical trial or large non-randomized studies. Level of evidence C Consensus of opinion of the experts and/or small studies, retrospective studies, registries. Table 1 Classes of recommendations © ESC 2019 Classes of recommendations Class I Evidence and/or general agreement that a given treatment or procedure is Is recommended or is indicated Wording to use Class III Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful. Is not recommended Class IIb established by evidence/opinion. May be considered Class IIa Weight of evidence/opinion is in Should be considered Class II 6 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    "modified our knowledge in respect of the optimal diagnosis, assess- ment, and treatment of patients with PE. These new aspects have been integrated into previous knowledge to suggest optimal and—whenever possible—objectively validated management strategies for patients with suspected or confirmed PE. To limit the length of the printed text, additional information, tables, figures, and references are available as supplementary data on the ESC website (www.escardio.org). These Guidelines focus on the diagnosis and management of acute PE in adult patients. For further details specifically related to the diag- nosis and management of deep vein thrombosis (DVT), the reader is referred to the joint consensus document of the ESC Working Groups of Aorta and Peripheral Vascular Diseases, and Pulmonary Circulation and Right Ventricular Function. 1 2.2 What is new in the 2019 Guidelines? 2.2.1 New/revised concepts in 2019 Diagnosis D-dimer cut-off values adjusted for age or clinical probability can be used as an alternative to the fixed cut-off value. Updated information is provided on the radiation dosage when using CTPA and a lung scan to diagnose PE ( Table 6 ). Risk assessment A clear definition of haemodynamic instability and high-risk PE is provided ( Table 4 ). Assessment of PE severity and early PE-related risk is recommended, in addition to comorbidity/aggravating conditions and overall death risk. A clear word of caution that RV dysfunction may be present, and affect early outcomes, in patients at ‘low risk’ based on clinical risk scores. Treatment in the acute phase Thoroughly revised section on haemodynamic and respiratory sup- port for high-risk PE (Section 6.1). A dedicated management algorithm is proposed for high-risk PE ( Supplementary Figure 1 ). NOACs are recommended as the first choice for anticoagulation treatment in a patient eligible for NOACs; VKAs are an alternative to NOACs. The risk-adjusted management algorithm ( Figure 6 ) was revised to take into consideration clinical PE severity, aggravating conditions/ comorbidity, and the presence of RV dysfunction. Chronic treatment after the first 3 months Risk factors for VTE recurrence have been classified according to high, intermediate, or low recurrence risk ( Table 11 ). Potential indications for extended anticoagulation are discussed, includ- ing the presence of a minor transient or reversible risk factor for the index PE, any persisting risk factor, or no identifiable risk factor. Terminology such as ‘provoked’ vs. ‘unprovoked’ PE/VTE is no lon- ger supported by the Guidelines, as it is potentially misleading and not helpful for decision-making regarding the duration of anticoagulation. Continued VTE recurrence scores are presented and discussed in parallel with bleeding scores for patients on anticoagulation treatment (Supplementary Tables 13 and 14 respectively). A reduced dose of apixaban or rivaroxaban for extended anticoagula- tion should be considered after the first 6 months of treatment. PE in cancer Edoxaban or rivaroxaban should be considered as an alternative to LMWH, with a word of caution for patients with gastrointestinal cancer due to the increased bleeding risk with NOACs. PE in pregnancy A dedicated diagnostic algorithm is proposed for suspected PE in pregnancy ( Figure 7 ). Updated information is provided on radiation absorption related to procedures used for diagnosing PE in pregnancy ( Table 12 ). Long-term sequelae An integrated model of patient care after PE is proposed to ensure optimal transition from hospital to community care. Recommendations on patient care have been extended to the entire spectrum of post-PE symptoms and functional limitation, not only CTEPH. A new comprehensive algorithm is proposed for patient follow-up after acute PE ( Figure 8 ). CTEPH = Chronic thromboembolic pulmonary hypertension; CTPA = computed tomography pulmonary angiography; LMWH = low-molecular weight heparin; NOAC(s) = non-vitamin K antagonist oral anticoagulant(s); PE = pulmonary embolism; RV = right ventricular; VKA(s) = vitamin K antagonist(s); VTE = venous thromboembolism. 2.2.2 Changes in recommendations 2014 \u0002 19 Recommendations 2014 2019 Rescue thrombolytic therapy is recommended for patients who deteriorate haemodynamically. IIa I Surgical embolectomy or catheter-directed treatment should be considered as alternatives to rescue thrombolytic therapy for patients who deteriorate haemodynamically. IIb IIa D-dimer measurement and clinical prediction rules should be considered to rule out PE during pregnancy or the post-partum period. IIb IIa Further evaluation may be considered for asymp- tomatic PE survivors at increased risk for CTEPH. III IIb CTEPH = Chronic thromboembolic pulmonary hypertension; PE = pulmonary embolism. Coloured columns indicate classes of recommendation (see Table 1 for colour coding). ESC Guidelines 7 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 General considerations 3.1 Epidemiology Venous thromboembolism (VTE), clinically presenting as DVT or PE, is globally the third most frequent acute cardiovascular syn- drome behind myocardial infarction and stroke. 2 In epidemiologi- cal studies, annual incidence rates for PE range from 39 \u0002 115 per 100 000 population; for DVT, incidence rates range from 53 \u0002 162 per 100 000 population. 3,4 Cross-sectional data show that the incidence of VTE is almost eight times higher in individuals aged > _80 years than in the fifth decade of life. 3 In parallel, longitudinal studies have revealed a rising tendency in annual PE incidence rates 4 \u0002 7 over time. Together with the substantial hospital- associated, preventable, and indirect annual expenditures for VTE (an estimated total of up to e 8.5 billion in the European Union), 8 these data demonstrate the importance of PE and DVT in ageing populations in Europe and other areas of the world. They further suggest that VTE will increasingly pose a burden on health systems worldwide in the years to come. PE may cause < _300 000 deaths per year in the US, ranking high among the causes of cardiovascular mortality. 3 In six European countries with a total population of 454.4 million, more than 370 000 deaths were related to VTE in 2004, as estimated on the basis of an epidemiological model. 9 Of these patients, 34% died sud- denly or within a few hours of the acute event, before therapy could be initiated or take effect. Of the other patients, death resulted from acute PE that was diagnosed after death in 59% and only 7% of patients who died early were correctly diagnosed with PE before death. 9 2.2.3 Main new recommendations 2019 Diagnosis A D-dimer test, using an age-adjusted cut-off or adapted to clinical probability, should be considered as an alternative to the fixed cut-off level. IIa If a positive proximal CUS is used to confirm PE, risk assessment should be considered to guide management. IIa V/Q SPECT may be considered for PE diagnosis. IIb Risk assessment Assessment of the RV by imaging or laboratory bio- markers should be considered, even in the presence of a low PESI or a sPESI of 0. IIa Validated scores combining clinical, imaging, and labo- ratory prognostic factors may be considered to fur- ther stratify PE severity. IIb Treatment in the acute phase When oral anticoagulation is initiated in a patient with PE who is eligible for a NOAC (apixaban, dabigatran, edoxaban, or rivaroxaban), a NOAC is the recom- mended form of anticoagulant treatment. I Set-up of multidisciplinary teams for management of high-risk and selected cases of intermediate-risk PE should be considered, depending on the resources and expertise available in each hospital. IIa ECMO may be considered, in combination with surgi- cal embolectomy or catheter-directed treatment, in refractory circulatory collapse or cardiac arrest. IIb Chronic treatment and prevention of recurrence Indefinite treatment with a VKA is recommended for patients with antiphospholipid antibody syndrome. I Extended anticoagulation should be considered for patients with no identifiable risk factor for the index PE event. IIa Extended anticoagulation should be considered for patients with a persistent risk factor other than anti- phospholipid antibody syndrome. IIa Extended anticoagulation should be considered for patients with a minor transient/reversible risk factor for the index PE event. IIa A reduced dose of apixaban or rivaroxaban should be considered after the first 6 months. IIa PE in cancer Edoxaban or rivaroxaban should be considered as an alternative to LMWH, with the exception of patients with gastrointestinal cancer. IIa PE in pregnancy Amniotic fluid embolism should be considered in a pregnant or post-partum woman, with unexplained haemodynamic instability or respiratory deteriora- tion, and disseminated intravascular coagulation. IIa Continued Thrombolysis or surgical embolectomy should be considered for pregnant women with high-risk PE. IIa NOACs are not recommended during pregnancy or lactation. III Post-PE care and long-term sequelae Routine clinical evaluation is recommended 3 \u0002 6 months after acute PE. I An integrated model of care is recommended after acute PE to ensure optimal transition from hospital to ambulatory care. I It is recommended that symptomatic patients with mismatched perfusion defects on a V/Q scan >3 months after acute PE are referred to a pulmonary hypertension/CTEPH expert centre, taking into account the results of echocardiography, natriu- retic peptide, and/or cardiopulmonary exercise testing. I CPET = cardiopulmonary exercise testing; CTEPH = Chronic thromboembolic pulmonary hypertension; CUS = compression ultrasonography; ECMO = extrac- orporeal membrane oxygenation; LMWH = low-molecular weight heparin; NOAC(s) = non-vitamin K antagonist oral anticoagulant(s); PE = pulmonary embolism; PESI = Pulmonary Embolism Severity Index; RV = right ventricular; SPECT = single-photon emission computed tomography; sPESI = simplified Pulmonary Embolism Severity Index; VKA(s) = vitamin K antagonist(s); V/Q = ventilation/perfusion (lung scintigraphy). Coloured columns indicate classes of recommendation (see Table 1 for colour coding). 8 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Time trend analyses in European, Asian, and North American populations suggest that case fatality rates of acute PE may be decreasing. 4 \u0002 7,10,11 Increased use of more effective therapies and interventions, and possibly better adherence to guidelines, 12,13 has most likely exerted a significant positive effect on the progno- sis of PE in recent years. However, there is also a tendency towards overdiagnosis of (subsegmental or even non-existent) PE in the modern era, 14 and this might in turn lead to a false drop in case fatality rates by inflating the denominator, i.e. the total num- ber of PE cases. Figure 1 summarizes the existing data on global trends in PE, high- lighting increasing incidence rates in parallel with decreasing case fatality rates over an \u0018 15 year period. In children, studies have reported an annual incidence of VTE of between 53 \u0002 57 per 100 000 among hospitalized patients, 19,20 and between 1.4 \u0002 4.9 per 100 000 in the community overall. 21,22 3.2 Predisposing factors There is an extensive collection of predisposing environmental and genetic factors for VTE; a list of predisposing (risk) factors is shown in Table 3 . VTE is considered to be a consequence of the interaction between patient-related—usually permanent—risk factors and set- ting-related—usually temporary—risk factors. Since categorization of temporary and permanent risk factors for VTE is important for assessing the risk of recurrence, and consequently for decision- making on chronic anticoagulation, it is discussed in more detail in sec- tion 8 of these Guidelines. Major trauma, surgery, lower-limb fractures and joint replace- ments, and spinal cord injury are strong provoking factors for VTE. 23,24 Cancer is a well-recognized predisposing factor for VTE. The risk of VTE varies with different types of cancer; 25,26 pancre- atic cancer, haematological malignancies, lung cancer, gastric can- cer, and brain cancer carry the highest risk. 27,28 Moreover, cancer is a strong risk factor for all-cause mortality following an episode of VTE. 29 Oestrogen-containing oral contraceptive agents are associated with an elevated VTE risk, and contraceptive use is the most frequent VTE risk factor in women of reproductive age. 30 \u0002 32 More specifically, combined oral contraceptives (containing both an oestrogen and a progestogen) are associated with an approximately two- to six-fold increase in VTE risk over baseline. 32,33 In general, the absolute VTE risk remains low in the majority of the >100 million combined oral contraceptive users worldwide; 34 however, VTE risk factors, includ- ing severe inherited thrombophilia (discussed in section 8 ), 35 increase this risk. Third-generation combined oral contraceptives, containing progestogens such as desogestrel or gestodene, are associated with a higher VTE risk than the second-generation combined oral contra- ceptives, which contain progestogens such as levonorgestrel or nor- gestrel. 36,37 On the other hand, hormone-releasing intrauterine devices and some progesterone-only pills (used at contraceptive doses) are not associated with a significant increase in VTE risk; 33,38 consequently, and following counselling and full risk assessment, these options are often proposed to women with a personal or strong family history of VTE. In post-menopausal women who receive hormone replacement therapy, the risk of VTE varies widely depending on the formulation used. 39 Infection is a common trigger for VTE. 23,40,41 Blood transfusion and erythropoiesis-stimulating agents are also associated with an increased risk of VTE. 23,42 In children, PE is usually associated with DVT and is rarely unpro- voked. Serious chronic medical conditions and central venous lines are considered likely triggers of PE. 43 VTE may be viewed as part of the cardiovascular disease con- tinuum, and common risk factors—such as cigarette smoking, obesity, hypercholesterolaemia, hypertension, and diabetes © ESC 2019 0 20 40 60 80 100 120 1997 1999 2001 2003 2005 2007 2009 2011 2013 0 16 18 20 22 24 26 04 02 06 08 10 12 14 1997 1999 2001 2003 2005 2007 2009 2011 2013 China a, 17 Italy a, 6 Spain a, 5 US b, 14 US a, 16 US a,11 US a, 14 US b,14 US a, 14 Australia a, 15 Italy a, 6 Spain a, 5 Year Year US b, 16 Annual Incidence Rate (number of PE diagnoses / 100.000 inhabitants) Case Finality Rate (number of in-hospital deaths / 100 PE diagnoses; %) Figure 1 Trends in annual incidence rates (left panel) and case fatality rates (right panel) of pulmonary embolism around the world, based on data retrieved from various references. 5,6,11,14 \u0002 17 Reproduced with permission from JACC 2016;67:976-90. PE = pulmonary embolism; US = United States. a PE listed as principal diagnosis. b Any listed code for PE was considered. ESC Guidelines 9 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . mellitus 44 \u0002 47 —are shared with arterial disease, notably athe- rosclerosis. 48 \u0002 51 However, this may be an indirect association mediated, at least in part, by the complications of coronary artery disease and, in the case of smoking, cancer. 52,53 Myocardial infarction and heart failure increase the risk of PE. 54,55 Conversely, patients with VTE have an increased risk of subsequent myocardial infarction and stroke, or peripheral arte- rial embolization. 56 3.3 Pathophysiology and determinants of outcome Acute PE interferes with both circulation and gas exchange. Right ventricular (RV) failure due to acute pressure overload is consid- ered the primary cause of death in severe PE. Pulmonary artery pressure (PAP) increases if >30 \u0002 50% of the total cross-sectional area of the pulmonary arterial bed is occluded by thromboem- boli. 57 PE-induced vasoconstriction, mediated by the release of thromboxane A2 and serotonin, contributes to the initial increase in pulmonary vascular resistance (PVR) after PE. 58 Anatomical obstruction and hypoxic vasoconstriction in the affected lung area lead to an increase in PVR, and a proportional decrease in arterial compliance. 59 The abrupt increase in PVR results in RV dilation, which alters the contractile properties of the RV myocardium via the Frank \u0002 Starling mechanism. The increase in RV pressure and volume leads to an increase in wall tension and myocyte stretch. The contraction time of the RV is prolonged, while neurohumoral activation leads to ino- tropic and chronotropic stimulation. Together with systemic vaso- constriction, these compensatory mechanisms increase PAP, improving flow through the obstructed pulmonary vascular bed and thus temporarily stabilizing systemic blood pressure (BP). However, the extent of immediate adaptation is limited, as a non- preconditioned, thin-walled RV is unable to generate a mean PAP >40 mmHg. Prolongation of RV contraction time into early diastole in the left ventricle (LV) leads to leftward bowing of the interventricular sep- tum. 60 The desynchronization of the ventricles may be exacerbated by the development of right bundle branch block. As a result, LV fill- ing is impeded in early diastole, and this may lead to a reduction in the cardiac output (CO), and contribute to systemic hypotension and haemodynamic instability. 61 As described above, excessive neurohumoral activation in PE can be the result of both abnormal RV wall tension and circulatory shock. The finding of massive infiltrates of inflammatory cells in the RV myo- cardia of patients who died within 48 h of acute PE may be explained by high levels of epinephrine released as a result of the PE-induced ‘myocarditis’. 62 This inflammatory response might explain the secon- dary haemodynamic destabilization that sometimes occurs 24 \u0002 48 h after acute PE, although early recurrence of PE may be an alternative explanation in some of these cases. Finally, the association between elevated circulating levels of bio- markers of myocardial injury and an adverse early outcome indicates that RV ischaemia is of pathophysiological significance in the acute phase of PE. 63,64 Although RV infarction is uncommon after PE, it is likely that the imbalance between oxygen supply and demand can result in damage to cardiomyocytes, and further reduce contractile forces. Systemic hypotension is a critical element in this process, lead- ing to impairment of the coronary driving pressure to the overloaded RV. The detrimental effects of acute PE on the RV myocardium and the circulation are summarized in Figure 2 . Respiratory failure in PE is predominantly a consequence of haemodynamic disturbances. 66 Low CO results in desaturation of the mixed venous blood. Zones of reduced flow in obstructed Table 3 Predisposing factors for venous thromboembo- lism (data modified from Rogers et al. 23 and Anderson and Spencer 24 ) Strong risk factors (OR > 10) Fracture of lower limb Hospitalization for heart failure or atrial fibrillation/flutter (within previous 3 months) Hip or knee replacement Major trauma Myocardial infarction (within previous 3 months) Previous VTE Spinal cord injury Moderate risk factors (OR 2 \u0002 9) Arthroscopic knee surgery Autoimmune diseases Blood transfusion Central venous lines Intravenous catheters and leads Chemotherapy Congestive heart failure or respiratory failure Erythropoiesis-stimulating agents Hormone replacement therapy (depends on formulation) In vitro fertilization Oral contraceptive therapy Post-partum period Infection (specifically pneumonia, urinary tract infection, and HIV) Inflammatory bowel disease Cancer (highest risk in metastatic disease) Paralytic stroke Superficial vein thrombosis Thrombophilia Weak risk factors (OR < 2) Bed rest >3 days Diabetes mellitus Arterial hypertension Immobility due to sitting (e.g. prolonged car or air travel) Increasing age Laparoscopic surgery (e.g. cholecystectomy) Obesity Pregnancy Varicose veins HIV = human immunodeficiency virus; OR = odds ratio; VTE = venous thromboembolism. 10 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . pulmonary arteries, combined with zones of overflow in the capil- lary bed served by non-obstructed pulmonary vessels, result in ventilation/perfusion mismatch, which contributes to hypoxaemia. In about one-third of patients, right-to-left shunting through a pat- ent foramen ovale can be detected by echocardiography; this is caused by an inverted pressure gradient between the right atrium (RA) and left atrium, and may lead to severe hypoxaemia, and an increased risk of paradoxical embolization and stroke. 67 Finally, even if they do not affect haemodynamics, small distal emboli may create areas of alveolar haemorrhage resulting in haemoptysis, pleuritis, and pleural effusion, which is usually mild. This clinical presentation is known as ‘pulmonary infarction’. Its effect on gas exchange is normally mild, except in patients with pre-existing cardiorespiratory disease. In view of the above pathophysiological considerations, acute RV failure, defined as a rapidly progressive syndrome with systemic con- gestion resulting from impaired RV filling and/or reduced RV flow out- put, 68 is a critical determinant of clinical severity and outcome in acute PE. Accordingly, clinical symptoms, and signs of overt RV failure and haemodynamic instability, indicate a high risk of early (in-hospital or 30 day) mortality. High-risk PE is defined by haemodynamic instability and encompasses the forms of clinical presentation shown in Table 4 . © ESC 2019 Increased RV afterload RV O 2 delivery Coronary perfusion of RV Systemic BP CO LV preload RV output RV contractility RV ischaemia, hypoxic injury Intrapulmonary A-V shunting RV O 2 demand Myocardial inflammation Neurohormonal activation RV wall tension TV insufficiency RV dilatation Obstructive shock Death a Figure 2 Key factors contributing to haemodynamic collapse and death in acute pulmonary embolism (modified from Konstantinides et al. 65 with permis- sion). A-V = arterio-venous; BP = blood pressure; CO = cardiac output; LV - left ventricular; O2 = oxygen; RV = right ventricular; TV = tricuspid valve. a The exact sequence of events following the increase in RV afterload is not fully understood. Table 4 Definition of haemodynamic instability, which delineates acute high-risk pulmonary embolism (one of the following clinical manifestations at presentation) (1) Cardiac arrest (2) Obstructive shock 68 \u0002 70 (3) Persistent hypotension Need for cardiopulmonary resuscitation Systolic BP < 90 mmHg or vasopressors required to achieve a BP > _90 mmHg despite adequate filling status Systolic BP < 90 mmHg or systolic BP drop > _40 mmHg, lasting longer than 15 min and not caused by new-onset arrhythmia, hypovolaemia, or sepsis And End-organ hypoperfusion (altered mental status; cold, clammy skin; oliguria/anuria; increased serum lactate) BP = blood pressure. ESC Guidelines 11 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . As an immediately life-threatening situation, high-risk PE requires an emergency diagnostic (upon suspicion) and therapeutic (upon confirmation or if the level of suspicion is sufficiently high) strategy, as outlined in section 7 . However, the absence of haemodynamic insta- bility does not exclude beginning (and possibly progressing) RV dys- function, and thus an elevated PE-related early risk. In this large population, further assessment (outlined in sections 5 and 7 ) is neces- sary to determine the level of risk and adjust management decisions accordingly. 4 Diagnosis The increased awareness of venous thromboembolic disease and the ever-increasing availability of non-invasive imaging tests, mainly com- puted tomography (CT) pulmonary angiography (CTPA), have gen- erated a tendency for clinicians to suspect and initiate a diagnostic workup for PE more frequently than in the past. This changing atti- tude is illustrated by the rates of PE confirmation among patients undergoing diagnostic workup: these were as low as 5% in recent North American diagnostic studies, in sharp contrast to the approxi- mately 50% prevalence reported back in the early 1980s. 71 Therefore, it is critical that, when evaluating non-invasive diagnostic strategies for PE in the modern era, it is ensured that they are capable of safely excluding PE in contemporary patient populations with a rather low pre-test probability of the disease. 72 Conversely, a posi- tive test should have an adequate specificity to set the indication for anticoagulant treatment. 4.1 Clinical presentation The clinical signs and symptoms of acute PE are non-specific. In most cases, PE is suspected in a patient with dyspnoea, chest pain, pre- syncope or syncope, or haemoptysis. 73 \u0002 75 Haemodynamic instability is a rare but important form of clinical presentation, as it indicates central or extensive PE with severely reduced haemodynamic reserve. Syncope may occur, and is associated with a higher preva- lence of haemodynamic instability and RV dysfunction. 76 Conversely, and according to the results of a recent study, acute PE may be a fre- quent finding in patients presenting with syncope (17%), even in the presence of an alternative explanation. 77 In some cases, PE may be asymptomatic or discovered incidentally during diagnostic workup for another disease. Dyspnoea may be acute and severe in central PE; in small periph- eral PE, it is often mild and may be transient. In patients with pre- existing heart failure or pulmonary disease, worsening dyspnoea may be the only symptom indicative of PE. Chest pain is a frequent symp- tom of PE and is usually caused by pleural irritation due to distal emboli causing pulmonary infarction. 78 In central PE, chest pain may have a typical angina character, possibly reflecting RV ischaemia, and requiring differential diagnosis from an acute coronary syndrome or aortic dissection. In addition to symptoms, knowledge of the predisposing factors for VTE is important in determining the clinical probability of the disease, which increases with the number of predisposing factors present; however, in 40% of patients with PE, no predisposing fac- tors are found. 79 Hypoxaemia is frequent, but < _40% of patients have normal arterial oxygen saturation (SaO 2 ) and 20% have a normal alveolar \u0002 arterial oxygen gradient. 80,81 Hypocapnia is also often present. A chest X-ray is frequently abnormal and, although its findings are usually non-specific in PE, it may be useful for excluding other causes of dyspnoea or chest pain. 82 Electrocardiographic changes indicative of RV strain—such as inversion of T waves in leads V1 \u0002 V4, a QR pattern in V1, a S1Q3T3 pattern, and incomplete or complete right bundle branch block—are usually found in more severe cases of PE; 83 in milder cases, the only abnormality may be sinus tachycardia, present in 40% of patients. Finally, atrial arrhythmias, most frequently atrial fibrillation, may be associated with acute PE. 4.2 Assessment of clinical (pre-test) probability The combination of symptoms and clinical findings with the presence of predisposing factors for VTE allows the classification of patients with suspected PE into distinct categories of clinical or pre-test proba- bility, which correspond to an increasing actual prevalence of con- firmed PE. This pre-test assessment can be done either by implicit (empirical) clinical judgement or by using prediction rules. As the post-test (i.e. after an imaging test) probability of PE depends not only on the characteristics of the diagnostic test itself but also on the pre- test probability, this is a key step in all diagnostic algorithms for PE. The value of empirical clinical judgement has been confirmed in several large series. 84,85 Clinical judgement usually includes ................................................ Table 5 The revised Geneva clinical prediction rule for pulmonary embolism Items Clinical decision rule points Original version 91 Simplified version 87 Previous PE or DVT 3 1 Heart rate 75 \u0002 94 b.p.m. 3 1 > _95 b.p.m. 5 2 Surgery or fracture within the past month 2 1 Haemoptysis 2 1 Active cancer 2 1 Unilateral lower-limb pain 3 1 Pain on lower-limb deep venous palpation and unilateral oedema 4 1 Age >65 years 1 1 Clinical probability Three-level score Low 0 \u0002 3 0 \u0002 1 Intermediate 4 \u0002 10 2 \u0002 4 High > _11 > _5 Two-level score PE-unlikely 0 \u0002 5 0 \u0002 2 PE-likely > _6 > _3 b.p.m. = beats per minute; DVT = deep vein thrombosis; PE = pulmonary embolism. 12 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . commonplace tests such as chest X-rays and electrocardiograms for differential diagnosis. However, as clinical judgement lacks standard- ization, several explicit clinical prediction rules have been developed. Of these, the most frequently used prediction rules are the revised Geneva rule ( Table 5 ) and the Wells rule (see Supplementary Data Table 1 ). 86 Both prediction rules have been simplified in an attempt to increase their adoption into clinical practice; 87,88 the simplified ver- sions have been externally validated. 89,90 Regardless of the score used, the proportion of patients with con- firmed PE can be expected to be \u0018 10% in the low-probability category, 30% in the moderate-probability category, and 65% in the high- probability category. 92 When the two-level classification is used, the proportion of patients with confirmed PE is \u0018 12% in the PE-unlikely cat- egory and 30% in the PE-likely category. 92 A direct prospective compar- ison of these rules confirmed a similar diagnostic performance. 89 4.3 Avoiding overuse of diagnostic tests for pulmonary embolism Searching for PE in every patient with dyspnoea or chest pain may lead to high costs and complications of unnecessary tests. The Pulmonary Embolism Rule-out Criteria (PERC) were developed for emergency department patients with the purpose of selecting, on clinical grounds, patients whose likelihood of having PE is so low that diagnostic workup should not even be initiated. 93 They comprise eight clinical variables significantly associated with an absence of PE: age < 50 years; pulse < 100 beats per minute; SaO 2 >94%; no unilat- eral leg swelling; no haemoptysis; no recent trauma or surgery; no history of VTE; and no oral hormone use. The results of a prospec- tive validation study, 94 and those of a randomized non-inferiority management study, 95 suggested safe exclusion of PE in patients with low clinical probability who, in addition, met all criteria of the PERC rule. However, the low overall prevalence of PE in these studies 94,95 does not support the generalizability of the results. 4.4 D-dimer testing D-dimer levels are elevated in plasma in the presence of acute throm- bosis because of simultaneous activation of coagulation and fibrinoly- sis. The negative predictive value of D-dimer testing is high, and a normal D-dimer level renders acute PE or DVT unlikely. On the other hand, the positive predictive value of elevated D-dimer levels is low and D-dimer testing is not useful for confirmation of PE. D-dimer is also more frequently elevated in patients with cancer, 96,97 in hospi- talized patients, 89,98 in severe infection or inflammatory disease, and during pregnancy. 99,100 Accordingly, the number of patients in whom D-dimer must be measured to exclude one PE (number needed to test) rises from 3 in the general population of an emergency depart- ment to > _10 in the specific situations listed above. As a number of D-dimer assays are available, clinicians should become aware of the diagnostic performance of the test used in their own hospital. The quantitative enzyme-linked immunosorbent assay (ELISA) or ELISA-derived assays have a diagnostic sensitivity of > _95%, and can be used to exclude PE in patients with either low or intermedi- ate pre-test probability. In the emergency department, a negative ELISA D-dimer can, in combination with clinical probability, exclude the dis- ease without further testing in \u0018 30% of patients with suspected PE. 101 \u0002 103 Outcome studies have shown that the 3 month thrombo- embolic risk was <1% in patients with low or intermediate clinical prob- ability who were left untreated on the basis of a negative test result. 104 4.4.1 Age-adjusted D-dimer cut-offs The specificity of D-dimer in suspected PE decreases steadily with age to \u0018 10% in patients >80 years of age. 105 The use of age-adjusted cut- offs may improve the performance of D-dimer testing in the elderly. A multinational prospective management study evaluated a previously validated age-adjusted cut-off (age \u0004 10 m g/L, for patients aged >50 years) in a cohort of 3346 patients. 106 Patients with a normal age- adjusted D-dimer value did not undergo CTPA; they were left untreated and followed for a 3 month period. Among the 766 patients who were > _75 years of age, 673 had a non-high clinical probability. Use of the age-adjusted (instead of the ‘standard’ 500 m g/L) D-dimer cut-off increased the number of patients in whom PE could be excluded from 6.4 to 30%, without additional false-negative findings. 106 4.4.2 D-dimer cut-offs adapted to clinical probability A prospective management trial used the ‘YEARS’ clinical decision rule, which consists of three clinical items of the Wells score (see Supplementary Data Table 1 )—namely signs of DVT, haemoptysis, and PE more likely than an alternative diagnosis—plus D-dimer con- centrations. 107 PE was considered to be excluded in patients without clinical items and D-dimer levels <1000 ng/mL, or in patients with one or more clinical items and D-dimer levels <500 ng/mL. All other patients underwent CTPA. Of the 2946 patients (85%) in whom PE was ruled out at baseline and who were left untreated, 18 [0.61%, 95% confidence interval (CI) 0.36 \u0002 0.96%] were diagnosed with symptomatic VTE during the 3 month follow-up. CTPA was avoided in 48% of the included patients using this algorithm, compared to 34% if the Wells rule and a fixed D-dimer threshold of 500 ng/mL would have been applied. 107 4.4.3 Point-of-care D-dimer assays In certain situations, notably in community or primary care medicine, ‘on-the-spot’ D-dimer testing may have advantages over referring a patient to a central laboratory for D-dimer testing. This may particu- larly apply to remote areas where access to healthcare is lim- ited. 108,109 However, point-of-care assays have a lower sensitivity and negative predictive value compared with laboratory-based D-dimer tests. In a systematic review and meta-analysis, sensitivity of point-of- care D-dimer assays was 88% (95% CI 83 \u0002 92%) whereas conven- tional laboratory-based D-dimer testing had a sensitivity of at least 95%. 110 As a result, point-of-care D-dimer assays should only be used in patients with a low pre-test probability. In these situations, PE could be ruled out in 46% of patients with suspected PE without pro- ceeding to imaging tests (with a failure rate of 1.5%), as suggested by a prospective study in Dutch primary care. 111 4.5 Computed tomographic pulmonary angiography Multidetector CTPA is the method of choice for imaging the pulmo- nary vasculature in patients with suspected PE. It allows adequate visu- alization of the pulmonary arteries down to the subsegmental level. 112 \u0002 114 The Prospective Investigation On Pulmonary Embolism Diagnosis (PIOPED) II study observed a sensitivity of 83% and a ESC Guidelines 13 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . specificity of 96% for (mainly four-detector) CTPA in PE diagnosis. 115 PIOPED II also highlighted the influence of pre-test clinical probability on the predictive value of multidetector CTPA. In patients with a low or intermediate clinical probability of PE, a negative CTPA had a high negative predictive value for PE (96 and 89%, respectively), but its neg- ative predictive value was only 60% if the pre-test probability was high. Conversely, the positive predictive value of a positive CTPA was high (92 \u0002 96%) in patients with an intermediate or high clinical probability, but much lower (58%) in patients with a low pre-test likelihood of PE. 115 Therefore, clinicians should consider further testing in case of discordance between clinical judgement and the CTPA result. Several studies have provided evidence in favour of CTPA as a stand-alone imaging test for excluding PE. Taken together, the avail- able data suggest that a negative CTPA result is an adequate criterion for the exclusion of PE in patients with low or intermediate clinical probability of PE. On the other hand, it remains controversial whether patients with a negative CTPA and a high clinical probability should be further investigated. Chronic thromboembolic pulmonary hypertension (CTEPH) is a potentially fatal late sequela of PE, but pre-existing CTEPH should not be missed in patients investigated for suspected acute PE. Signs of pre- existing CTEPH on CTPA are listed in Supplementary Data Table 2 ; the diagnosis and management of CTEPH is discussed in section 10 . The major strengths, weaknesses/limitations, and radiation issues related to the use of CTPA in the diagnosis of PE are summarized in Table 6 . 4.6 Lung scintigraphy The planar ventilation/perfusion [V/Q (lung scintigraphy)] scan is an established diagnostic test for suspected PE. Perfusion scans are com- bined with ventilation studies, for which multiple tracers such as xenon-133 gas, krypton-81 gas, technetium-99m-labelled aerosols, or technetium-99m-labelled carbon microparticles (Technegas) can be used. The purpose of the ventilation scan is to increase specificity: in acute PE, ventilation is expected to be normal in hypoperfused seg- ments (mismatched). Being a lower-radiation and contrast medium- sparing procedure, the V/Q scan may preferentially be applied in out- patients with a low clinical probability and a normal chest X-ray, in young (particularly female) patients, in pregnant women, in patients Table 6 Imaging tests for diagnosis of pulmonary embolism Strengths Weaknesses/limitations Radiation issues a CTPA • Readily available around the clock in most centres • Excellent accuracy • Strong validation in prospective manage- ment outcome studies • Low rate of inconclusive results (3 \u0002 5%) • May provide alternative diagnosis if PE excluded • Short acquisition time • Radiation exposure • Exposure to iodine contrast: \u0002 limited use in iodine allergy and hyperthyroidism \u0002 risks in pregnant and breastfeeding women \u0002 contraindicated in severe renal failure • Tendency to overuse because of easy accessibility • Clinical relevance of CTPA diagnosis of subsegmental PE unknown • Radiation effective dose 3 \u0002 10 mSv b • Significant radiation exposure to young female breast tissue Planar V/Q scan • Almost no contraindications • Relatively inexpensive • Strong validation in prospective manage- ment outcome studies • Not readily available in all centres • Interobserver variability in interpretation • Results reported as likelihood ratios • Inconclusive in 50% of cases • Cannot provide alternative diagnosis if PE excluded • Lower radiation than CTPA, effective dose \u0018 2 mSv b V/Q SPECT • Almost no contraindications • Lowest rate of non-diagnostic tests (<3%) • High accuracy according to available data • Binary interpretation (‘PE’ vs. ‘no PE’) • Variability of techniques • Variability of diagnostic criteria • Cannot provide alternative diagnosis if PE excluded • No validation in prospective management outcome studies • Lower radiation than CTPA, effective dose \u0018 2 mSv b Pulmonary angiography • Historical gold standard • Invasive procedure • Not readily available in all centres • Highest radiation, effective dose 10 \u0002 20 mSv b CTPA = computed tomographic pulmonary angiography; mGy = milligray; mSv = millisieverts; PE = pulmonary embolism; SPECT = single-photon emission computed tomogra- phy; V/Q = ventilation/perfusion (lung scintigraphy). a In this section, effective radiation dose is expressed in mSv [dose in mSv = absorbed dose in mGy \u0004 radiation weighting factor (1.0 for X-rays) \u0004 tissue weighting factor]. This reflects the effective doses of all organs that have been exposed, that is, the overall radiation dose to the body from the imaging test. Compare with Table 12 , in which the absorbed radiation dose is expressed in mGy to reflect the radiation exposure to single organs or to the foetus. b For comparison, the whole-body effective dose of a chest X-ray examination is 0.1 mSv. 141 14 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . with history of contrast medium-induced anaphylaxis, and patients with severe renal failure. 116 Planar lung scan results are frequently classified according to the criteria established in the PIOPED study. 117 These criteria were the subject of debate and have been revised. 118,119 To facilitate communi- cation with clinicians, a three-tier classification is preferable: normal scan (excluding PE), high-probability scan (considered diagnostic of PE in most patients), and non-diagnostic scan. 120 \u0002 122 Prospective clinical outcome studies suggested that it is safe to withhold anticoa- gulant therapy in patients with a normal perfusion scan. This was con- firmed by a randomized trial comparing the V/Q scan with CTPA. 122 An analysis from the PIOPED II study suggested that a high- probability V/Q scan could confirm PE, although other sources sug- gest that the positive predictive value of a high-probability lung scan is not sufficient to confirm PE in patients with a low clinical probability. 123,124 Performing only a perfusion scan might be acceptable in patients with a normal chest X-ray; any perfusion defect in this situation would be considered a mismatch. The high frequency of non- diagnostic scans is a limitation because they indicate the necessity for further diagnostic testing. Various strategies to overcome this prob- lem have been proposed, notably the incorporation of clinical proba- bility. Although the use of perfusion scanning and chest X-ray with the Prospective Investigative Study of Acute Pulmonary Embolism Diagnosis (PISAPED) criteria may be associated with a low rate of inconclusive results, the sensitivity appears too low to exclude PE and thus this approach may be less safe than CTPA. 123,125 Several studies suggest that data acquisition in single-photon emis- sion CT (SPECT) imaging, with or without low-dose CT, may decrease the proportion of non-diagnostic scans to as low as 0 \u0002 5%. 121,126 \u0002 128 However, most studies reporting on the accuracy of SPECT are limited by their retrospective design 129,130 or the inclu- sion of SPECT itself in the reference standard, 127 and only one study used a validated diagnostic algorithm. 131 The diagnostic criteria for SPECT also varied; most studies defined PE as one or two subseg- mental perfusion defects without ventilation defects, but these crite- ria are infrequently used in clinical practice. In addition, the optimal scanning technique (perfusion SPECT, V/Q SPECT, perfusion SPECT with non-enhanced CT, or V/Q SPECT with non-enhanced CT) remains to be defined. Finally, few outcome studies are available, and with incomplete follow-up. 132 Large-scale prospective studies are needed to validate SPECT techniques. The major strengths, weaknesses/limitations, and radiation issues related to the use of V/Q scan and V/Q SPECT in the diagnosis of PE are summarized in Table 6 . 4.7 Pulmonary angiography For several decades, pulmonary angiography was the ‘gold standard’ for the diagnosis or exclusion of acute PE, but it is now rarely per- formed as less-invasive CTPA offers similar diagnostic accuracy. 133 The diagnosis of acute PE is based on direct evidence of a thrombus in two projections, either as a filling defect or as amputation of a pulmo- nary arterial branch. 134 Thrombi as small as 1 \u0002 2 mm within the sub- segmental arteries can be visualized by digital subtraction angiography, but there is substantial interobserver variability at this level. 135,136 Pulmonary angiography is not free of risk. In a study of 1111 patients, procedure-related mortality was 0.5%, major non-fatal complications occurred in 1%, and minor complications in 5%. 137 The majority of deaths occurred in patients with haemodynamic compromise or respiratory failure. The amount of contrast agent should be reduced and non-selective injections avoided in patients with haemodynamic compromise. 138 The major strengths, weaknesses/limitations, and radiation issues related to the use of pulmonary angiography in the diagnosis of PE are summarized in Table 6 . 4.8 Magnetic resonance angiography Magnetic resonance angiography (MRA) has been evaluated for sev- eral years regarding suspected PE. However, the results of large-scale studies 139,140 show that this technique, although promising, is not yet ready for clinical practice due to its low sensitivity, the high propor- tion of inconclusive MRA scans, and its low availability in most emer- gency settings. The hypothesis that a negative MRA, combined with the absence of proximal DVT on compression ultrasonography (CUS), may safely rule out clinically significant PE is currently being investigated in an ongoing multicentre outcome study [Clinicaltrials.gov National Clinical Trial (NCT) number 02059551]. 4.9 Echocardiography Acute PE may lead to RV pressure overload and dysfunction, which can be detected by echocardiography. Given the peculiar geometry of the RV, there is no individual echocardiographic parameter that provides fast and reliable information on RV size or function. This is why echocardiographic criteria for the diagnosis of PE have differed between studies. Because of the reported negative predictive value of 40 \u0002 50%, a negative result cannot exclude PE. 124,142,143 On the other hand, signs of RV overload or dysfunction may also be found in the absence of acute PE, and may be due to concomitant cardiac or respiratory disease. 144 Echocardiographic findings of RV overload and/or dysfunction are graphically presented in Figure 3 . RV dilation is found in > _25% of patients with PE on transthoracic echocardiography (TTE) and is use- ful for risk stratification of the disease. 145 More specific echocardio- graphic findings were reported to retain a high positive predictive value for PE even in the presence of pre-existing cardiorespiratory disease. Thus, the combination of a pulmonary ejection acceleration time (measured in the RV outflow tract) <60 ms with a peak systolic tricuspid valve gradient <60 mmHg (‘60/60’ sign), or with depressed contractility of the RV free wall compared to the ‘echocardiographic’ RV apex (McConnell sign), is suggestive of PE. 146 However, these findings are present in only \u0018 12 and 20% of unselected PE patients, respectively. 145 Detection of echocardiographic signs of RV pressure overload helps to distinguish acute PE from RV free wall hypokinesia or akinesia due to RV infarction, which may mimic the McConnell sign. 147 It should be noted that in \u0018 10% of PE patients, echocardiog- raphy can show potentially misleading incidental findings such as sig- nificant LV systolic dysfunction or valvular heart disease. 145 Decreased tricuspid annular plane systolic excursion (TAPSE) may also be present in PE patients. 148,149 Echocardiographic parameters of RV function derived from Doppler tissue imaging and wall strain assessment may also be affected by the presence of acute PE ( Figure 3 ). However, they probably have low sensitivity as stand-alone findings, as they were reported to be normal in haemodynamically stable patients despite the presence of PE. 150,151 ESC Guidelines 15 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Echocardiographic examination is not mandatory as part of the routine diagnostic workup in haemodynamically stable patients with suspected PE, 124 although it may be useful in the differential diagnosis of acute dyspnoea. This is in contrast to suspected high-risk PE, in which the absence of echocardiographic signs of RV overload or dys- function practically excludes PE as the cause of haemodynamic insta- bility. In the latter case, echocardiography may be of further help in the differential diagnosis of the cause of shock, by detecting pericar- dial tamponade, acute valvular dysfunction, severe global or regional LV dysfunction, aortic dissection, or hypovolaemia. 152 Conversely, in a haemodynamically compromised patient with suspected PE, unequivocal signs of RV pressure overload, especially with more spe- cific echocardiographic findings (60/60 sign, McConnell sign, or right- heart thrombi), justify emergency reperfusion treatment for PE if immediate CT angiography is not feasible in a patient with high clinical probability and no other obvious causes for RV pressure overload. 152 Mobile right-heart thrombi are detected by TTE or transoesopha- geal echocardiography (TOE), or by CT angiography, in <4% of unse- lected patients with PE. 153 \u0002 155 Their prevalence may reach 18% among PE patients in the intensive care setting. 156 Mobile right-heart thrombi essentially confirm the diagnosis of PE and are associated with high early mortality, especially in patients with RV dysfunction. 155,157 \u0002 159 In some patients with suspected acute PE, echocardiography may detect increased RV wall thickness or tricuspid insufficiency jet veloc- ity beyond values compatible with acute RV pressure overload (>3.8 m/s or a tricuspid valve peak systolic gradient >60 mmHg). 160 In these cases, chronic thromboembolic (or other) pulmonary hypertension (PH) should be included in the differential diagnosis. 4.10 Compression ultrasonography In the majority of cases, PE originates from DVT in a lower limb, and only rarely from upper-limb DVT (mostly following venous catheterization). In a study using venography, DVT was found in 70% of patients with pro- ven PE. 161 Nowadays, lower-limb CUS has largely replaced venography for diagnosing DVT. CUS has a sensitivity >90% and a specificity of \u0018 95% for proximal symptomatic DVT. 162,163 CUS shows a DVT in 30 \u0002 50% of patients with PE, 162 \u0002 164 and finding a proximal DVT in patients suspected of having PE is considered sufficient to warrant antico- agulant treatment without further testing. 165 However, patients in whom PE is indirectly confirmed by the presence of a proximal DVT should undergo risk assessment for PE severity and the risk of early death. In the setting of suspected PE, CUS can be limited to a simple four- point examination (bilateral groin and popliteal fossa). The only vali- dated diagnostic criterion for DVT is incomplete compressibility of the vein, which indicates the presence of a clot, whereas flow measure- ments are unreliable. A positive proximal CUS result has a high positive predictive value for PE. The high diagnostic specificity (96%) along with a low sensitivity (41%) of CUS in this setting was shown by a recent meta-analysis. 165,166 CUS is a useful procedure in the diagnostic strat- egy of patients with CT contraindications. The probability of a positive proximal CUS in suspected PE is higher in patients with signs and symp- toms related to the leg veins than in asymptomatic patients. 162,163 © ESC 2019 A. Enlarged right ventricle, parasternal long axis view C. Flattened intraventricle septum (arrows) parasternal short axis view B. Dilated RV with basal RV/LV ratio >1.0, and McConnell sign (arrow), four chamber view D. Distended inferior vena cava with diminished inspiratory collapsibility, subcostal view E. 60/60 sign: coexistence of acceleration time of pulmonary ejection <60 ms and midsystolic “notch” with mildy elevated (<60 mmHg) peak systolic gradient at the tricuspic valve F. Right heart mobile thrombus detected in right heart cavities (arrow) G. Decreased tricuspid annular plane systolic excursion (TAPSE) measured with M-Mode (<16 mm) H. Decreased peak systolic (S’) velocity of tricuspid annulus (<9.5 cm/s) S’ E’ A’ RV RV LV RA RV LV RA IVC RV RA RV RiHTh M-Mode TAPSE <16 mm LV Ao LA AcT <60 ms TRPG <60 mmHg Tissue Doppler Imaging S’ <9.5/s ”notch” Figure 3 Graphic representation of transthoracic echocardiographic parameters in the assessment of right ventricular pressure overload. A 0 = peak late diastolic (during atrial contraction) velocity of tricuspid annulus by tissue Doppler imaging; AcT = right ventricular outflow Doppler acceleration time; Ao = aorta; E 0 = peak early diastolic velocity of tricuspid annulus by tissue Doppler imaging; IVC = inferior vena cava; LA = left atrium; LV = left ventricle; RA = right atrium; RiHTh = right heart thrombus (or thrombi); RV = right ventricle/ventricular; S 0 = peak systolic velocity of tricuspid annulus by tissue Doppler imaging; TAPSE = tricuspid annular plane systolic excursion; TRPG = tricuspid valve peak systolic gradient. 16 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    "4.11 Recommendations for diagnosis Recommendations Class a Level b Suspected PE with haemodynamic instability In suspected high-risk PE, as indicated by the presence of haemodynamic instability, bedside echocardiography or emer- gency CTPA (depending on availability and clinical circumstances) is recommended for diagnosis. 169 I C It is recommended that i.v. anticoagulation with UFH, including a weight-adjusted bolus injection, be initiated without delay in patients with suspected high-risk PE. I C Suspected PE without haemodynamic instability The use of validated criteria for diagnosing PE is recommended. 12 I B Initiation of anticoagulation is recommended without delay in patients with high or intermediate clinical probability of PE while diagnostic workup is in progress. I C Clinical evaluation It is recommended that the diagnostic strategy be based on clinical probability, assessed either by clinical judgement or by a validated prediction rule. 89,91,92,103,134,170 \u0002 172 I A D-dimer Plasma D-dimer measurement, preferably using a highly sensitive assay, is recommended in outpatients/emergency depart- ment patients with low or intermediate clinical probability, or those that are PE-unlikely, to reduce the need for unneces- sary imaging and irradiation. 101 \u0002 103,122,164,171,173,174 I A As an alternative to the fixed D-dimer cut-off, a negative D-dimer test using an age-adjusted cut-off (age \u0004 10 m g/L, in patients aged >50 years) should be considered for excluding PE in patients with low or intermediate clinical probability, or those that are PE-unlikely. 106 IIa B As an alternative to the fixed or age-adjusted D-dimer cut-off, D-dimer levels adapted to clinical probability c should be considered to exclude PE. 107 IIa B D-dimer measurement is not recommended in patients with high clinical probability, as a normal result does not safely exclude PE, even when using a highly sensitive assay. 175,176 III A CTPA It is recommended to reject the diagnosis of PE (without further testing) if CTPA is normal in a patient with low or inter- mediate clinical probability, or who is PE-unlikely. 101,122,164,171 I A It is recommended to accept the diagnosis of PE (without further testing) if CTPA shows a segmental or more proximal filling defect in a patient with intermediate or high clinical probability. 115 I B It should be considered to reject the diagnosis of PE (without further testing) if CTPA is normal in a patient with high clini- cal probability or who is PE-likely. 171 IIa B Further imaging tests to confirm PE may be considered in cases of isolated subsegmental filling defects. 115 IIb C CT venography is not recommended as an adjunct to CTPA. 115,164 III B V/Q scintigraphy It is recommended to reject the diagnosis of PE (without further testing) if the perfusion lung scan is normal. 75,122,134,174 I A It should be considered to accept that the diagnosis of PE (without further testing) if the V/Q scan yields high probability for PE. 134 IIa B A non-diagnostic V/Q scan should be considered as exclusion of PE when combined with a negative proximal CUS in patients with low clinical probability, or who are PE-unlikely. 75,122,174 IIa B Continued ESC Guidelines 17 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . In patients admitted to the emergency department with haemody- namic instability and suspicion of PE, a combination of venous ultra- sound with cardiac ultrasound may further increase specificity. Conversely, an echocardiogram without signs of RV dysfunction and a normal venous ultrasound excluded PE with a high (96%) negative predictive value in one study. 167 For further details on the diagnosis and management of DVT, the reader is referred to the joint consensus document of the ESC Working Groups of Aorta and Peripheral Vascular Diseases, and Pulmonary Circulation and Right Ventricular Function. 1 4.12 Computed tomography venography When using CTPA, it is possible to image the deep veins of the legs during the same acquisition. 115 However, this approach has not been widely validated and the added value of venous imaging is limited. 164 Moreover, using CT venography is associated with increased radia- tion doses. 168 5 Assessment of pulmonary embolism severity and the risk of early death Risk stratification of patients with acute PE is mandatory for deter- mining the appropriate therapeutic management approach. As described in section 3.3 , initial risk stratification is based on clinical symptoms and signs of haemodynamic instability ( Table 4 ), which indi- cate a high risk of early death. In the large remaining group of patients with PE who present without haemodynamic instability, further (advanced) risk stratification requires the assessment of two sets of prognostic criteria: (i) clinical, imaging, and laboratory indicators of PE severity, mostly related to the presence of RV dysfunction; and (ii) presence of comorbidity and any other aggravating conditions that may adversely affect early prognosis. 5.1 Clinical parameters of pulmonary embolism severity Acute RV failure, defined as a rapidly progressive syndrome with sys- temic congestion resulting from impaired RV filling and/or reduced RV flow output, 68 is a critical determinant of outcome in acute PE. Tachycardia, low systolic BP, respiratory insufficiency (tachypnoea and/or low SaO 2 ), and syncope, alone or in combination, have been associated with an unfavourable short-term prognosis in acute PE. 5.2 Imaging of right ventricular size and function 5.2.1 Echocardiography Echocardiographic parameters used to stratify the early risk of patients with PE are graphically presented in Figure 3 , and their prog- nostic values are summarized in Supplementary Data Table 3 . Of these, an RV/LV diameter ratio > _1.0 and a TAPSE <16 mm are the findings for which an association with unfavourable prognosis has most frequently been reported. 148 Overall, evidence for RV dysfunction on echocardiography is found in > _25% of unselected patients with acute PE. 145 Systematic reviews and meta-analyses have suggested that RV dysfunction on echocardiography is associated with an elevated risk of short-term mortality in patients who appear haemody- namically stable at presentation, 180,181 but its overall positive predictive value for PE-related death was low (<10%) in a meta- analysis. 180 This weakness is partly related to the fact that echo- cardiographic parameters have proved difficult to standard- ize. 148,180 Nevertheless, echocardiographic assessment of the morphology and function of the RV is widely recognized as a val- uable tool for the prognostic assessment of normotensive patients with acute PE in clinical practice. In addition to RV dysfunction, echocardiography can identify right- to-left shunt through a patent foramen ovale and the presence of right heart thrombi, both of which are associated with increased V/Q SPECT V/Q SPECT may be considered for PE diagnosis. 121,126 \u0002 128 IIb d B Lower-limb CUS It is recommended to accept the diagnosis of VTE (and PE) if a CUS shows a proximal DVT in a patient with clinical suspi- cion of PE. 164,165 I A If CUS shows only a distal DVT, further testing should be considered to confirm PE. 177 IIa B If a positive proximal CUS is used to confirm PE, assessment of PE severity should be considered to permit risk-adjusted management. 178,179 IIa C MRA MRA is not recommended for ruling out PE. 139,140 III A CT = computed tomographic; CTPA = computed tomography pulmonary angiography/angiogram; CUS = compression ultrasonography; DVT = deep vein thrombosis; i.v. = intravenous; MRA = magnetic resonance angiography; PE = pulmonary embolism; SPECT = single-photon emission computed tomography; UFH = unfractionated heparin; V/Q = ventilation/perfusion (lung scintigraphy); VTE = venous thromboembolism. a Class of recommendation. b Level of evidence. c D-dimer cut-off levels adapted to clinical probability according to the YEARS model (signs of DVT, haemoptysis, and whether an alternative diagnosis is less likely than PE) may be used. According to this model, PE is excluded in patients without clinical items and D-dimer levels <1000 m g/L, or in patients with one or more clinical items and D-dimer levels <500 m g/L. 107 d Low level of recommendation in view of the limitations summarized in Table 5 . 18 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . mortality in patients with acute PE. 67,158 A patent foramen ovale also increases the risk of ischaemic stroke due to paradoxical embolism in patients with acute PE and RV dysfunction. 182,183 5.2.2 Computed tomographic pulmonary angiography CTPA parameters used to stratify the early risk of patients with PE are summarized in Supplementary Data Table 3 . Four- chamber views of the heart by CT angiography can detect RV enlargement (RV end-diastolic diameter and RV/LV ratio meas- ured in the transverse or four-chamber view) as an indicator of RV dysfunction. The prognostic value of an enlarged RV is sup- ported by the results of a prospective multicentre cohort study in 457 patients. 184 In that study, RV enlargement (defined as an RV/LV ratio > _0.9) was an independent predictor of an adverse in- hospital outcome, both in the overall population with PE [hazard ratio (HR) 3.5, 95% CI 1.6 \u0002 7.7] and in haemodynamically stable patients (HR 3.8, 95% CI 1.3 \u0002 10.9). 184 A meta-analysis of 49 studies investigating >13 000 patients with PE confirmed that an increased RV/LV ratio of > _1.0 on CT was associated with a 2.5- fold increased risk for all-cause mortality [odds ratio (OR) 2.5, 95% CI 1.8 \u0002 3.5], and with a five-fold risk for PE-related mortality (OR 5.0, 95% CI 2.7 \u0002 9.2). 185 Mild RV dilation (RV/LV slightly above 0.9) on CT is a frequent finding (>50% of haemodynamically stable PE patients 186 ), but it probably has minor prognostic significance. However, increasing RV/ LV diameter ratios are associated with rising prognostic specific- ity, 187,188 even in patients considered to be at ‘low’ risk on the basis of clinical criteria. 186 Thus, RV/LV ratios > _ 1.0 (instead of 0.9) on CT angiography may be more appropriate to indicate poor prognosis. Apart from RV size and the RV/LV ratio, CT may provide further prognostic information based on volumetric analysis of the heart chambers 189 \u0002 191 and assessment of contrast reflux to the inferior vena cava (IVC). 185,192,193 5.3 Laboratory biomarkers 5.3.1 Markers of myocardial injury Elevated plasma troponin concentrations on admission may be associ- ated with a worse prognosis in the acute phase of PE. Cardiac troponin I or T elevation are defined as concentrations above the normal limits, and thresholds depend on the assay used; an overview of the cut-off val- ues has been provided by a meta-analysis. 194 Of patients with acute PE, between 30 (using conventional assays) 194,195 and 60% (using high- sensitivity assays) 196,197 have elevated cardiac troponin I or T concentra- tions. A meta-analysis showed that elevated troponin concentrations were associated with an increased risk of mortality, both in unselected patients (OR 5.2, 95% CI 3.3 \u0002 8.4) and in those who were haemody- namically stable at presentation (OR 5.9, 95% CI 2.7 \u0002 13.0). 195 On their own, increased circulating levels of cardiac troponins have relatively low specificity and positive predictive value for early mortality in normotensive patients with acute PE. However, when interpreted in combination with clinical and imaging findings, they may improve the identification of an elevated PE-related risk and the further prognostic stratification of such patients (Supplementary Data Table 4 ). At the other end of the severity spectrum, high-sensitivity troponin assays possess a high negative predictive value in the setting of acute PE. 197 For example, in a prospective multicentre cohort of 526 normotensive patients, high-sensitivity troponin T concentrations <14 pg/mL had a nega- tive predictive value of 98% for excluding an adverse in-hospital clinical outcome. 63 Age-adjusted high-sensitivity troponin T cut- off values (> _14 pg/mL for patients aged <75 years and > _45 pg/mL for those > _75 years) may further improve the negative predictive value of this biomarker. 196 Heart-type fatty acid-binding protein (H-FABP), an early and sensi- tive marker of myocardial injury, provides prognostic information in acute PE, both in unselected 198,199 and normotensive patients. 200,201 In a meta-analysis investigating 1680 patients with PE, H-FABP con- centrations > _6 ng/mL were associated with an adverse short-term outcome (OR 17.7, 95% CI 6.0 \u0002 51.9) and all-cause mortality (OR 32.9, 95% CI 8.8 \u0002 123.2). 202 5.3.2 Markers of right ventricular dysfunction RV pressure overload due to acute PE is associated with increased myocardial stretch, which leads to the release of B-type natriuretic peptide (BNP) and N-terminal (NT)-proBNP. Thus, the plasma levels of natriuretic peptides reflect the severity of RV dysfunction and hae- modynamic compromise in acute PE. 203 A meta-analysis found that 51% of 1132 unselected patients with acute PE had elevated BNP or NT-proBNP concentrations on admission; these patients had a 10% risk of early death (95% CI 8.0 \u0002 13%) and a 23% (95% CI 20 \u0002 26%) risk of an adverse clinical outcome. 204 Similar to cardiac troponins (see above), elevated BNP or NT- proBNP concentrations possess low specificity and positive predic- tive value (for early mortality) in normotensive patients with PE, 205 but low levels of BNP or NT-proBNP are capable of excluding an unfavourable early clinical outcome, with high sensitivity and a nega- tive predictive value. 180 In this regard, an NT-proBNP cut-off value <500 pg/mL was used to select patients for home treatment in a mul- ticentre management study. 206 If emphasis is placed on increasing the prognostic specificity for an adverse early outcome, higher cut-off val- ues > _600 pg/mL might be more appropriate. 207 5.3.3 Other laboratory biomarkers Lactate is a marker of imbalance between tissue oxygen supply and demand, and consequently of severe PE with overt or imminent hae- modynamic compromise. Elevated arterial plasma levels > _2 mmol/L predict PE-related complications, both in unselected 208 and in initially normotensive 209,210 PE patients. Elevated serum creatinine levels and a decreased (calculated) glo- merular filtration rate are related to 30 day all-cause mortality in acute PE. 211 Elevated neutrophil gelatinase-associated lipocalin and cystatin C, both indicating acute kidney injury, are also of prognostic value. 212 A recent meta-analysis investigating 18 616 patients with acute PE found that hyponatraemia predicted in-hospital mortality (OR 5.6, 95% CI 3.4 \u0002 9.1). 213 Vasopressin is released upon endogenous stress, hypotension, and low CO. Its surrogate marker, copeptin, has been reported to be useful for risk stratification of patients with acute PE. 214,215 In a single- centre derivation study investigating 268 normotensive PE patients, copeptin levels > _24 pmol/L were associated with a 5.4-fold (95% CI 1.7 \u0002 17.6) increased risk of an adverse outcome. 216 These results ESC Guidelines 19 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . were confirmed in 843 normotensive PE patients prospectively included in three European cohorts. 217 5.4 Combined parameters and scores for assessment of pulmonary embolism severity In patients who present without haemodynamic instability, individual baseline findings may not suffice to determine and further classify PE severity and PE-related early risk when used as stand-alone parame- ters. As a result, various combinations of the clinical, imaging, and lab- oratory parameters described above have been used to build prognostic scores, which permit a (semi)quantitative assessment of early PE-related risk of death. Of these, the Bova 218 \u0002 221 and the H- FABP (or high-sensitivity troponin T), Syncope, Tachycardia (FAST) scores 219,222,223 have been validated in cohort studies (see Supplementary Data Table 4 ). However, their implications for patient management remain unclear. To date, only a combination of RV dys- function on an echocardiogram (or CTPA) with a positive cardiac troponin test has directly been tested as a guide for early therapeutic decisions (anticoagulation plus reperfusion treatment vs. anticoagula- tion alone) in a large randomized controlled trial (RCT) of PE patients presenting without haemodynamic instability. 224 5.5 Integration of aggravating conditions and comorbidity into risk assessment of acute pulmonary embolism In addition to the clinical, imaging, and laboratory findings, which are directly linked to PE severity and PE-related early death, baseline parameters related to aggravating conditions and comorbidity are necessary to assess a patient’s overall mortality risk and early out- come. Of the clinical scores integrating PE severity and comorbidity, the Pulmonary Embolism Severity Index (PESI) ( Table 7 ) is the one that has been most extensively validated to date. 225 \u0002 228 The principal strength of the PESI lies in the reliable identification of patients at low risk for 30 day mortality (PESI classes I and II). One randomized trial employed a low PESI as the principal inclusion criterion for home treatment of acute PE. 178 In view of the complexity of the original PESI, which includes 11 dif- ferently weighed variables, a simplified version (sPESI; Table 7 ) has been developed and validated. 229 \u0002 231 As with the original version of the PESI, the strength of the sPESI lies in the reliable identification of patients at low risk for 30 day mortality. The prognostic performance of the sPESI has been confirmed in observational cohort stud- ies, 227,228 although this index has not yet been prospectively used to guide therapeutic management of low-risk PE patients. The diagnosis of concomitant DVT has been identified as an adverse prognostic factor, being independently associated with death within the first 3 months after acute PE. 232 In a meta-analysis investi- gating 8859 patients with PE, the presence of concomitant DVT was confirmed as a predictor of 30 day all-cause mortality (OR 1.9, 95% CI 1.5 \u0002 2.4), although it did not predict PE-related adverse outcomes at 90 days. 233 Thus, concomitant DVT can be regarded as an indica- tor of significant comorbidity in acute PE. 5.6 Prognostic assessment strategy The classification of PE severity and the risk of early (in-hospital or 30 day) death is summarized in Table 8 . Risk assessment of acute PE begins upon suspicion of the disease and initiation of the diagnostic workup. At this early stage, it is critical to identify patients with (sus- pected) high-risk PE. This clinical setting necessitates an emergency Table 7 Original and simplified Pulmonary Embolism Severity Index Parameter Original version 226 Simplified version 229 Age Age in years 1 point (if age >80 years) Male sex þ 10 points \u0002 Cancer þ 30 points 1 point Chronic heart failure þ 10 points 1 point Chronic pulmonary disease þ 10 points Pulse rate > _110 b.p.m. þ 20 points 1 point Systolic BP <100 mmHg þ 30 points 1 point Respiratory rate >30 breaths per min þ 20 points \u0002 Temperature <36 \u000e C þ 20 points \u0002 Altered mental status þ 60 points \u0002 Arterial oxyhaemo- globin saturation <90% þ 20 points 1 point Risk strata a Class I: \u0014 65 points very low 30 day mor- tality risk (0 \u0002 1.6%) Class II: 66 \u0002 85 points low mortality risk (1.7 \u0002 3.5%) 0 points 5 30 day mortality risk 1.0% (95% CI 0.0 \u0002 2.1%) Class III: 86 \u0002 105 points moderate mortality risk (3.2 \u0002 7.1%) Class IV: 106 \u0002 125 points high mortality risk (4.0 \u0002 11.4%) Class V: > 125 points very high mortality risk (10.0 \u0002 24.5%) \u0015 1 point(s) 5 30 day mortality risk 10.9% (95% CI 8.5 \u0002 13.2%) BP = blood pressure; b.p.m. = beats per minute; CI = confidence interval. a Based on the sum of points. 20 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . diagnostic algorithm ( Figure 4 ) and immediate referral for reperfusion treatment, as explained in section 7 , and displayed in Figure 6 and Supplementary Data Figure 1 . Testing for laboratory biomarkers such as cardiac troponins or natriuretic peptides is not necessary for immediate therapeutic decisions in patients with high-risk PE. In the absence of haemodynamic instability at presentation, further risk stratification of PE is recommended, as it has implications for early discharge vs. hospitalization or monitoring of the patient (explained in section 7 ). Table 8 provides an overview of the clinical, imaging, and laboratory parameters used to distinguish intermediate- and low-risk PE. The PESI is—in its original or simplified form—the most extensively validated and most broadly used clinical score to date, as it integrates baseline indicators of the severity of the acute PE episode with aggravating conditions and the comorbidity of the patient. Overall, a PESI of class I \u0002 II or an sPESI of 0 is a reliable pre- dictor of low-risk PE. In addition to clinical parameters, patients in the intermediate-risk group who display evidence of both RV dysfunction (on echocardiog- raphy or CTPA) and elevated cardiac biomarker levels in the circula- tion (particularly a positive cardiac troponin test) are classified into the intermediate-high-risk category. As will be discussed in more detail in section 7 , close monitoring is recommended in these cases to permit the early detection of haemodynamic decompensation or col- lapse, and consequently the need for rescue reperfusion therapy. 179 Patients in whom the RV appears normal on echocardiography or CTPA, and/or who have normal cardiac biomarker levels, belong to the intermediate-low-risk category. As an alternative approach, use of further prognostic scores combining clinical, imaging, and labora- tory parameters may be considered to semi-quantitatively assess the severity of the PE episode, and distinguish intermediate-high-risk and intermediate-low-risk PE. Supplementary Data Table 4 lists the scores most frequently investigated for this purpose in observational (cohort) studies; however, none of them has been used in RCTs to date. A recent meta-analysis included 21 cohort studies with a total of 3295 patients with ‘low-risk’ PE based on a PESI of I \u0002 II or an sPESI of 0. 234 Overall, 34% (95% CI 30 \u0002 39%) of them were reported to have signs of RV dysfunction on echocardiography or CTPA. Data on early mortality were provided in seven studies (1597 patients) and revealed an OR of 4.19 (95% CI 1.39 \u0002 12.58) for death from any cause in the presence of RV dysfunction; ele- vated cardiac troponin levels were associated with a comparable magnitude of risk elevation. 234 Early all-cause mortality rates (1.8% for RV dysfunction and 3.8% for elevated troponin lev- els 234 ) were in the lower range of those previously reported for patients with intermediate-risk PE. 235 Until the clinical implica- tions of such discrepancies are clarified, patients with signs of RV dysfunction or elevated cardiac biomarkers, despite a low PESI or an sPESI of 0, should be classified into the intermediate-low-risk category. Table 8 Classification of pulmonary embolism severity and the risk of early (in-hospital or 30 day) death Early mortality risk Indicators of risk Haemodynamic instability a Clinical parameters of PE severity and/ or comorbidity: PESI class III–V or sPESI ≥ 1 RV dysfunction on TTE or CTPA b Elevated cardiac troponin levels c High + (+) d + (+) Intermediate Intermediate–high - + e + + Intermediate–low - + e One (or none) positive Low - - - Assesment optional; if assessed, negative ©ESC 2019 BP = blood pressure; CTPA = computed tomography pulmonary angiography; H-FABP = heart-type fatty acid-binding protein; NT-proBNP = N-terminal pro B-type natriuretic peptide; PE = pulmonary embolism; PESI = Pulmonary Embolism Severity Index; RV = right ventricular; sPESI = simplified Pulmonary Embolism Severity Index; TTE = trans- thoracic echocardiogram. a One of the following clinical presentations ( Table 4 ): cardiac arrest, obstructive shock (systolic BP <90 mmHg or vasopressors required to achieve a BP > _90 mmHg despite an adequate filling status, in combination with end-organ hypoperfusion), or persistent hypotension (systolic BP <90 mmHg or a systolic BP drop > _40 mmHg for >15 min, not caused by new-onset arrhythmia, hypovolaemia, or sepsis). b Prognostically relevant imaging (TTE or CTPA) findings in patients with acute PE, and the corresponding cut-off levels, are graphically presented in Figure 3 , and their prognostic value is summarized in Supplementary Data Table 3 . c Elevation of further laboratory biomarkers, such as NT-proBNP > _600 ng/L, H-FABP > _6 ng/mL, or copeptin > _24 pmol/L, may provide additional prognostic information. These markers have been validated in cohort studies but they have not yet been used to guide treatment decisions in randomized controlled trials. d Haemodynamic instability, combined with PE confirmation on CTPA and/or evidence of RV dysfunction on TTE, is sufficient to classify a patient into the high-risk PE category. In these cases, neither calculation of the PESI nor measurement of troponins or other cardiac biomarkers is necessary. e Signs of RV dysfunction on TTE (or CTPA) or elevated cardiac biomarker levels may be present, despite a calculated PESI of I \u0002 II or an sPESI of 0. 234 Until the implications of such discrepancies for the management of PE are fully understood, these patients should be classified into the intermediate-risk category. ESC Guidelines 21 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 Treatment in the acute phase 6.1 Haemodynamic and respiratory support 6.1.1 Oxygen therapy and ventilation Hypoxaemia is one of the features of severe PE, and is mostly due to the mismatch between ventilation and perfusion. Administration of supplemental oxygen is indicated in patients with PE and SaO 2 <90%. Severe hypoxaemia/respiratory failure that is refractory to conven- tional oxygen supplementation could be explained by right-to-left shunt through a patent foramen ovale or atrial septal defect. 67 Further oxygenation techniques should also be considered, including high-flow oxygen (i.e. a high-flow nasal cannula) 236,237 and mechanical ventilation (non-invasive or invasive) in cases of extreme instability (i.e. cardiac arrest), taking into consideration that correction of hypo- xaemia will not be possible without simultaneous pulmonary reperfusion. Patients with RV failure are frequently hypotensive or are highly susceptible to the development of severe hypotension during induc- tion of anaesthesia, intubation, and positive-pressure ventilation. Consequently, intubation should be performed only if the patient is unable to tolerate or cope with non-invasive ventilation. When feasi- ble, non-invasive ventilation or oxygenation through a high-flow nasal cannula should be preferred; if mechanical ventilation is used, care should be taken to limit its adverse haemodynamic effects. In particu- lar, positive intrathoracic pressure induced by mechanical ventilation may reduce venous return and worsen low CO due to RV failure in patients with high-risk PE; therefore, positive end-expiratory pres- sure should be applied with caution. Tidal volumes of approximately 6 mL/kg lean body weight should be used in an attempt to keep the end-inspiratory plateau pressure <30 cm H 2 O. If intubation is needed, anaesthetic drugs more prone to cause hypotension should be avoided for induction. 6.1.2 Pharmacological treatment of acute right ventricular failure Acute RV failure with resulting low systemic output is the leading cause of death in patients with high-risk PE. The principles of acute right heart failure management have been reviewed in a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the ESC. 68 An overview of the current treatment options for acute RV failure is provided in Table 9 . If the central venous pressure is low, modest (< _500 mL) fluid chal- lenge can be used as it may increase the cardiac index in patients with acute PE. 238 However, volume loading has the potential to over- distend the RV and ultimately cause a reduction in systemic CO. 239 Experimental studies suggest that aggressive volume expansion is of no benefit and may even worsen RV function. 240 Cautious volume loading may be appropriate if low arterial pressure is combined with an absence of elevated filling pressures. Assessment of central venous pressure by ultrasound imaging of the IVC (a small and/or collapsible IVC in the setting of acute high-risk PE indicates low volume status) or, alternatively, by central venous pressure monitoring may help guide volume loading. If signs of elevated central venous pressure are observed, further volume loading should be withheld. Use of vasopressors is often necessary, in parallel with (or while waiting for) pharmacological, surgical, or interventional reperfusion treatment. Norepinephrine can improve systemic haemodynamics by bringing about an improvement in ventricular systolic interaction and coronary perfusion, without causing a change in PVR. 240 Its use should be limited to patients in cardiogenic shock. Based on the results of a small series, the use of dobutamine may be considered for patients with PE, a low cardiac index, and normal BP; however, raising the cardiac index may aggravate the ventilation/perfusion mis- match by further redistributing flow from (partly) obstructed to unobstructed vessels. 241 Although experimental data suggest that 5.7 Recommendations for prognostic assessment Recommendations Class a Level b Initial risk stratification of suspected or confirmed PE, based on the presence of haemodynamic instability, is recom- mended to identify patients at high risk of early mortality. 218,219,235 I B In patients without haemodynamic instability, further stratification of patients with acute PE into intermediate- and low- risk categories is recommended. 179,218,219,235 I B In patients without haemodynamic instability, use of clinical prediction rules integrating PE severity and comorbidity, pref- erably the PESI or sPESI, should be considered for risk assessment in the acute phase of PE. 178,226,229 IIa B Assessment of the RV by imaging methods c or laboratory biomarkers d should be considered, even in the presence of a low PESI or a negative sPESI. 234 IIa B In patients without haemodynamic instability, use of validated scores combining clinical, imaging, and laboratory PE-related prognostic factors may be considered to further stratify the severity of the acute PE episode. 218 \u0002 223 IIb C PE = pulmonary embolism; PESI = Pulmonary Embolism Severity Index; RV = right ventricle; sPESI = simplified Pulmonary Embolism Severity Index. a Class of recommendation. b Level of evidence. c Transthoracic echocardiography or computed tomography pulmonary angiography. d Cardiac troponins or natriuretic peptides. 22 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . levosimendan may restore RV \u0002 pulmonary arterial coupling in acute PE by combining pulmonary vasodilation with an increase in RV con- tractility, 242 no evidence of clinical benefit is available. Vasodilators decrease PAP and PVR, but may worsen hypotension and systemic hypoperfusion due to their lack of specificity for the pul- monary vasculature after systemic [intravenous (i.v.)] administration. Although small clinical studies have suggested that inhalation of nitric oxide may improve the haemodynamic status and gas exchange of patients with PE, 243 \u0002 245 no evidence for its clinical efficacy or safety is available to date. 246 6.1.3 Mechanical circulatory support and oxygenation The temporary use of mechanical cardiopulmonary support, mostly with veno \u0002 arterial extracorporeal membrane oxygenation (ECMO), may be helpful in patients with high-risk PE, and circulatory collapse or cardiac arrest. Survival of critically ill patients has been described in a number of case series, 247 \u0002 252 but no RCTs testing the efficacy and safety of these devices in the setting of high-risk PE have been conducted to date. Use of ECMO is associated with a high inci- dence of complications, even when used for short periods, and the results depend on the experience of the centre as well as patient selection. The increased risk of bleeding related to the need for vas- cular access should be considered, particularly in patients undergoing thrombolysis. At present, the use of ECMO as a stand-alone techni- que with anticoagulation is controversial 247,252 and additional thera- pies, such as surgical embolectomy, have to be considered. A few cases suggesting good outcomes with use of the Impella V R catheter in patients in shock caused by acute PE have been reported. 253,254 6.1.4 Advanced life support in cardiac arrest Acute PE is part of the differential diagnosis of cardiac arrest with non-shockable rhythm against a background of pulseless electrical activity. In cardiac arrest presumably caused by acute PE, current guidelines for advanced life support should be followed. 255,256 The decision to treat for acute PE must be taken early, when a good out- come is still possible. Thrombolytic therapy should be considered; once a thrombolytic drug is administered, cardiopulmonary resuscita- tion should be continued for at least 60 \u0002 90 min before terminating resuscitation attempts. 257 6.2 Initial anticoagulation 6.2.1 Parenteral anticoagulation In patients with high or intermediate clinical probability of PE (see sec- tion 4 ), anticoagulation should be initiated while awaiting the results of diagnostic tests. This is usually done with subcutaneous, weight- adjusted low-molecular weight heparin (LMWH) or fondaparinux (Supplementary Data Table 5 ), or i.v. unfractionated heparin (UFH). Based on pharmacokinetic data (Supplementary Data Table 6 ), 259 an equally rapid anticoagulant effect can also be achieved with a non- vitamin K antagonist oral anticoagulant (NOAC), and phase III clinical trials have demonstrated the non-inferior efficacy of a single-oral drug anticoagulation strategy using higher doses of apixaban for 7 days or rivaroxaban for 3 weeks. 259 \u0002 261 LMWH and fondaparinux are preferred over UFH for initial anticoagulation in PE, as they carry a lower risk of inducing major bleeding and heparin-induced thrombocytopenia. 262 \u0002 265 Neither LMWH nor fondaparinux need routine monitoring of anti-Xa lev- els. Use of UFH is nowadays largely restricted to patients with overt haemodynamic instability or imminent haemodynamic decompensation in whom primary reperfusion treatment will be necessary. UFH is also recommended for patients with serious renal impairment [creatinine clearance (CrCl) < _30 mL/min] or severe obesity. If LMWH is prescribed in patients with CrCl 15 - 30 mL/min, an adapted dosing scheme should be used. The Table 9 Treatment of right ventricular failure in acute high-risk pulmonary embolism Strategy Properties and use Caveats Volume optimization Cautious volume loading, saline, or Ringer’s lactate, < _500 mL over 15 \u0002 30 min Consider in patients with normal \u0002 low central venous pressure (due, for example, to con- comitant hypovolaemia) Volume loading can over-distend the RV, wor- sen ventricular interdependence, and reduce CO 239 Vasopressors and inotropes Norepinephrine, 0.2 \u0002 1.0 m g/kg/min a 240 Increases RV inotropy and systemic BP, pro- motes positive ventricular interactions, and restores coronary perfusion gradient Excessive vasoconstriction may worsen tissue perfusion Dobutamine, 2 \u0002 20 m g/kg/min 241 Increases RV inotropy, lowers filling pressures May aggravate arterial hypotension if used alone, without a vasopressor; may trigger or aggravate arrhythmias Mechanical circulatory support Veno \u0002 arterial ECMO/extracorporeal life support 251,252,258 Rapid short-term support combined with oxygenator Complications with use over longer periods (>5 \u0002 10 days), including bleeding and infec- tions; no clinical benefit unless combined with surgical embolectomy; requires an experienced team CO = cardiac output; BP = blood pressure; ECMO = extracorporeal membrane oxygenation; RV = right ventricle/ventricular. a Epinephrine is used in cardiac arrest. ESC Guidelines 23 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . dosing of UFH is adjusted based on the activated partial thrombo- plastin time (Supplementary Data Table 7 ). 266 6.2.2 Non-vitamin K antagonist oral anticoagulants NOACs are small molecules that directly inhibit one activated coagu- lation factor, which is thrombin for dabigatran and factor Xa for apix- aban, edoxaban, and rivaroxaban. The characteristics of NOACs used in the treatment of acute PE are summarized in Supplementary Data Table 6 . Owing to their predictable bioavailability and pharma- cokinetics, NOACs can be given at fixed doses without routine labo- ratory monitoring. Compared with vitamin K antagonists (VKAs), there are fewer interactions when NOACs are given concomitantly with other drugs. 259 In the phase III VTE trials, the dosages of dabiga- tran, rivaroxaban, and apixaban were not reduced in patients with mild \u0002 moderate renal dysfunction (CrCl between 30 \u0002 60 mL/min), whereas edoxaban was given at a 30 mg dose in these patients. Patients with CrCl <25 mL/min were excluded from the trials testing apixaban, whereas patients with CrCl <30 mL/min were excluded from those investigating rivaroxaban, edoxaban, and dabigatran (Supplementary Data Table 8 ). Phase III trials on the treatment of acute VTE (Supplementary Data Table 8 ), as well as those on extended treatment beyond the first 6 months (see section 8 ), demonstrated the non-inferiority of NOACs compared with the combination of LMWH with VKA for the preven- tion of symptomatic or lethal VTE recurrence, along with significantly reduced rates of major bleeding. 267 The different drug regimens tested in these trials are displayed in Supplementary Data Table 8 . In a meta-analysis, the incidence rate of the primary efficacy outcome was 2.0% for NOAC-treated patients and 2.2% for VKA-treated patients [relative risk (RR) 0.88, 95% CI 0.74 \u0002 1.05]. 268 Major bleeding occurred in 1.1% of NOAC-treated patients and 1.7% of VKA- treated patients for an RR of 0.60 (95% CI 0.41 \u0002 0.88). Compared with VKA-treated patients, critical site major bleeding occurred less frequently in NOAC-treated patients (RR 0.38, 95% CI 0.23 \u0002 0.62); in particular, there was a significant reduction in intracranial bleeding (RR 0.37, 95% CI 0.21 \u0002 0.68) and in fatal bleeding (RR 0.36, 95% CI 0.15 \u0002 0.87) with NOACs compared with VKAs. 268 Suggestions for the anticoagulation management of PE in specific clinical situations, for which conclusive evidence is lacking, are pre- sented in Supplementary Data Table 9 . Practical guidance for clinicians regarding the handling of NOACs and the management of emergency situations related to their use are regularly updated by the European Heart Rhythm Association. 259 6.2.3 Vitamin K antagonists VKAs have been the gold standard in oral anticoagulation for more than 50 years. When VKAs are used, anticoagulation with UFH, LMWH, or fondaparinux should be continued in parallel with the oral anticoagulant for > _5 days and until the international normalized ratio (INR) value has been 2.0 \u0002 3.0 for 2 consecutive days. Warfarin may be started at a dose of 10 mg in younger (e.g. aged <60 years) otherwise healthy patients and at a dose < _5 mg in older patients. 269 The daily dose is adjusted according to the INR over the next 5 \u0002 7 days, aiming for an INR level of 2.0 \u0002 3.0. Pharmacogenetic testing may increase the precision of warfarin dosing. 270,271 When used in addition to clinical parameters, pharmacogenetic testing improves anticoagulation control and may be associated with a reduced risk of bleeding, but does not reduce the risk of thromboembolic events or mortality. 272 The implementation of a structured anticoagulant service (most commonly, anticoagulant clinics) appears to be associated with increased time in the therapeutic range and improved clinical out- come, compared with control of anticoagulation by the general prac- titioner. 273,274 Finally, in patients who are selected and appropriately trained, self-monitoring of VKA is associated with fewer thrombo- embolic events and increased time in the therapeutic range com- pared with usual care. 275 6.3 Reperfusion treatment 6.3.1 Systemic thrombolysis Thrombolytic therapy leads to faster improvements in pulmonary obstruction, PAP, and PVR in patients with PE, compared with UFH alone; these improvements are accompanied by a reduction in RV dilation on echocardiography. 276 \u0002 279 The greatest benefit is observed when treatment is initiated within 48 h of symptom onset, but thrombolysis can still be useful in patients who have had symp- toms for 6 \u0002 14 days. 280 Unsuccessful thrombolysis, as judged by per- sistent clinical instability and unchanged RV dysfunction on echocardiography after 36 h, has been reported in 8% of high-risk PE patients. 281 A meta-analysis of thrombolysis trials that included (but were not confined to) patients with high-risk PE, defined mainly as the presence of cardiogenic shock, indicated a significant reduction in the com- bined outcome of mortality and recurrent PE (Supplementary Data Table 10 ). This was achieved with a 9.9% rate of severe bleeding and a 1.7% rate of intracranial haemorrhage. 282 In normotensive patients with intermediate-risk PE, defined as the presence of RV dysfunction and elevated troponin levels, the impact of thrombolytic treatment was investigated in the Pulmonary Embolism Thrombolysis (PEITHO) trial. 179 Thrombolytic therapy was associated with a significant reduction in the risk of haemody- namic decompensation or collapse, but this was paralleled by an increased risk of severe extracranial and intracranial bleeding. 179 In the PEITHO trial, 30 day death rates were low in both treatment groups, although meta-analyses have suggested a reduction in PE- related and overall mortality of as much as 50 \u0002 60% following throm- bolytic treatment in the intermediate-risk category (Supplementary Data Table 10 ). 282,283 The approved regimens and doses of thrombolytic agents for PE, as well as the contraindications to this type of treatment, are shown in Table 10 . Accelerated i.v. administration of recombinant tissue- type plasminogen activator (rtPA; 100 mg over 2 h) is preferable to prolonged infusions of first-generation thrombolytic agents (strepto- kinase and urokinase). Preliminary reports on the efficacy and safety of reduced-dose rtPA 284,285 need confirmation by solid evidence before any recommendations can be made in this regard. UFH may be administered during continuous infusion of alteplase, but should be discontinued during infusion of streptokinase or urokinase. 65 Reteplase, 286 desmoteplase, 287 or tenecteplase 179,278,279 have also been investigated; at present, none of these agents are approved for use in acute PE. It remains unclear whether early thrombolysis for (intermediate- or high-risk) acute PE has an impact on clinical symptoms, functional 24 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . limitation, or CTEPH at long-term follow-up. A small randomized trial of 83 patients suggested that thrombolysis might improve func- tional capacity at 3 months compared with anticoagulation alone. 278 In the PEITHO trial, 179 mild persisting symptoms, mainly dyspnoea, were present in 33% of the patients at long-term (at 41.6 ± 15.7 months) clinical follow-up. 288 However, the majority of patients (85% in the tenecteplase arm and 96% in the placebo arm) had a low or intermediate probability—based on the ESC Guidelines defini- tion 289 —of persisting or new-onset PH at echocardiographic follow- up. 288 Consequently, the findings of this study do not support a role for thrombolysis with the aim of preventing long-term sequelae ( sec- tion 10 ) after intermediate-risk PE, although they are limited by the fact that clinical follow-up was available for only 62% of the study population. 6.3.2 Percutaneous catheter-directed treatment Mechanical reperfusion is based on the insertion of a catheter into the pulmonary arteries via the femoral route. Different types of cath- eters (summarized in Supplementary Data Table 11 ) are used for mechanical fragmentation, thrombus aspiration, or more commonly a pharmacomechanical approach combining mechanical or ultra- sound fragmentation of the thrombus with in situ reduced-dose thrombolysis. Most knowledge about catheter-based embolectomy is derived from registries and pooled results from case series. 290,291 The overall procedural success rates (defined as haemodynamic stabi- lization, correction of hypoxia, and survival to hospital discharge) of percutaneous catheter-based therapies reported in these stud- ies have reached 87%; 292 however, these results may be subject to publication bias. One RCT compared conventional heparin-based treatment and a catheter-based therapy combining ultrasound- based clot fragmentation with low-dose in situ thrombolysis in 59 patients with intermediate-risk PE. In that study, ultrasound- assisted thrombolysis was associated with a larger decrease in the RV/LV diameter ratio at 24 h, without an increased risk of bleed- ing. 293 Data from two prospective cohort studies 294,295 and a registry, 296 with a total of 352 patients, support the improvement in RV function, lung perfusion, and PAP in patients with intermedi- ate- or high-risk PE using this technique. Intracranial haemorrhage was rare, although the rate of Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) severe and moderate bleeding complications was 10% in one of these cohorts. 294 These results should be inter- preted with caution, considering the relatively small numbers of patients treated, the lack of studies directly comparing catheter- directed with systemic thrombolytic therapy, and the lack of data from RCTs on clinical efficacy outcomes. 6.3.3 Surgical embolectomy Surgical embolectomy in acute PE is usually carried out with car- diopulmonary bypass, without aortic cross-clamping and cardio- plegic cardiac arrest, followed by incision of the two main pulmonary arteries with the removal or suction of fresh clots. Recent reports have indicated favourable surgical results in high- risk PE, with or without cardiac arrest, and in selected cases of intermediate-risk PE. 297 \u0002 300 Among 174 322 patients hospital- ized between 1999 and 2013 with a diagnosis of PE in New York state, survival and recurrence rates were compared between patients who underwent thrombolysis ( n = 1854) or surgical embolectomy ( n = 257) as first-line therapy. 297 Overall, there Table 10 Thrombolytic regimens, doses, and contraindications Molecule Regimen Contraindications to fibrinolysis rtPA 100 mg over 2 h Absolute History of haemorrhagic stroke or stroke of unknown origin Ischaemic stroke in previous 6 months Central nervous system neoplasm Major trauma, surgery, or head injury in previous 3 weeks Bleeding diathesis Active bleeding Relative Transient ischaemic attack in previous 6 months Oral anticoagulation Pregnancy or first post-partum week Non-compressible puncture sites Traumatic resuscitation Refractory hypertension (systolic BP >180 mmHg) Advanced liver disease Infective endocarditis Active peptic ulcer 0.6 mg/kg over 15 min (maximum dose 50 mg) a Streptokinase 250 000 IU as a loading dose over 30 min, followed by 100 000 IU/h over 12 \u0002 24 h Accelerated regimen: 1.5 million IU over 2 h Urokinase 4400 IU/kg as a loading dose over 10 min, followed by 4400 IU/kg/h over 12 \u0002 24 h Accelerated regimen: 3 million IU over 2 h BP = blood pressure; IU = international units; rtPA, recombinant tissue-type plasminogen activator. a This is the accelerated regimen for rtPA in pulmonary embolism; it is not officially approved, but it is sometimes used in extreme haemodynamic instability such as cardiac arrest. ESC Guidelines 25 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . was no difference between the two types of reperfusion treat- ment regarding 30 day mortality (15 and 13%, respectively), but thrombolysis was associated with a higher risk of stroke and re- intervention at 30 days. No difference was found in terms of 5 year actuarial survival, but thrombolytic therapy was associated with a higher rate of recurrent PE requiring readmission compared with surgery (7.9 vs. 2.8%). However, the two treatments were not randomly allocated in this observational retrospective study, and the patients referred for surgery may have been selected. An analysis of the Society of Thoracic Surgery Database with multicentre data collec- tion, including 214 patients submitted for surgical embolectomy for high- ( n = 38) or intermediate-risk ( n = 176) PE, revealed an in-hospital mortality rate of 12%, with the worst outcome (32%) in the group experiencing pre-operative cardiac arrest. 299 Recent experience appears to support combining ECMO with surgical embolectomy, particularly in patients with high-risk PE with or without the need for cardiopulmonary resuscitation. Among patients who presented with intermediate-risk PE ( n = 28), high-risk PE without cardiac arrest ( n = 18), and PE with car- diac arrest ( n = 9), the in-hospital and 1 year survival rates were 93 and 91%, respectively. 300 6.4 Multidisciplinary pulmonary embolism teams The concept of multidisciplinary rapid-response teams for the man- agement of ‘severe’ (high-risk and selected cases of intermediate- risk) PE emerged in the USA, with increasing acceptance by the medi- cal community and implementation in hospitals in Europe and world- wide. Set-up of PE response teams (PERTs) is encouraged, as they address the needs of modern systems-based healthcare. 301 A PERT brings together a team of specialists from different disciplines includ- ing, for example, cardiology, pulmonology, haematology, vascular medicine, anaesthesiology/intensive care, cardiothoracic surgery, and (interventional) radiology. The team convenes in real time (face-to- face or via web conference) to enhance clinical decision-making. This allows the formulation of a treatment plan and facilitates its immedi- ate implementation. 301 The exact composition and operating mode of a PERT are not fixed, depending on the resources and expertise available in each hospital for the management of acute PE. 6.5 Vena cava filters The aim of vena cava interruption is to mechanically prevent venous clots from reaching the pulmonary circulation. Most devices in cur- rent use are inserted percutaneously and can be retrieved after sev- eral weeks or months, or left in place over the long-term, if needed. Potential indications include VTE and absolute contraindication to anticoagulant treatment, recurrent PE despite adequate anticoagula- tion, and primary prophylaxis in patients with a high risk of VTE. Other potential indications for filter placement, including free- floating thrombi, have not been confirmed in patients without contra- indications to therapeutic anticoagulation. Only two phase III randomized trials have compared anticoagu- lation with or without vena cava interruption in patients with proximal DVT, with or without associated PE. 302 \u0002 304 In the Prevention of Recurrent Pulmonary Embolism by Vena Cava Interruption (PREPIC) study, insertion of a permanent vena cava filter was associated with a significant reduction in the risk of recurrent PE and a significant increase in the risk of DVT, without a significant difference in the risk of recurrent VTE or death. 303,304 The PREPIC-2 trial randomized 399 patients with PE and venous thrombosis to receive anticoagulant treatment, with or without a retrievable vena cava filter. In this study, the rate of recurrent VTE was low in both groups and did not differ between groups. 302 A systematic review and meta-analysis of published reports on the efficacy and safety of vena cava filters included 11 studies, with a total of 2055 patients who received a filter vs. 2149 controls. 305 Vena cava filter placement was associated with a 50% decrease in the incidence of PE and an \u0018 70% increase in the risk of DVT over time. Neither all-cause mortality nor PE-related mortality differed between patients with or without filter placement. The broad indication for placement of a venous filter in patients with recent (<1 month) proximal DVT and an absolute contraindication to anticoagulant treatment is based mainly on the perceived high risk of recurrent PE in this setting, and the lack of other treatment options. Complications associated with vena cava filters are common and can be serious. A systematic literature review revealed penetration of the venous wall in 1699 (19%) of 9002 procedures; of these cases, 19% showed adjacent organ involvement and > _8% were sympto- matic. 306 Lethal complications were rare (only two cases), but 5% of the patients required major interventions such as surgical removal of the filter, endovascular stent placement or embolization, endovascu- 6.6 Recommendations for acute-phase treatment of high-risk pulmonary embolism a Recommendations Class b Level c It is recommended that anticoagulation with UFH, including a weight-adjusted bolus injec- tion, be initiated without delay in patients with high-risk PE. I C Systemic thrombolytic therapy is recom- mended for high-risk PE. 282 I B Surgical pulmonary embolectomy is recom- mended for patients with high-risk PE, in whom thrombolysis is contraindicated or has failed. d 281 I C Percutaneous catheter-directed treatment should be considered for patients with high- risk PE, in whom thrombolysis is contraindi- cated or has failed. d IIa C Norepinephrine and/or dobutamine should be considered in patients with high-risk PE. IIa C ECMO may be considered, in combination with surgical embolectomy or catheter-directed treat- ment, in patients with PE and refractory circula- tory collapse or cardiac arrest. d 252 IIb C ECMO = extracorporeal membrane oxygenation; PE = pulmonary embolism; UFH = unfractionated heparin. a See Table 4 for definition of high-risk PE. After haemodynamic stabilization of the patient, continue with anticoagulation treatment as in intermediate- or low-risk PE ( section 6.7 ). b Class of recommendation. c Level of evidence. d If appropriate expertise and resources are available on-site. 26 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    "6.7 Recommendations for acute-phase treatment of intermediate- or low-risk pulmonary embolism Recommendations Class a Level b Initiation of anticoagulation Initiation of anticoagulation is recommended without delay in patients with high or inter- mediate clinical probability of PE, c while diag- nostic workup is in progress. I C If anticoagulation is initiated parenterally, LMWH or fondaparinux is recommended (over UFH) for most patients. 262,309 \u0002 311 I A When oral anticoagulation is started in a patient with PE who is eligible for a NOAC (apixaban, dabigatran, edoxaban, or rivaroxa- ban), a NOAC is recommended in preference to a VKA. 260,261,312 \u0002 314 I A When patients are treated with a VKA, over- lapping with parenteral anticoagulation is rec- ommended until an INR of 2.5 (range 2.0 \u0002 3.0) is reached. 315,316 I A NOACs are not recommended in patients with severe renal impairment, d during pregnancy and lactation, and in patients with antiphospholipid antibody syndrome. 260,261,312 \u0002 314 III C Reperfusion treatment Rescue thrombolytic therapy is recommended for patients with haemodynamic deterioration on anticoagulation treatment. 282 I B As an alternative to rescue thrombolytic ther- apy, surgical embolectomy e or percutaneous catheter-directed treatment e should be con- sidered for patients with haemodynamic dete- rioration on anticoagulation treatment. IIa C Routine use of primary systemic thrombolysis is not recommended in patients with inter- mediate- or low-risk PE. c,f 179 III B CrCl = creatinine clearance; INR = international normalized ratio; LMWH = low-molecular weight heparin; NOAC(s) = non-vitamin K antagonist oral antico- agulant(s); PE = pulmonary embolism; UFH = unfractionated heparin; VKA = vita- min K antagonist. a Class of recommendation. b Level of evidence. c See Table 8 for definition of the PE severity and PE-related risk. d Dabigatran is not recommended in patients with CrCl <30 mL/min. Edoxaban should be given at a dose of 30 mg once daily in patients with CrCl of 15 - 50 mL/ min and is not recommended in patients with CrCl <15 mL/min. Rivaroxaban and apixaban are to be used with caution in patients with CrCl 15 - 29 mL/min, and their use is not recommended in patients with CrCl <15 mL/min. e If appropriate expertise and resources are available on-site. f The risk-to-benefit ratios of surgical embolectomy or catheter-directed proce- dures have not yet been established in intermediate- or low-risk PE. 6.9 Recommendations for inferior vena cava filters Recommendations Class a Level b IVC filters should be considered in patients with acute PE and absolute contraindications to anticoagulation. IIa C IVC filters should be considered in cases of PE recurrence despite therapeutic anticoagulation. IIa C Routine use of IVC filters is not recommended. 302 \u0002 304 III A IVC = inferior vena cava; PE = pulmonary embolism. a Class of recommendation. b Level of evidence. 6.8 Recommendations for multidisciplinary pulmonary embolism teams Recommendation Class a Level b Set-up of a multidisciplinary team and a pro- gramme for the management of high- and (in selected cases) intermediate-risk PE should be considered, depending on the resources and expertise available in each hospital. IIa C PE = pulmonary embolism. a Class of recommendation. b Level of evidence. 6.10 Recommendations for early discharge and home treatment Recommendation Class a Level b Carefully selected patients with low-risk PE should be considered for early discharge and continuation of treatment at home, if proper outpatient care and anticoagulant treatment can be provided. c 178,206,317 \u0002 319 IIa A PE = pulmonary embolism. a Class of recommendation. b Level of evidence. c See section 7 and Figure 6 for further guidance on defining low-risk PE and deci- sion-making. ESC Guidelines 27 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . lar retrieval of the permanent filter, or percutaneous nephrostomy or ureteral stent placement. 306 Further reported complications include filter fracture and/or embolization, and DVT occasionally extending up to the vena cava. 303,307,308 7 Integrated risk-adapted diagnosis and management 7.1 Diagnostic strategies Various combinations of clinical assessments, plasma D-dimer meas- urements, and imaging tests have been proposed and validated for PE diagnosis. These strategies have been tested in patients presenting with suspected PE in the emergency department or during their hos- pital stay, 101,164,171,320 and more recently in the primary care set- ting. 111 Withholding of anticoagulation without adherence to evidence-based diagnostic strategies was associated with a significant increase in the number of VTE episodes and sudden cardiac death at 3 month follow-up. 12 The most straightforward diagnostic algorithms for suspected PE—with and without haemodynamic instability—are presented in Figures 4 and 5 , respectively. However, it is recognized that the diagnostic approach for suspected PE may vary, depending on the availability of, and expertise in, specific tests in various hospi- tals and clinical settings. © ESC 2019 Bedside TTE b CTPA RV dysfunction? c Treatment of high-risk PE a Search for other causes of shock or instability Search for other causes of shock or instability Suspected PE in a patient with haemodynamic instability a Yes Yes Negative No No d Positive CTPA immediately available and feasible? Figure 4 Diagnostic algorithm for patients with suspected high-risk pulmonary embolism presenting with haemodynamic instability. CTPA = computed tomography pulmonary angiography; CUS = compression ultrasonography; DVT = deep vein thrombosis; LV = left ventricle; PE = pulmonary embolism; RV = right ventricle; TOE = transoesophageal echocardiography; TTE = transthoracic echocardiogram. a See Table 4 for definition of haemodynamic instability and high-risk PE. b Ancillary bedside imaging tests may include TOE, which may detect emboli in the pulmonary artery and its main branches; and bilateral venous CUS, which may confirm DVT and thus VTE. c In the emergency situation of suspected high-risk PE, this refers mainly to a RV/LV diameter ratio >1.0; the echocardiographic findings of RV dysfunction, and the corresponding cut-off levels, are graphically presented in Figure 3 , and their prognostic value summarized in Supplementary Data Table 3 . d Includes the cases in which the patient’s condition is so critical that it only allows bedside diagnostic tests. In such cases, echocardiographic findings of RV dysfunction confirm high-risk PE and emergency reperfusion therapy is recommended 28 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . The diagnostic strategy for suspected acute PE in pregnancy is dis- cussed in section 9 . 7.1.1 Suspected pulmonary embolism with haemodynamic instability The proposed strategy is shown in Figure 4 . The clinical probability is usually high and the differential diagnosis includes cardiac tampo- nade, acute coronary syndrome, aortic dissection, acute valvular dysfunction, and hypovolaemia. The most useful initial test in this sit- uation is bedside TTE, which will yield evidence of acute RV dysfunc- tion if acute PE is the cause of the patient’s haemodynamic decompensation. In a highly unstable patient, echocardiographic evi- dence of RV dysfunction is sufficient to prompt immediate reperfu- sion without further testing. This decision may be strengthened by the (rare) visualization of right heart thrombi. 155,157,321,322 Ancillary bedside imaging tests include TOE, which may allow direct visualiza- tion of thrombi in the pulmonary artery and its main branches, espe- cially in patients with RV dysfunction. TOE should be cautiously performed in hypoxaemic patients. Moreover, bedside CUS can detect proximal DVT. As soon as the patient is stabilized using sup- portive treatment, final confirmation of the diagnosis by CT angiog- raphy should be sought. For unstable patients admitted directly to the catheterization labo- ratory with suspected acute coronary syndrome, pulmonary angiog- raphy may be considered as a diagnostic procedure after the acute coronary syndrome has been excluded, provided that PE is a prob- able diagnostic alternative and particularly if percutaneous catheter- directed treatment is a therapeutic option. © ESC 2019 Suspected PE in a patient without haemodynamic instability a Assess clinical probability of PE Clinical judgement or prediction rule b Low or intermediate clinical probability, or PE unlikely Positive Negative No PE PE confirmed d No PE PE confirmed d High clinical probability or PE likely D-dimer test CTPA CTPA No treatment c Treatment c No treatment c or investigate further e Treatment c Figure 5 Diagnostic algorithm for patients with suspected pulmonary embolism without haemodynamic instability. CTPA = computed tomography pulmonary angiography/angiogram; PE = pulmonary embolism. a The proposed diagnostic strategy for pregnant women with suspected acute PE is discussed in section 9 . b Two alternative classification schemes may be used for clinical probability assessment, i.e. a three-level scheme (clinical probability defined as low, inter- mediate, or high) or a two-level scheme (PE unlikely or PE likely). When using a moderately sensitive assay, D-dimer measurement should be restricted to patients with low clinical probability or a PE-unlikely classification, while highly sensitive assays may also be used in patients with intermediate clinical proba- bility of PE due to a higher sensitivity and negative predictive value. Note that plasma D-dimer measurement is of limited use in suspected PE occurring in hospitalized patients. c Treatment refers to anticoagulation treatment for PE. d CTPA is considered diagnostic of PE if it shows PE at the segmental or more proximal level. e In case of a negative CTPA in patients with high clinical probability, investigation by further imaging tests may be considered before withholding PE-specific treatment. ESC Guidelines 29 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.1.2 Suspected pulmonary embolism without haemodynamic instability 7.1.2.1 Strategy based on computed tomographic pulmonary angiography The proposed strategy based on CTPA is shown in Figure 5 . In patients admitted to the emergency department, measurement of plasma D- dimer is the logical first step following the assessment of clinical proba- bility and allows PE to be ruled out in \u0018 30% of outpatients. D-dimer should not be measured in patients with a high clinical probability of PE, owing to a low negative predictive value in this population. 323 It is also less useful in hospitalized patients because the number that needs to be tested to obtain a clinically relevant negative result is high. In most centres, multidetector CTPA is the second-line test in patients with an elevated D-dimer level and the first-line test in patients with a high clinical probability of PE. CTPA is considered to be diagnostic of PE when it shows a clot at least at the segmental level of the pulmonary arterial tree. False-negative results of CTPA have been reported in patients with a high clinical probability of PE; 115 however, such discrepancies are infrequent and the 3 month throm- boembolic risk was low in these patients. 171 Accordingly, both the necessity of performing further tests and the nature of these tests remain controversial in these clinical situations. 7.1.2.2 Strategy based on ventilation/perfusion scintigraphy In hospitals in which V/Q scintigraphy is readily available, it is a valid option for patients with an elevated D-dimer and a contraindication to CTPA. Also, V/Q scintigraphy may be preferred over CTPA to avoid unnecessary radiation, particularly in younger patients and in female patients in whom thoracic CT might raise the lifetime risk of breast cancer. 324 V/Q lung scintigraphy is diagnostic (with either normal- or high-probability findings) in \u0018 30 \u0002 50% of emergency ward patients with suspected PE. 75,122,134,325 The proportion of diagnostic V/Q scans is higher in patients with a normal chest X-ray, and this might support the use of a V/Q scan as a first-line imaging test for PE in younger patients, depending on local availability. 326 The number of patients with inconclusive findings may further be reduced by taking into account clinical probability. Thus, patients with a non-diagnostic lung scan and low clinical probability of PE have a low prevalence of confirmed PE, 124,325 and the negative predictive value of this combination is fur- ther increased by the absence of a DVT on lower-limb CUS. If a high- probability lung scan is obtained from a patient with low clinical proba- bility of PE, confirmation by other tests should be considered. 7.2 Treatment strategies 7.2.1 Emergency treatment of high-risk pulmonary embolism The algorithm for a risk-adjusted therapeutic approach to acute PE is shown in Figure 6 ; an emergency management algorithm specifically for patients with suspected acute high-risk PE is proposed in Supplementary Data Figure 1 . Primary reperfusion treatment, in most cases systemic thrombolysis, is the treatment of choice for patients with high-risk PE. Surgical pulmonary embolectomy or percutaneous catheter-directed treatment are alternative reperfusion options in patients with contraindi- cations to thrombolysis, if expertise with either of these methods and the appropriate resources are available on-site. Following reperfusion treatment and haemodynamic stabilization, patients recovering from high-risk PE can be switched from parenteral to oral anticoagulation. As patients belonging to this risk category were excluded from the phase III NOAC trials, the optimal time point for this transition has not been determined by existing evi- dence but should instead be based on clinical judgement. The specifi- cations concerning the higher initial dose of apixaban or rivaroxaban (for 1 and 3 weeks after PE diagnosis, respectively), or the minimum overall period (5 days) of heparin anticoagulation before switching to dabigatran or edoxaban, must be followed (see Supplementary Data Table 8 for tested and approved regimens). 7.2.2 Treatment of intermediate-risk pulmonary embolism For most cases of acute PE without haemodynamic compromise, parenteral or oral anticoagulation (without reperfusion techniques) is adequate treatment. As shown in Figure 6 , normotensive patients with at least one indicator of elevated PE-related risk, or with aggra- vating conditions or comorbidity, should be hospitalized. In this group, patients with signs of RV dysfunction on echocardiography or CTPA (graphically presented in Figure 3 ), accompanied by a positive troponin test, should be monitored over the first hours or days due to the risk of early haemodynamic decompensation and circulatory collapse. 179 Routine primary reperfusion treatment, notably full-dose systemic thrombolysis, is not recommended, as the risk of potentially life-threatening bleeding complications appears too high for the expected benefits from this treatment. 179 Rescue thrombolytic ther- apy or, alternatively, surgical embolectomy or percutaneous catheter-directed treatment should be reserved for patients who develop signs of haemodynamic instability. In the PEITHO trial, the mean time between randomization and death or haemodynamic decompensation was 1.79 ± 1.60 days in the placebo (heparin-only) arm. 179 Therefore, it appears reasonable to leave patients with inter- mediate-high-risk PE on LMWH anticoagulation over the first 2 - 3 days and ensure that they remain stable before switching to oral anti- coagulation. As mentioned in the previous section, the specifications concerning the increased initial dose of apixaban or rivaroxaban, or the minimum overall period of heparin anticoagulation before switch- ing to dabigatran or edoxaban, must be followed. Suggestions for the anticoagulation and overall management of acute PE in specific clinical situations, for which conclusive evidence is lacking, are presented in Supplementary Data Table 9 . 7.2.3 Management of low-risk pulmonary embolism: tri- age for early discharge and home treatment As a general rule, early discharge of a patient with acute PE and con- tinuation of anticoagulant treatment at home should be considered if three sets of criteria are fulfilled: (i) the risk of early PE-related death or serious complications is low ( section 5 ); (ii) there is no serious comorbidity or aggravating condition(s) (see section 5 ) that would mandate hospitalization; and (iii) proper outpatient care and anticoa- gulant treatment can be provided, considering the patient’s (antici- pated) compliance, and the possibilities offered by the healthcare system and social infrastructure. Randomized trials and prospective management cohort studies that investigated the feasibility and safety of early discharge, and home treatment, of PE adhered to these principles, even though 30 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    "©ESC 2019 Figure 6 Central Illustration. Risk-adjusted management strategy for acute pulmonary embolism. CTPA = computed tomography pulmonary angiography/angiogram; PE = pulmonary embolism; PESI = Pulmonary Embolism Severity Index; RV = right ventricular; sPESI = simplified Pulmonary Embolism Severity Index; TTE = transthoracic echocardiogram. a See also emergency management algorithm shown in the online Supplementary Data. b Refer to Table 8 for definition of high, intermediate-high-, intermediate-low-, and low-risk PE. c Cancer, heart failure and chronic lung disease are included in the PESI and sPESI ( Table 7 ). d See Supplementary Data Table 12 for the Hestia criteria. e Prognostically relevant imaging (TTE or CTPA) findings in patients with acute PE, are graphically presented in Figure 3 . f A cardiac troponin test may already have been performed during initial diagnostic work-up. g Included in the Hestia criteria. ESC Guidelines 31 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . slightly different criteria or combinations thereof were used to ensure the above three requirements. The Hestia exclusion criteria (Supplementary Data Table 12 ) represent a checklist of clinical parameters or questions that can be obtained/answered at the bedside. They integrate aspects of PE severity, comorbidity, and the feasibility of home treatment. If the answer to one or more of the questions is ‘yes’, then the patient cannot be discharged early. In a single-arm management trial that used these criteria to select candidates for home treat- ment, the 3 month rate of recurrent VTE was 2.0% (0.8 \u0002 4.3%) in patients with acute PE who were discharged within 24 h. 317 In a subsequent non-inferiority trial that randomized 550 patients to direct discharge based on the Hestia criteria alone vs. additional NT-proBNP testing and discharge if levels were < _500 pg/mL, the primary outcome (30 day PE- or bleeding-related mortality, cardi- opulmonary resuscitation, or admission to an intensive care unit) was very low in both arms. The results suggest no incremental value of natriuretic-peptide testing in patients who are eligible for home treatment based on the Hestia criteria, although the study was not powered to exclude this possibility. 318 The PESI and its simplified form, the sPESI ( Table 7 ), also integrate clinical parameters of PE severity and comorbidity to permit assess- ment of overall 30 day mortality. Compared with the Hestia criteria, the PESI is more standardized, but it contains a less-comprehensive list of aggravating conditions; moreover, the sPESI excludes all patients with cancer from the low-risk category (compare Table 7 with Supplementary Data Table 12 ). The PESI was not primarily developed as a tool to select candidates for home treatment, but it has been used—in combination with additional feasibility criteria—in a trial of 344 patients randomized to inpatient vs. outpatient treat- ment of PE. 178 One (0.6%) patient in each treatment group died within 90 days. 178 In patients who were included in prospective cohort studies and treated at home, with or without a short hospitalization period, the 3 month rates of thromboembolic recurrence, major bleeding, and death were 1.75, 1.43, and 2.83%, respectively. 327 In summary, the currently available evidence indicates that both the Hestia rule and the PESI or sPESI appear capable of reliably identi- fying patients who are (i) at low PE-related risk, and (ii) free of serious comorbidity. Consequently, either may be used for clinical triage according to local experience and preference. If a PESI- or sPESI- based approach is chosen, it must be combined with assessment of the feasibility of early discharge and home treatment; this assessment is already integrated into the Hestia criteria. A more difficult decision related to immediate or early dis- charge is whether the exclusion of intermediate-risk PE on clinical grounds alone is adequate, or whether the assessment of RV dys- function or myocardial injury (see section 5 ) by an imaging test or a laboratory biomarker is necessary to provide maximal safety for the patient in this ‘vulnerable’ early period. A systematic review and meta-analysis of cohort studies suggested that the prognostic sensitivity is increased further when clinical criteria (e.g. PESI or sPESI) are combined with imaging findings, or laboratory bio- marker levels. 234 A multicentre prospective management trial tested this hypothesis, investigating the efficacy and safety of early discharge, and ambulatory rivaroxaban treatment, in patients selected by clinical criteria and an absence of RV dysfunction. Overall, \u0018 20% of the screened unselected patients with PE were included. At the predefined interim analysis of 525 patients (50% of the planned population), the 3 month rate of symptomatic or fatal recurrent VTE was 0.6% (one-sided upper 99.6% CI 2.1%), permitting the early rejection of the null hypothesis and termina- tion of the trial. Major bleeding occurred in six (1.2%) of the patients in the safety population. There were no PE-related deaths. 319 In view of the existing evidence—and taking into con- sideration (i) the catastrophic scenario of early death if a patient with acute PE is falsely judged to be at low risk on clinical grounds alone and discharged ‘too early’ (as described in a prematurely terminated trial 328 ), and (ii) the ease and minimal additional effort of assessing RV size and function at presentation by echocardiog- raphy, or on the CTPA performed to diagnose the PE event itself 329 ( section 5 )—it is wise to exclude RV dysfunction and right heart thrombi if immediate or early (within the first 24 \u0002 48 h) dis- charge of the patient is planned. 8 Chronic treatment and prevention of recurrence The aim of anticoagulation after acute PE is to complete the treat- ment of the acute episode and prevent recurrence of VTE over the long-term. Current drugs and regimens for the initial phase, and the first months of anticoagulant treatment, are described in section 6 . Most of the randomized studies focusing on long-term anticoagula- tion for VTE have included patients with DVT, with or without PE; only two randomized studies have specifically focused on patients with PE. 330,331 The incidence of recurrent VTE does not appear to depend on the clinical manifestation of the first event (i.e. it is similar after PE and after proximal DVT). However, in patients who have had a PE, VTE more frequently recurs as PE, while in patients who have had a DVT, it tends to recur more frequently as DVT. 332 As a consequence, the case fatality rate of recurrent VTE in patients who have previously had a PE is twice as high as that of VTE recurrence after DVT. 333,334 Landmark clinical trials have evaluated various durations of antico- agulant treatment with VKAs for VTE. 330,331,335 \u0002 337 The findings of these studies permit the following conclusions. First, all patients with PE should receive > _3 months of anticoagulant treatment. Second, after withdrawal of anticoagulant treatment, the risk of recurrence is expected to be similar if anticoagulants are stopped after 3 \u0002 6 months compared with longer treatment periods (e.g. 12 \u0002 24 months). Third, extended oral anticoagulant treatment reduces the risk for recurrent VTE by < _90%, but this benefit is partially offset by the risk of bleeding. Oral anticoagulants are highly effective in preventing recurrent VTE during treatment, but they do not eliminate the risk of subse- quent recurrence after the discontinuation of treatment. 330,331 Based on this fact on the one hand, and considering the bleeding risk of anticoagulation treatment on the other, the clinically important question is how to best select candidates for extended or indefinite anticoagulation. Involvement of the patient in the decision-making process is crucial to optimize and maintain treat- ment adherence. 32 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8.1 Assessment of venous thromboembolism recurrence risk The risk for recurrent VTE after discontinuation of treatment is related to the features of the index PE (or, in the broader sense, VTE) event. A study, which followed patients after a first episode of acute PE, found that the recurrence rate after discontinuation of treatment was \u0018 2.5% per year after PE associated with transient risk factors, compared with 4.5% per year after PE occurring in the absence of known cancer, known thrombophilia, or any transient risk factor. 331 Similar observations were made in other prospective stud- ies in patients with DVT. 337 Advancing the concept further, random- ized anticoagulation trials over the past 15 years, which have focused on secondary VTE prevention, have classified patients into distinct groups based on their risk of VTE recurrence after discontinuation of anticoagulant treatment. In general, these groups are: (i) patients in whom a strong (major) transient or reversible risk factor, most com- monly major surgery or trauma, can be identified as being responsible for the acute (index) episode; (ii) patients in whom the index episode might be partly explained by the presence of a weak (minor) transient or reversible risk factor, or if a non-malignant risk factor for thrombo- sis persists; (iii) patients in whom the index episode occurred in the absence of any identifiable risk factor (the present Guidelines avoid terms such as ‘unprovoked’ or ‘idiopathic’ VTE); (iv) patients with one or more previous episodes of VTE, and those with a major persistent pro-thrombotic condition such as antiphospholipid antibody syn- drome; and (v) patients with active cancer. 338 Table 11 shows examples of transient/reversible and persistent risk factors for VTE, classified by the risk of long-term recurrence. As active cancer is a major risk factor for recurrence of VTE, but also for bleeding while on anticoagulant treatment, 339 section 8.4 is specifically dedicated to the management of PE in patients with cancer. Overall, assessment of the VTE recurrence risk after acute PE, in the absence of a major transient or reversible risk factor, is a complex issue. Beyond the examples listed in Table 11 , patients who are car- riers of some forms of hereditary thrombophilia, notably those with confirmed deficiency of antithrombin, protein C, or protein S, and patients with homozygous factor V Leiden or homozygous pro- thrombin G20210A mutation, are often candidates for indefinite anti- coagulant treatment after a first episode of PE occurring in the absence of a major reversible risk factor. In view of these possible implications, testing for thrombophilia (including antiphospholipid Table 11 Categorization of risk factors for venous thromboembolism based on the risk of recurrence over the long- term Estimated risk for long-term recurrence a Risk factor category for index PE b Examples b Low (<3% per year) Major transient or reversible factors associated with >10-fold increased risk for the index VTE event (compared to patients without the risk factor) • Surgery with general anaesthesia for >30 min to bed in hospital (only “bathroom privileges”) for ≥ 3 days due to an acute illness, or acute exacerbation of a chronic illness • Trauma with fractures Intermediate (3–8% per year) Transient or reversible factors associated with ≤ 10-fold increased risk for (index) VTE • Minor surgery (general anaesthesia for < 30 min) • Admission to hospital for < 3 days with an acute illness • Oestrogen therapy/contraception • Pregnancy or puerperium to bed out of hospital for ≥ 3 days with an acute illness • Leg injury (without fracture) associated with reduced mobility for ≥ 3 days • Long-haul Non-malignant persistent risk factors bowel disease • Active autoimmune disease No risk factor High ( > 8% per year) • Active cancer • One or more previous episodes of VTE in the absence of a major transient or reversible factor • Antiphospholipid antibody syndrome ©ESC 2019 PE = pulmonary embolism; VTE = venous thromboembolism. a If anticoagulation is discontinued after the first 3 months (based on data from Baglin et al. 340 and Iorio et al. 341 ). b The categorization of risk factors for the index VTE event is in line with that proposed by the International Society on Thrombosis and Haemostasis. 338 The present Guidelines avoid terms such as ‘provoked’, ‘unprovoked’, or ‘idiopathic’ VTE. ESC Guidelines 33 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . antibodies and lupus anticoagulant) 342 may be considered in patients in whom VTE occurs at a young age (e.g. aged <50 years) and in the absence of an otherwise identifiable risk factor, especially when this occurs against the background of a strong family history of VTE. In such cases, testing may help to tailor the regimen and dose of the anticoagulant agent over the long-term. On the other hand, no evi- dence of a clinical benefit of extended anticoagulant treatment is cur- rently available for carriers of heterozygous factor V Leiden or prothrombin 20210A mutation. A number of risk prediction models have been developed for the assessment of the risk of recurrence in an individual patient (Supplementary Data Table 13 ). 343,344 The clinical value and, in partic- ular, the possible therapeutic implications of these models in the NOAC era are unclear. 8.2 Anticoagulant-related bleeding risk Incidence estimates from cohort studies conducted more than 15 years ago reported an \u0018 3% annual incidence of major bleeding in patients treated with VKAs. 345 Meta-analyses of phase III studies focusing on the first 3 - 12 months of anticoagulant treatment showed an \u0018 40% reduction in the risk for major bleeding with NOACs com- pared with VKAs. 346 The risk of major bleeding is higher in the first month of anticoagulant treatment, and then declines and remains sta- ble over time. Based on currently available evidence, risk factors include: (i) advanced age (particularly >75 years); (ii) previous bleed- ing (if not associated with a reversible or treatable cause) or anaemia; (iii) active cancer; (iv) previous stroke, either haemorrhagic or ischae- mic; (v) chronic renal or hepatic disease; (vi) concomitant antiplatelet therapy or non-steroidal anti-inflammatory drugs (to be avoided, if possible); (vii) other serious acute or chronic illness; and (viii) poor anticoagulation control. Existing bleeding risk scores and their current validation status are reviewed in Supplementary Data Table 14 . The patient’s bleed- ing risk should be assessed, either by implicit judgement after eval- uating individual risk factors or by the use of a bleeding risk score, at the time of initiation of anticoagulant treatment. It should be reassessed periodically (e.g. once a year in patients at low risk, and every 3 or 6 months in patients at high risk for bleeding). Bleeding risk assessment should be used to identify and treat modifiable bleeding risk factors, and it may influence decision-making on the duration and regimen/dose of anticoagulant treatment after acute PE. 8.3 Regimens and treatment durations with non-vitamin K antagonist oral anti- coagulants, and with other non-vitamin K antagonist antithrombotic drugs All patients with PE should be treated with anticoagulants for > _3 months. 347 Beyond this period, the balance between the risk of VTE recurrence and that of bleeding, which has been used to select candidates for extended anticoagulation after a first VTE event in the VKA era, is currently being revisited based on the lower bleeding rates with NOACs. However, despite the improved safety of these drugs compared with VKAs, treatment with NOACs is not without risk. Phase III clinical trials on the extended treatment of VTE have shown that the rate of major bleeding may be \u0018 1%, and that of clinically relevant non-major (CRNM) bleeding as high as 6%. Bleeding rates may be higher in everyday clinical practice. 348,349 The NOAC trials that focused on extended VTE treatment are summarized in Supplementary Data Table 15 . In all studies, patients with PE made up approximately one-third of the entire study popula- tion, while the remaining two-thirds were patients with proximal DVT but no clinically overt PE. Patients needed to have completed the initial and long-term anticoagulation phase to be included in the extended studies. Dabigatran was compared with warfarin or placebo in two differ- ent studies (Supplementary Data Table 15 ). 350 In these studies, dabi- gatran was non-inferior to warfarin for the prevention of confirmed recurrent symptomatic VTE or VTE-related death, and more effec- tive than placebo for the prevention of symptomatic recurrent VTE or unexplained death. 350 The rate of major bleeding was 0.9% with dabigatran compared to 1.8% with warfarin (HR 0.52, 95% CI 0.27 \u0002 1.02). 350 Rivaroxaban was compared with placebo or aspirin in two differ- ent studies in patients who had completed 6 \u0002 12 months of anticoa- gulation treatment for a first VTE event (Supplementary Data Table 15 ). Treatment with rivaroxaban [20 mg once a day (o.d.)] reduced recurrent VTE by \u0018 80%, with a 6.0% incidence of major or CRNM bleeding as compared to 1.2% with placebo. 351 Rivaroxaban given at a dose of 20 or 10 mg o.d. was compared with aspirin (100 mg o.d.) in 3365 patients. 352 Both doses of rivaroxaban reduced symptomatic recurrent fatal or non-fatal VTE by \u0018 70% in compari- son with aspirin. No significant differences in the rates of major or CRNM bleeding were shown between either dose of rivaroxaban and aspirin. 352 Patients with VTE were randomized to receive two different doses of apixaban [2.5 or 5 mg twice a day (bis in die: b.i.d.)] or placebo after 6 \u0002 12 months of initial anticoagulation (Supplementary Data Table 15 ). 353 Both doses of apixaban reduced the incidence of symp- tomatic recurrent VTE or death from any cause compared with pla- cebo, with no safety concerns. 353 Patients at high bleeding risk—based on the investigator’s judge- ment, the patient’s medical history, and the results of laboratory examinations—were excluded from the extension studies men- tioned above; this was also the case for studies on extended anticoa- gulation with VKAs. 330,331 This fact should be taken into account during triage of a patient for extended anticoagulation with one of the above regimens. In a randomized, open-label study in high-risk patients with antiphospholipid syndrome (testing triple positive for lupus anticoa- gulant, anticardiolipin, and anti- b 2-glycoprotein I), rivaroxaban was associated with an increased rate of thromboembolic and major bleeding events compared with warfarin (HR for the compo- site primary outcome 6.7; 95% CI 1.5 \u0002 30.5). 354 At present, NOACs are not an alternative to VKAs for patients with antiphospholipid syndrome. In two trials with a total of 1224 patients, extended therapy with aspirin (after termination of standard oral anticoagulation) was 34 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . associated with a 30 \u0002 35% reduction in the risk of recurrence com- pared with placebo (Supplementary Data Table 15 ). 355,356 However, more recently, another trial demonstrated the superiority of anticoa- gulation with rivaroxaban, either 20 or 10 mg o.d., over aspirin for secondary prophylaxis of VTE recurrence. 352 A randomized, placebo controlled study evaluated sulodexide (2 \u0004 250 lipasemic unit capsules b.i.d.) for the prevention of recurrence in 615 patients with a first VTE event without an identifiable risk fac- tor, who had completed 3 \u0002 12 months of oral anticoagulant treat- ment (Supplementary Data Table 15 ). 357 Sulodexide reduced the risk of recurrence by \u0018 50% with no apparent increase in bleeding events. However, only 8% of patients in this study had PE as the index VTE event. 357 8.4 Recommendations for the regimen and duration of anticoagulation after pulmonary embolism in patients without cancer Recommendations Class a Level b Therapeutic anticoagulation for > _ 3 months is recommended for all patients with PE. 347 I A Patients in whom discontinuation of anticoagulation after 3 months is recommended For patients with first PE/VTE secondary to a major transient/reversible risk factor, discontinuation of therapeutic oral anticoagulation is recommended after 3 months. 331,340,341 I B Patients in whom extension of anticoagulation beyond 3 months is recommended Oral anticoagulant treatment of indefinite duration is recommended for patients presenting with recurrent VTE (that is, with at least one previous episode of PE or DVT) not related to a major transient or reversible risk factor. 358 I B Oral anticoagulant treatment with a VKA for an indefinite period is recommended for patients with antiphospholipid anti- body syndrome. 359 I B Patients in whom extension of anticoagulation beyond 3 months should be considered c,d Extended oral anticoagulation of indefinite duration should be considered for patients with a first episode of PE and no identifiable risk factor. 330,331,347,351 \u0002 353 IIa A Extended oral anticoagulation of indefinite duration should be considered for patients with a first episode of PE associated with a persistent risk factor other than antiphospholipid antibody syndrome. 330,352,353 IIa C Extended oral anticoagulation of indefinite duration should be considered for patients with a first episode of PE associated with a minor transient or reversible risk factor. 330,331,352 IIa C NOAC dose in extended anticoagulation e If extended oral anticoagulation is decided after PE in a patient without cancer, a reduced dose of the NOACs apixaban (2.5 mg b.i.d.) or rivaroxaban (10 mg o.d.) should be considered after 6 months of therapeutic anticoagulation. 352,353 IIa A Extended treatment with alternative antithrombotic agents In patients who refuse to take or are unable to tolerate any form of oral anticoagulants, aspirin or sulodexide may be con- sidered for extended VTE prophylaxis. 355 \u0002 357 IIb B Follow-up of the patient under anticoagulation In patients who receive extended anticoagulation, it is recommended that their drug tolerance and adherence, hepatic and renal f function, and bleeding risk be reassessed at regular intervals. 259 I C b.i.d. = bis in die (twice a day); DVT = deep vein thrombosis; NOAC(s) = non-vitamin K antagonist oral anticoagulant(s); o.d. = omni die (once a day); PE = pulmonary embo- lism; VKA = vitamin K antagonist; VTE = venous thromboembolism. a Class of recommendation. b Level of evidence. c The patient’s bleeding risk should be assessed (see Supplementary Data Table 14 for prediction models) to identify and treat modifiable bleeding risk factors, and it may influ- ence decision-making on the duration and regimen/dose of anticoagulant treatment. d Refer to Supplementary Data Table 9 for therapeutic decisions in specific clinical situations. e If dabigatran or edoxaban is chosen for extended anticoagulation after PE, the dose should remain unchanged, as reduced-dose regimens were not investigated in dedicated extension trials. 313,350 f Especially for patients receiving NOACs. ESC Guidelines 35 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8.5 Management of pulmonary embolism in patients with cancer Five RCTs compared LMWH vs. conventional VTE treatment (hepa- rin followed by VKA) in the treatment of VTE in cancer-associated thrombosis. 360 \u0002 364 In 2003, a significant reduction in VTE recurrence was reported with LMWH compared with conventional (VKA) treat- ment without an increase in bleeding complications. 362 In a more recent trial, long-term administration of tinzaparin failed to achieve a statistically significant reduction in overall VTE recurrence over con- ventional treatment (HR 0.65, 95% CI 0.41 \u0002 1.03); however, the overall rate of recurrent VTE in the control arm was lower than that previously observed, probably as a result of the recruitment of patients with a lower cancer-specific thrombotic risk. 360 Overall, LMWHs were found to decrease the risk of recurrent VTE by 40% with a risk of major bleeding complications similar to that of VKAs. 365 Accordingly, LMWHs have become the standard of care. However, these agents are associated with a relevant cost and burden for patients. In addition, the absolute rate of recurrent VTE while on LMWH remains high (7 \u0002 9%) compared with that observed in non- cancer patients with VTE on conventional treatment (1.5 \u0002 3%). 365 NOACs could make the treatment of VTE easier and more con- venient in patients with cancer, due to their oral administration in fixed-dose regimens and their lower cost compared with LMWH. However, only 3 \u0002 9% of patients included in phase III studies with NOACs for the treatment of VTE had concomitant can- cer. 260,261,312,314,351 A randomized, open-label trial compared edoxa- ban with LMWH in the secondary prevention of VTE in 1050 patients with cancer-associated thrombosis (mostly symptomatic or asymptomatic PE). 366 Edoxaban (60 mg o.d., reduced to 30 mg in sub- jects with moderate renal impairment, low body weight, or concomi- tant need for strong inhibitors of glycoprotein-P) was started after 5 days of LMWH and treatment was given for > _6 months. Edoxaban was non-inferior to dalteparin in the prevention of VTE recurrence or major bleeding over 12 months after randomization (HR 0.97, 95% CI 0.70 \u0002 1.36). Major bleeding occurred in 6.9% of the patients in the edoxaban arm and 4.0% in the dalteparin arm (difference in risk 2.9 percentage points, 95% CI 0.1 \u0002 5.6). This difference appears to have been mainly accounted for by the high rate of bleeding in patients with gastrointestinal cancer allocated to the edoxaban group. 366 Similar results were reported by a randomized, open-label pilot trial comparing rivaroxaban with dalteparin in 406 patients with VTE and cancer, 58% of whom had metastases. 367 A significant decrease in the risk of recurrent VTE was observed with rivaroxaban (HR 0.43, 95% CI 0.19 \u0002 0.99). The 6 month cumulative rate of major bleeding, which was mostly gastrointestinal, was 6% (95% CI 3 \u0002 11%) for rivaroxaban and 4% (95% CI 2 \u0002 8%) for dalteparin (HR 1.83, 95% CI 0.68 \u0002 4.96). Corresponding rates of CRNM bleeds were 13% (95% CI 9 \u0002 19%) and 4% (95% CI 2 \u0002 9%), respectively (HR 3.76, 95% CI 1.63 \u0002 8.69). 367 Based on the currently available evidence, as described above, patients with acute PE and cancer, particularly those with gastrointes- tinal cancer, should be encouraged to continue LMWH for > _ 3 \u0002 6 months. This also applies to patients in whom oral treatment is unfea- sible due to problems of intake or absorption, and to those with severe renal impairment. In all other cases, especially in patients with an anticipated low risk of bleeding and without gastrointestinal tumours, the choice between LMWH and edoxaban or rivaroxaban is left to the discretion of the physician, and the patient’s preference. Owing to the high risk for recurrence, patients with cancer should receive indefinite anticoagulation after a first episode of VTE. Although existing evidence is limited, it is conceivable that once can- cer is cured the risk for recurrence decreases and anticoagulation can be stopped. However, the definition of cured cancer is not always clear. The risk of recurrence of PE in cancer was assessed in a cohort study of 543 patients and was validated in an independent set of 819 patients. 368 The proposed score to predict the risk of recurrence included breast cancer (minus 1 point), Tumour Node Metastasis stage I or II (minus 1 point), and female sex, lung cancer, and previous VTE (plus 1 point each). Patients with a score < _0 were at low risk (< _4.5%) and those with a score > _1 were at high (> _19%) risk of VTE recurrence over the first 6 months. 368 After the first 3 \u0002 6 months, extended anticoagulation may consist of continuation of LMWH or transition to an oral anticoagulant. Two cohort studies have assessed the safety of extended treatment with LMWH (< _12 months) in cancer-associated thrombosis. 369,370 In both studies, the incidence of bleeding complications was higher in the first months and then reached a plateau that remained unchanged after the sixth month. In the absence of conclusive evidence, the deci- sion to continue with LMWH or to change to VKA or a NOAC should be made on a case-by-case basis after consideration of the success of anticancer therapy, the estimated risk of recurrence of VTE, the bleeding risk, and the preference of the patient. Periodic reassessment of the risk-to-benefit ratio of continued anticoagulant treatment is mandatory. As mentioned in section 5 , venous filters are principally indicated when anticoagulation is impossible due to active haemorrhage or an excessive bleeding risk. However, the risk of VTE recurrence in the absence of anticoagulation is particularly high in patients with cancer, and the insertion of a filter should not delay the initiation of anticoa- gulation as soon as it is safe to do so. There is no evidence to support the use of venous filters as an adjunct to anticoagulation treatment in patients with cancer. A number of studies have reported that a proportion of patients presenting with PE in the absence of identifiable risk factors develop cancer within the first year after diagnosis. 371 Consequently, the opti- mal strategy to achieve early diagnosis of these occult cancers was investigated. Two large randomized trials failed to show that compre- hensive CT of the abdomen or 18 F deoxy-fluoro-glucose positron emission tomography were able to detect more cancers than limited screening in patients with an unprovoked VTE. 372,373 Therefore, based on current evidence, the search for occult cancer after an epi- sode of VTE may be restricted to careful history taking, physical examination, basic laboratory tests, and a chest X-ray (if no CTPA was performed to diagnose PE). 372,374,375 In patients with cancer, incidental PE should be managed in the same manner as symptomatic PE, whether it involves segmental or more proximal branches, multiple subsegmental vessels, or a single subsegmental vessel in association with detectable DVT. 376,377 36 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Pulmonary embolism and pregnancy 9.1 Epidemiology and risk factors for pulmonary embolism in pregnancy Acute PE remains one of the leading causes of maternal death in high-income countries. 379,380 For example, in the UK and Ireland, thrombosis and thromboembolism were the most common causes of direct maternal death (death resulting from the preg- nancy rather than pre-existing conditions) in the triennium 2013 \u0002 15, resulting in 1.13 mortalities per 100 000 maternities (https://www.npeu.ox.ac.uk/mbrrace-uk). VTE risk is higher in pregnant women compared with non-pregnant women of similar age; it increases during pregnancy and reaches a peak during the post-partum period. 381 The baseline pregnancy-related risk increases further in the presence of additional VTE risk fac- tors, including in vitro fertilization: in a cross-sectional study derived from a Swedish registry, the HR for VTE following in vitro fertilization was 1.77 (95% CI 1.41 \u0002 2.23) overall and 4.22 (95% CI 2.46 \u0002 7.20) during the first trimester. 382 Other important and common risk factors include prior VTE, obesity, medical comor- bidities, stillbirth, pre-eclampsia, post-partum haemorrhage, and caesarean section; documented risk assessment is therefore essential. 383 The recommendations provided in these Guidelines are in line with those included in the 2018 ESC Guidelines on the management of cardiovascular diseases during pregnancy. 384 9.2 Diagnosis of pulmonary embolism in pregnancy 9.2.1 Clinical prediction rules and D-dimers Diagnosis of PE during pregnancy can be challenging as symptoms frequently overlap with those of normal pregnancy. The overall prevalence of confirmed PE is low among women investigated for the disease, between 2 and 7%. 385 \u0002 388 D-dimer levels continu- ously increase during pregnancy, 389,390 and levels are above the threshold for VTE ‘rule-out’ in almost one-quarter of pregnant women in the third trimester. 390 The results of a multinational prospective management study of 441 pregnant women present- ing to emergency departments with clinically suspected PE sug- gest that a diagnostic strategy \u0002 based on the assessment of clinical probability, D-dimer measurement, CUS, and CTPA \u0002 may safely exclude PE in pregnancy. 388 In that study, PE exclusion on the basis of a negative D-dimer result (without imaging) was possible in 11.7% of the 392 women with a non-high pre-test probability (Geneva) score, a rate that was reduced to 4.2% in the third trimester. 388 A further prospective management study evaluated a combination of a pregnancy-adapted YEARS algorithm with D-dimer levels in 498 women with suspected PE during pregnancy. PE was ruled out without CTPA in women deemed to be at low PE risk according to the combination of the algorithm and D-dimer results. At 3 months, only one woman with PE excluded on the basis of the algorithm developed a popli- teal DVT (0.21%, 95% CI 0.04 \u0002 1.2) and no women developed PE. 391 9.2.2 Imaging tests A proposed algorithm for the investigation of suspected PE in women who are pregnant, or < _6 weeks post-partum, is shown in Figure 7 . Both maternal and foetal radiation exposure are low using modern imaging techniques ( Table 12 ). 385,392 \u0002 398 For V/Q scans and CTPA, foetal radiation doses are well below the threshold associated with foetal radiation complications (which is 50 \u0002 100 mSv). 399,400 In the past, CTPA has been reported to cause high radiation exposure to the breast; 395,401 however, CT technology has evolved, and several techniques can now reduce radiation exposure without compromising image quality. These 8.6 Recommendations for the regimen and the duration of anticoagulation after pulmonary embolism in patients with active cancer Recommendations Class a Level b For patients with PE and cancer, weight-adjusted subcutaneous LMWH should be considered for the first 6 months over VKAs. 360 \u0002 363 IIa A Edoxaban should be considered as an alternative to weight-adjusted subcutaneous LMWH in patients without gastrointes- tinal cancer. 366 IIa B Rivaroxaban should be considered as an alternative to weight-adjusted subcutaneous LMWH in patients without gastroin- testinal cancer. 367 IIa C For patients with PE and cancer, extended anticoagulation (beyond the first 6 months) c should be considered for an indef- inite period or until the cancer is cured. 378 IIa B In patients with cancer, management of incidental PE in the same manner as symptomatic PE should be considered, if it involves segmental or more proximal branches, multiple subsegmental vessels, or a single subsegmental vessel in associa- tion with proven DVT. 376,377 IIa B DVT = deep vein thrombosis; LMWH = low-molecular weight heparin; PE = pulmonary embolism; VKAs = vitamin K antagonists. a Class of recommendation. b Level of evidence. c Refer to Supplementary Data Table 9 for further guidance on therapeutic decisions after the first 6 months. ESC Guidelines 37 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . include reducing the anatomical coverage of the scan, 393 reducing the kilovoltage, using iterative reconstructive techniques, and reducing the contrast-monitoring component of the CTPA. 392,393 Modern CTPA imaging techniques may therefore expose the maternal breast to median doses as low as 3 \u0002 4 mGy ( Table 12 ). 392 The effect on maternal cancer risk with modern CTPA techniques is negligible (lifetime cancer risk is reportedly increased by a factor of 1.0003 \u0002 1.0007); avoiding CTPA on the grounds of maternal cancer risk is therefore not justified. 394 A normal perfusion scan and a negative CTPA appear equally safe for ruling out PE in pregnancy, as suggested by retrospective series. 385,386,402 \u0002 404 Inconclusive results can be a problem (4 \u0002 33% of investigations), 385,386,405 especially late in preg- nancy. 405 A recent survey of 24 sites in the UK, representing a population of 15.5 million, revealed a similar rate of inadequate or indeterminate CTPA and scintigraphy scans, suggesting that the initial choice of imaging is best determined by local expertise and resources. 406 V/Q SPECT is associated with low foetal and maternal radiation exposure, and has promise in PE diagnosis in pregnancy. 407 However, © ESC 2019 Negative Indeterminate or positive Proximal DVT not present SUSPECTED PE DURING PREGNANCY High pretest probability, or intermediate/low probability and positive D-dimer result Anticoagulate with LMWH SPECIFIC INVESTIGATION FOR PE • If chest X-ray normal => CTPA or perfusion lung scan • If chest X-ray abnormal a => CTPA c • Chest X-ray a • Compression proximal duplex ultrasound, if symptoms or signs suggestive of DVT b Review by radiologist or nuclear physician experienced in diagnosis of PE in pregnancy PE ruled out Negative Proximal DVT present Positive • Continue with LMWH at therapeutic dose d • Assess PE severity and the risk of early death e • Refer to multidisciplinary team with experience of PE management in pregnancy • Provide plan to guide management of pregnancy, labour and delivery, postnatal and future care Figure 7 Diagnostic workup and management of suspected pulmonary embolism during pregnancy, and up to 6 weeks post-partum. CTPA = computed tomography pulmonary angiography; CUS = compression ultrasonography; DVT = deep vein thrombosis; LMWH = low-molecular- weight heparin; PE = pulmonary embolism. a If chest X-ray abnormal, consider also alternative cause of chest symptoms. b DVT in pelvic veins may not be ruled out by CUS. If the entire leg is swollen, or there is buttock pain or other symptoms suggestive of pelvic thrombosis, consider magnetic resonance venography to rule out DVT. c CTPA technique must ensure very low foetal radiation exposure (see Table 12 ). d Perform full blood count (to measure haemoglobin and platelet count) and calculate creatinine clearance before administration. Assess bleeding risk and ensure absence of contra-indications. e See Table 8 . 38 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . further evaluation of this technique is required before its widespread incorporation into diagnostic algorithms. For MRA, the long-term effects of gadolinium contrast on the foetus are not known. In non- pregnant patients, technically inadequate images are frequently obtained and the rate of inconclusive scan results is high. 140 Therefore, use of this technique for diagnosing or ruling out PE during pregnancy cannot be recommended at present. Conventional pul- monary angiography involves significantly higher radiation exposure of the foetus (2.2 \u0002 3.7 mSv) and should be avoided during pregnancy. 400 Overdiagnosis of PE is a potential pitfall that can have significant, lifelong implications for a pregnant woman, including the risk of bleeding at the time of delivery, the withholding of oestrogen contra- ception, and the requirement for thromboprophylaxis during future pregnancies. Consequently, avoiding PE overdiagnosis in pregnancy is as important as not missing a PE diagnosis. 9.3 Treatment of pulmonary embolism in pregnancy LMWH is the treatment of choice for PE during pregnancy. 384 In con- trast to VKAs and NOACs, LMWH does not cross the placenta, and consequently does not confer a risk of foetal haemorrhage or terato- genicity. Moreover, while UFH is also safe in pregnancy, LMWH has more predictable pharmacokinetics and a more favourable risk profile. 408 \u0002 411 Although no RCT has evaluated the optimal dose of LMWH for the treatment of PE during pregnancy, currently pub- lished data favour similar dosing to non-pregnant patients, either with o.d. or b.i.d. regimens based on early pregnancy weight. 408,410 For the majority of patients receiving LMWH treatment for PE during preg- nancy, 412,413 it remains uncertain whether using serial measurements of plasma anti-activated coagulation factor X activity to guide dosing may be of clinical benefit. It is important to bear in mind that: (i) LMWH has a predictable pharmacokinetic profile, (ii) data on optimal anti-activated coagulation factor levels are lacking, and (iii) the assay itself has limitations. 414 In addition, there are no solid data on the clin- ical benefit vs. harm of frequent, weight-based dose adjustments of LMWH during pregnancy. Thus, anti-activated coagulation factor X monitoring may be reserved for specific high-risk circumstances such as recurrent VTE, renal impairment, and extremes of body weight. The use of UFH has been associated with heparin-induced throm- bocytopenia and bone loss. It remains uncertain whether, and to what extent, the risk of bone loss is increased with LMWH use. In a recent observational cohort study, in which bone mineral density was measured by dual-energy X-ray absorptiometry 4 \u0002 7 years after the last delivery in 152 women (92 of whom received prolonged LMWH during pregnancy), lumbar spine bone mineral density was similar in LWMH-treated women and controls following adjustment for potential confounders. No osteoporosis or osteoporotic frac- tures were reported. 415 Fondaparinux may be considered if there is an allergy or adverse response to LMWH, although solid data are lacking and minor trans- placental passage has been demonstrated. 416 VKAs cross the placenta and are associated with a well-defined embryopathy during the first trimester. Administration of VKAs in the third trimester can result in foetal and neonatal haemorrhage, as well as placental abruption. Warfarin may be associated with central nervous system anomalies in the foetus throughout pregnancy. NOACs are contraindicated in pregnant patients. 417 The management of labour and delivery requires particular atten- tion. In women receiving therapeutic LMWH, strong consideration should be given to planned delivery in collaboration with the multidisci- plinary team to avoid the risk of spontaneous labour while fully antico- agulated. The incidence of spinal haematoma after regional anaesthesia is unknown in pregnant women under anticoagulation treatment. If regional analgesia is considered for a woman receiving therapeutic LMWH, > _24 h should have elapsed since the last LMWH dose before insertion of a spinal or epidural needle (assuming normal renal function and including risk assessment at extremes of body weight). In high-risk situations, for example in patients with recent PE, it is recommended that LMWH be converted to UFH > _36 h prior to delivery. The UFH infusion should be stopped 4 - 6 h prior to antici- pated delivery and the activated partial thromboplastin time should be normal (i.e. not prolonged) prior to regional anaesthesia. 418 Data are limited on the optimal timing of post-partum reinitiation of LMWH. 419,420 Timing will depend upon the mode of delivery and an assessment of the thrombotic vs. bleeding risk by a multidiscipli- nary team. LMWH should not be given for > _4 h after removal of the epidural catheter; the decision on timing and dose should consider whether the epidural insertion was traumatic, and take into account the risk profile of the woman. For example, an interim dose of a pro- phylactic LMWH dose may be considered post-operatively (after caesarean section), once at least 4 h have elapsed since epidural cath- eter removal, and allowing for an interval of > _8 \u0002 12 h between the prophylactic and the next therapeutic dose. Close collaboration between the obstetrician, the anaesthesiologist, and the attending physician is recommended. Anticoagulant treatment should be administered for > _6 weeks after delivery and with a minimum overall treatment duration of 3 months. LMWH and warfarin can be given to breastfeeding mothers; the use of NOACs is not recommended. 417 Table 12 Estimated amounts of radiation absorbed in procedures used to diagnose pulmonary embolism (based on various references 385,392–398 ) Test Estimated foetal radiation exposure (mGy) a Estimated maternal radiation exposure to breast tissue (mGy) a Chest X-ray <0.01 <0.1 Perfusion lung scan with technetium-99m- labelled albumin Low dose: \u0018 40 MBq High dose: \u0018 200 MBq 0.02 \u0002 0.20 0.20 \u0002 0.60 0.16 \u0002 0.5 1.2 Ventilation lung scan 0.10 \u0002 0.30 <0.01 CTPA 0.05 \u0002 0.5 3 \u0002 10 CTPA = computed tomography pulmonary angiography; mGy = milligray; MBq = megabecquerel; PE = pulmonary embolism. a In this section, absorbed radiation dose is expressed in mGy to reflect the radia- tion exposure to single organs, or the foetus, as a result of various diagnostic techniques. Compare with Table 6 , in which effective radiation dose is expressed in millisieverts to reflect the effective doses of all organs that have been exposed. ESC Guidelines 39 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . High-risk, life-threatening PE during pregnancy is a rare, but poten- tially devastating, event. A recent systematic review included 127 cases of severe PE during pregnancy (and until 6 weeks post-partum) treated with thrombolysis, thrombectomy, and/or ECMO. 421 Both high- and intermediate-risk PE cases were included, and 23% of women experienced cardiac arrest. Reported survival rates were 94 and 86% following thrombolysis and surgical thrombectomy, respec- tively; however, these favourable rates may reflect reporting bias. Following thrombolysis, major bleeding occurred in 18 and 58% of cases during pregnancy and in the post-partum period, respec- tively. 421 Finally, foetal deaths occurred in 12 and 20% of the cases following thrombolysis and thrombectomy, respectively. 421 Thrombolytic treatment should not be used peri-partum, except in the setting of life-threatening PE. Typically, UFH is used in the acute treatment of high-risk PE. Although the indications for vena cava filters are similar to those for non-pregnant patients (discussed in section 6 ), there is limited experience with their use in pregnancy and the risk associated with the procedure may be increased. Suggestions for the anticoagulation management of PE in specific clinical situations (also) related to pregnancy, for which conclusive evidence is lacking, are presented in Supplementary Data Table 9 . 9.3.1 Role of a multidisciplinary pregnancy heart team A team of multidisciplinary colleagues should collaborate in the plan- ning of ante-, peri-, and post-partum care pathways for women with cardiovascular diseases, including PE. As many members as possible of this team should have expertise in the management of PE during pregnancy and the post-partum period. Jointly agreed, written care pathways should be available (if timelines permit) for effective com- munication (an example is shown in Figure 7 ). 9.4 Amniotic fluid embolism Amniotic fluid embolism (AFE) is a rare condition that occurs dur- ing pregnancy or shortly after delivery. It remains one of the leading causes of direct maternal death (i.e. death resulting from the preg- nancy rather than from pre-existing conditions) in high-income countries. 422 Diagnosis of AFE is challenging, being primarily a clini- cal diagnosis of exclusion. Awareness of AFE, prompt diagnosis, and aggressive life support are of critical importance. AFE is character- ized by unexplained sudden cardiovascular or respiratory deterio- ration, often accompanied by disseminated intravascular coagulation, 422 and occurring during pregnancy or after deliv- ery. 423,424 The reported incidence is approximately 2 \u0002 7 per 100 000 maternities, with a mortality rate of 0.5 \u0002 6 deaths per 100 000 deliveries. 422,425,426 Reported case fatality rates vary, reflecting the challenges in making the diagnosis and the rarity of AFE. In a retro- spective Californian study including more than 3.5 million deliveries, a case fatality rate of 13% was reported, as in other US and Canadian studies. 425 Similarly, a case fatality rate of 19% was reported in a recent prospective UK population-based study with validated case criteria. 422 Recent literature have suggested that risk factors for AFE may include pre-existing cardiac, cerebrovascular, and renal disorders, placenta previa, polyhydramnios, stillbirth, cho- rioamnionitis, hypertensive disorders, instrumental delivery, and caesarean section. 422,425 Management of AFE is supportive, and based on high-quality emergency care following the recognition and diagnosis of the condition, with prompt treatment of bleeding and coagulopathy. 423 Awareness of AFE should be integral to the education of involved physicians and to emergency algorithms. 9.5 Recommendations for pulmonary embolism in pregnancy Recommendations Class a Level b Diagnosis Formal diagnostic assessment with validated methods is recommended if PE is suspected dur- ing pregnancy or in the post-partum period. 388,391 I B D-dimer measurement and clinical prediction rules should be considered to rule out PE during pregnancy or the post-partum period. 388,391 IIa B In a pregnant patient with suspected PE (par- ticularly if she has symptoms of DVT), venous CUS should be considered to avoid unneces- sary irradiation. 388 IIa B Perfusion scintigraphy or CTPA (with a low-radi- ation dose protocol) should be considered to rule out suspected PE in pregnant women; CTPA should be considered as the first-line option if the chest X-ray is abnormal. 385,386 IIa C Treatment A therapeutic, fixed dose of LMWH based on early pregnancy body weight is the recom- mended therapy for PE in the majority of preg- nant women without haemodynamic instability. 408,410 I B Thrombolysis or surgical embolectomy should be considered for pregnant women with high- risk PE. 421 IIa C Insertion of a spinal or epidural needle is not rec- ommended, unless > _24 h have passed since the last therapeutic dose of LMWH. III C Administration of LMWH is not recom- mended within 4 h of removal of an epidural catheter. III C NOACs are not recommended during preg- nancy or lactation. III C Amniotic fluid embolism Amniotic fluid embolism should be considered in a pregnant or post-partum woman with otherwise unexplained cardiac arrest, sus- tained hypotension, or respiratory deteriora- tion, especially if accompanied by disseminated intravascular coagulation. 422,425,426 IIa C CTPA = computed tomography pulmonary angiography; CUS = compression ultraso- nography; DVT = deep vein thrombosis; LMWH = low-molecular weight heparin; NOACs = non-vitamin K antagonist oral anticoagulants; PE = pulmonary embolism. a Class of recommendation. b Level of evidence. 40 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Long-term sequelae of pulmonary embolism The patency of the pulmonary arterial bed is restored in the majority of PE survivors within the first few months following the acute epi- sode; therefore, no routine follow-up CTPA imaging is needed in such patients treated for PE. 427 However, in other patients, thrombi become persistent and organized, which in rare cases may result in CTEPH, a potentially life-threatening obstructing vasculopathy. The rarity of this condition is in contrast to the relatively large number of patients who report persisting dyspnoea or poor physical perform- ance over several months after acute PE. Thus, the aims of an efficient follow-up strategy after PE should be to: (i) provide appropriate care (exercise rehabilitation, treatment of comorbidity, behavioural edu- cation, and modification of risk factors) to patients with persisting symptoms, and (ii) ensure early detection of CTEPH to refer the patient for further diagnostic workup and specific treatment. 10.1 Persisting symptoms and functional limitation after pulmonary embolism Cohort studies conducted over the past decade (summarized in Klok et al. 428 ) have revealed that persisting or deteriorating dyspnoea, and poor physical performance, are frequently present 6 months to 3 years after an acute PE episode. The proportion of patients claiming that their health status is worse at 6 month follow-up than it was at the time of PE diagnosis varies widely, ranging between 20 and 75%. 429 \u0002 431 The following baseline parameters and findings could be identified as predictors of exertional dyspnoea at long-term follow- up after PE: advanced age, cardiac or pulmonary comorbidity, higher body mass index, and history of smoking; 429 higher systolic PAP and RV dysfunction at diagnosis; 430,432,433 and residual pulmonary vascular obstruction at discharge. 434 More recently, a prospective cohort study enrolled 100 patients at five Canadian hospitals between 2010 and 2013, and followed them over 1 year. 435 As many as 47% of the patients had reduced maximal aerobic capacity, defined as peak oxygen consumption <80% of the predicted value on cardiopulmonary exercise testing (CPET). This functional outcome was associated with significantly worse generic health-related quality of life and dyspnoea scores, as well as with a sig- nificantly reduced 6 min walk distance. 435 Independent predictors of reduced functional exercise capacity and quality of life over time included female sex, higher body mass index, history of lung disease, higher pulmonary artery systolic pressures on the 10 day echocardio- gram, and higher main pulmonary artery diameter on the baseline CTPA. 436 Of note, pulmonary function tests and echocardiographic results at follow-up were largely within normal limits, both in patients with and without reduced maximal aerobic capacity. 435 Lack of an association between exercise impairment, and persistent RV dilation or dysfunction, was also reported by a study of 20 survivors of mas- sive or submassive PE. 437 Taken together, older and more recent cohort studies have sug- gested that muscle deconditioning, particularly in the presence of excess body weight and cardiopulmonary comorbidity, is largely responsible for the frequently reported dyspnoea and signs of exer- cise limitation after acute PE. This also means that, at least in the majority of cases, poor physical performance after PE does not appear to be attributable to ‘large’ residual thrombi, or persisting/ progressive PH and RV dysfunction. Ongoing prospective studies in large numbers of patients may help to better identify predictors of functional and/or haemodynamic impairment after acute PE, and their possible implications for shaping follow-up programmes. 438 As mentioned in section 6 , it remains unclear whether early reper- fusion treatment, notably thrombolysis, has an impact on clinical symptoms, functional limitation, or persistent (or new-onset) PH at long-term follow-up after PE. Consequently, prevention of long-term PE sequelae is, at present, no justification for thrombolytic treatment in the acute phase of PE. 10.2 Chronic thromboembolic pulmonary hypertension 10.2.1 Epidemiology, pathophysiology, and natural history CTEPH is a disease caused by the persistent obstruction of pulmo- nary arteries by organized thrombi, leading to flow redistribution and secondary remodelling of the pulmonary microvascular bed. CTEPH has been reported with a cumulative incidence of between 0.1 and 9.1% in the first 2 years after a symptomatic PE event; the large mar- gin of error is due to referral bias, the paucity of early symptoms, and the difficulty of differentiating acute PE from symptoms of pre- existing CTEPH. 439,440 A prospective, multicentre, observational screening survey for the detection of CTEPH included patients with acute PE from 11 centres in Switzerland, from March 2009 to November 2016. Screening for possible CTEPH was performed at 6, 12, and 24 months using a stepwise algorithm that included a phone- based dyspnoea survey, TTE, right heart catheterization, and radio- logical confirmation of CTEPH. Of 508 patients assessed for CTEPH screening over 2 years, CTEPH incidence following PE was 3.7 per 1000 patient-years, with a 2 year cumulative incidence of 0.79%. 441 In Germany, the incidence of CTEPH in 2016 was estimated at 5.7 per million adult population. 442 The hallmark of CTEPH is fibrotic transformation of a pulmonary arterial thrombus, causing fixed mechanical obstruction of pulmo- nary arteries and leading to overflow of the open pulmonary arte- rial bed. Together with collateral supply from systemic arteries downstream of pulmonary arterial occlusions, this contributes to microvascular remodelling causing a progressive increase in PVR. 443 Owing to this complex pathophysiology, there is no clear correlation between the degree of mechanical obstruction found at imaging and haemodynamics, which can deteriorate in the absence of recurrent PE. 444 Two historical trials assessed survival in patients with CTEPH before the availability of surgical treatment. In both studies, mean PAP >30 mmHg was related to poor survival, similar to that reported for idiopathic pulmonary arterial hypertension. 445,446 The most frequently cited risk factors and predisposing conditions for CTEPH are shown in Table 13 . In an international registry, a his- tory of acute PE was reported by 75% of patients. 447 Associated con- ditions and comorbidities included thrombophilic disorders, particularly antiphospholipid antibody syndrome and high coagulation factor VIII levels, cancer, a history of splenectomy, inflammatory bowel disease, ventriculo-atrial shunts, and infection of chronic i.v. lines and devices such as implantable pacemakers. ESC Guidelines 41 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.2.2 Clinical presentation and diagnosis Diagnosing CTEPH is difficult. Algorithms for predicting 450 or ruling out CTEPH 451,452 are limited by a lack of specificity. The clinical char- acteristics of patients enrolled in an international CTEPH registry have shown that the median age at diagnosis is 63 years and that both sexes are equally affected; paediatric cases are rare. 447 Clinical symp- toms and signs are non-specific or absent in early CTEPH, with signs of right heart failure only becoming evident in advanced disease. Thus, early diagnosis remains a challenge in CTEPH, with a median time of 14 months between symptom onset and diagnosis in expert centres. 453 When present, the clinical symptoms of CTEPH may resemble those of acute PE or of pulmonary arterial hypertension; in the latter context, oedema and haemoptysis occur more often in CTEPH, while syncope is more common in pulmonary arterial hypertension. 453 The diagnosis of CTEPH is based on findings obtained after at least 3 months of effective anticoagulation, to distinguish this condition from acute PE. The diagnosis requires a mean PAP of > _25 mmHg along with a pulmonary arterial wedge pressure of < _15 mmHg, docu- mented at right heart catheterization in a patient with mismatched perfusion defects on V/Q lung scan. Specific diagnostic signs for CTEPH on multidetector CT angiography or conventional pulmo- nary cineangiography include ring-like stenoses, webs, slits, and chronic total occlusions. 289 Some patients may present with normal pulmonary haemodynam- ics at rest despite symptomatic disease. If other causes of exercise limitation are excluded, these patients are considered as having chronic thromboembolic disease (CTED). Identification of patients with chronic thromboembolism without PH, who may have an indi- cation for surgical or interventional treatment, requires particular expertise and should be done in CTEPH referral centres. Among 1019 patients who were submitted to pulmonary endarterectomy (PEA) in a UK referral centre, 42 patients did not have pulmonary hypertension at rest but showed functional improvement after the operation. 454 Planar V/Q lung scan is a suitable first-line imaging modality for CTEPH as it has 96 \u0002 97% sensitivity and 90 \u0002 95% specificity for the diagnosis. 455 SPECT seems less sensitive than planar V/Q scanning if assessed at a level of individual segmental arteries, but it is unlikely to miss clinically relevant CTEPH in an individual patient. In contrast to CTEPH, abnormal mismatched perfusion defects sometimes found in pulmonary arterial hypertension and pulmonary veno-occlusive dis- ease typically have a non-segmental pattern. CTPA is gaining ground as a diagnostic modality in CTEPH, 456 but it should not be used as a stand-alone test to exclude the disease. 455 Newer diagnostic tests include dual-energy CT, which allows the simultaneous assessment of patency of the pulmonary arteries and of lung perfusion, probably at a cost of some increase in radiation deliv- ered to the patient. Magnetic resonance imaging of the pulmonary vasculature is still considered inferior to CT. 457 Cone-beam CT, 458 angioscopy, 459 intravascular ultrasound, and optical coherence tomography are more suitable for the characterization of lesions dur- ing interventional treatment than for diagnosis. High-resolution CT scan of the chest may assist in the differential diagnosis of CTEPH, showing emphysema, bronchial, or interstitial lung disease, as well as infarcts, and vascular and thoracic wall malformations. Perfusion inequalities manifesting as a mosaic parenchymal pattern are fre- quently found in CTEPH, but may also be observed in < _12% of patients with other causes of PH. Differential diagnosis of CTEPH should also include pulmonary arteritis, pulmonary angiosarcoma, tumour embolism, parasites (hydatid cyst), foreign body embolism, and congenital or acquired pulmonary artery stenoses. 289 10.2.3 Surgical treatment Surgical PEA is the treatment of choice for operable CTEPH. In con- trast to surgical embolectomy for acute PE, treatment of CTEPH Table 13 Risk factors and predisposing conditions for chronic thromboembolic pulmonary hypertension 447 \u0002 449 Findings related to the acute PE event (obtained at PE diagnosis) Concomitant chronic diseases and conditions predisposing to CTEPH (documented at PE diagnosis or at 3 \u0002 6 month follow-up) Previous episodes of PE or DVT Ventriculo-atrial shunts Large pulmonary arterial thrombi on CTPA Infected chronic i.v. lines or pacemakers Echocardiographic signs of PH/RV dysfunction a History of splenectomy CTPA findings suggestive of pre-existing chronic thromboembolic disease b Thrombophilic disorders, particularly antiphospholipid antibody syndrome and high coagulation factor VIII levels Non-O blood group Hypothyroidism treated with thyroid hormones History of cancer Myeloproliferative disorders Inflammatory bowel disease Chronic osteomyelitis CTEPH = Chronic thromboembolic pulmonary hypertension; CTPA = computed tomographic pulmonary angiography; DVT = deep vein thrombosis; i.v. = intravenous; LV = left ventricular; PE = pulmonary embolism; PH = pulmonary hypertension; RV = right ventricular. a Echocardiographic criteria of RV dysfunction are graphically presented in Figure 3 , and their prognostic value summarized in Supplementary Data Table 3 . On CTPA (four- chamber views of the heart), RV dysfunction is defined as RV/LV diameter ratio >1.0. b Direct and indirect vascular signs, as well as lung parenchymal findings, are summarized in Supplementary Data Table 2 . 42 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . necessitates a true bilateral endarterectomy through the medial layer of the pulmonary arteries. It requires deep hypothermia and intermit- tent circulatory arrest, without a need for cerebral perfusion. 460,461 In-hospital mortality is currently as low as 4.7% 462 and is even lower in high-volume single centres. 463 The majority of patients experience substantial relief from symptoms and near-normalization of haemodynamics. 461 \u0002 464 Owing to the complexity of both the surgical technique and peri-procedural management, PEA is performed in specialized centres. Eligibility for surgery requires a decision taken during a dedicated meeting of a multidisciplinary CTEPH team includ- ing experienced surgeons for PEA, interventional radiologists or car- diologists, radiologists experienced in pulmonary vascular imaging, and clinicians with expertise in PH. The CTEPH team should confirm the diagnosis, assess the surgical accessibility of chronic post- thrombotic obstructions (‘surgical operability’), and consider the risks related to comorbidities (‘medical operability’). The operability of patients with CTEPH is determined by multiple factors that cannot easily be standardized. These are related to the suitability of the patient, the expertise of the surgical team, and available resources. General criteria include pre-operative New York Heart Association (NYHA) functional class and the surgical accessibility of thrombi in the main, lobar, or segmental pulmonary arteries. 462 Advanced age per se is no contraindication for surgery. There is no haemodynamic threshold or measure of RV dysfunction that can be considered to preclude PEA. Data from the international CTEPH registry, set up in 27 centres to evaluate the long-term outcome and outcome predictors in 679 operated and not-operated patients, showed estimated survival at 3 years of 89% in operated and 70% in not-operated patients. 465 Mortality was associated with NYHA functional class, RA pressure, and a history of cancer. 465 In this prospective registry, the long-term prognosis of operated patients was better than the outcome of not- operated patients. 465 Additional correlates of mortality were bridging therapy with pulmonary vasodilators, post-operative PH, surgical complications, and additional cardiac procedures in operated patients, and comorbidities such as coronary disease, left heart fail- ure, and chronic obstructive pulmonary disease in not-operated patients. 465 A recent report identified mean PAP > _38 mmHg and PVR > _425 dyn * s * cm -5 as determinants of poor prognosis in survivors of surgical treatment for CTEPH. 466 Post-operative ECMO is recommended as the standard of care in PEA centres. 461 Early post-operative reperfusion oedema may require veno-arterial ECMO, and severe persistent PH may be bridged to emergency lung transplantation with ECMO. After PEA, patients should be followed in CTEPH centres to exclude persistent or recurrent PH, with at least one haemodynamic assessment to be considered at 6 \u0002 12 months after the intervention. 10.2.4 Balloon pulmonary angioplasty Over the past decade, balloon pulmonary angioplasty (BPA) has emerged as an effective treatment for technically inoperable CTEPH. It allows dilatation of obstructions down to subsegmental vessels, which are inaccessible to surgery. BPA is a stepwise procedure requiring several (usually 4 \u0002 10) separate sessions. This is necessary to engage all under-perfused lung segments, while limiting the con- trast burden and radiation delivered per session. Navigation in distal pulmonary arteries requires particular expertise, as the complexity and individual variability of the pulmonary arterial tree greatly exceeds that of other vascular beds. Complications include wire- and balloon-induced injury, which may result in intrapulmonary bleeding, haemoptysis, and reperfusion lung injury. Usually, bleeding resolves spontaneously, but sometimes it has to be controlled by transient balloon inflation proximal to the site of perforation; in rare cases it requires embolization. Mild hypoxaemia is frequent and can be con- trolled by oxygen delivery. Mechanical ventilation or ECMO is rarely needed. The largest published registry to date included 249 patients with a mean age of 61.5 years, who were treated with BPA between 2004 and 2013 in seven Japanese centres. 467 Mean PAP decreased from 43 to 24 mmHg after terminating BPA sessions, and this result was main- tained in 196 patients who underwent follow-up right heart catheter- ization. Complications occurred in 36% of the patients, including pulmonary injury (18%), haemoptysis (14%), and pulmonary artery perforation (2.9%). After BPA, 30 day mortality was 2.6% and overall survival was 97% at 1 year. 467 While most of the BPA procedures are performed in technically inoperable patients, this method has also been used for sequential treatment for PH persisting after PEA. Few ‘rescue’ BPA interven- tions performed in unstable patients remaining on ECMO after PEA were ineffective. 468 10.2.5 Pharmacological treatment Optimal medical treatment for CTEPH consists of anticoagulants, as well as diuretics and oxygen in cases of heart failure or hypoxaemia. Lifelong oral anticoagulation with VKAs is recommended, and also after successful PEA or BPA. No data exist on the efficacy and safety of NOACs. Pulmonary microvascular disease in CTEPH has provided the rationale for also testing drugs that have been approved for pulmo- nary arterial hypertension for this indication. Based on available data, medical treatment of CTEPH with targeted therapy is now justified for technically inoperable patients, 469,470 as well as for patients with PH persisting after PEA. 469 To date, the only drug approved for inop- erable CTEPH or persistent/recurrent PH after PEA is riociguat, an oral stimulator of soluble guanylate cyclase. 469 In a prospective randomized trial of 261 patients with inoperable CTEPH or persis- tent/recurrent PH after PEA, treatment with riociguat significantly increased 6 min walking distance and reduced PVR. 469 In a similar population of 157 patients, the dual endothelin antagonist bosentan showed a positive effect on haemodynamics, but no improvement was observed in exercise capacity and the primary outcome was not met. 471 Another dual endothelin antagonist, macitentan, was found to significantly improve PVR and 6 min walking distance compared to placebo in a phase II trial focusing on inoperable patients with CTEPH. 470 Currently, riociguat is being tested in trials addressing its efficacy and safety: (i) as bridging therapy for patients scheduled to undergo PEA (NCT 03273257) and (ii) in comparison to BPA (NCT 02634203). Overall, the effects on clinical worsening of drugs tested with RCTs in patients with CTEPH have not yet been clarified. Furthermore, no data exist on medical treatment in technically oper- able patients with prohibitive comorbidities or those refusing surgery. ESC Guidelines 43 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . Off-label combination of drugs approved for pulmonary arterial hypertension has been proposed for CTEPH patients presenting with severe haemodynamic compromise, but only limited prospective data are available to date. 470 Medical therapy is not indicated in symptomatic survivors of acute PE with documented post-thrombotic obstructions but an absence of PH at right heart catheterization at rest (CTED). 10.3 Strategies for patient follow-up after pulmonary embolism Figure 8 displays a proposed follow-up strategy for survivors of acute PE following discharge from hospital. Evaluation of the patients 3 \u0002 6 months after the acute PE episode is recommended to assess the persistence (or new onset) and severity of dyspnoea or functional limitation, and to check for possible signs of VTE recurrence, cancer, © ESC 2019 DIAGNOSIS OF ACUTE PE Refer to PH/CTEPH expert centre for further diagnostic work-up V/Q SCAN: Mismatched perfusion defects? Anticoagulate TTE: Determine probability of PH c FOLLOW-UP AT 3–6 MONTHS a Dyspnoea and/or functional limitation b ? CONSIDER: 1) Elevated NT-proBNP 2) Risk factors for CTEPH d 3) Abnormal CPET results e Low Intermediate No Yes No Yes High None present None present ≥ 1 present ≥ 1 present: may consider TTE Seek alternative causes of dyspnoea f and/or common causes of PH Focus on anticoagulation and secondary prophylaxis; advise to return if symptoms appear ASSESS: Risk factors for CTEPH d Figure 8 Follow-up strategy and diagnostic workup for long-term sequelae of pulmonary embolism. CPET = cardiopulmonary exercise testing; CTEPH = chronic thromboembolic pulmonary hypertension; NT-proBNP = N-terminal pro B-type natriuretic peptide; PE = pulmonary embolism; PH = pulmonary hypertension; TTE = transthoracic echocardiography/echocardiogram; V/Q = ventilation/perfusion (lung scin- tigraphy). a Assess the persistence (or new onset) and severity of dyspnoea or functional limitation, and also check for possible signs of VTE recurrence, cancer, or bleeding complications of anticoagulation. b The Medical Research Council scale can be used to standardize the evaluation of dyspnoea; 160 alternatively, the World Health Organization functional class can be determined (Supplementary Data Table16 ). 289 c As defined by the ESC/ERS guidelines on the diagnosis and treatment of Pulmonary Hypertension (Supplementary Data Tables 17 and 18 ). 289 d Risk factors and predisposing conditions for CTEPH are listed in Table 13 . e Cardiopulmonary exercise testing, if appropriate expertise and resources are available on site; abnormal results include, among others, reduced maximal aerobic capacity (peak oxygen consumption), reduced ventilatory equivalent for carbon dioxide, and reduced end-tidal carbon dioxide pressure. f Consider CPET in the diagnostic work-up. 44 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . or bleeding complications of anticoagulation. The severity of dysp- noea can be assessed using the Medical Research Council scale; 160 alternatively, the World Health Organization functional class can be determined (Supplementary Data Table 16 ). 289 In patients complaining of persisting dyspnoea and poor physical performance, TTE should be considered as the next step to assess the probability of (chronic) PH and thus possible CTEPH. The cri- teria and levels of PH probability are defined by current ESC Guidelines, 289 and are listed in Supplementary Data Tables 17 and 18 . Patients with a high echocardiographic probability of PH, or those with intermediate probability combined with elevated NT- proBNP levels or risk factors/predisposing conditions for CTEPH, such as those listed in Table 13 , should be considered for a V/Q scan. If mismatched perfusion defects are found on the V/Q scan, referral to a PH or CTEPH expert centre for further diagnostic workup is indicated. If, on the other hand, the V/Q scan is normal and the patient’s symptoms remain unexplained, CPET may be performed. By providing evidence of reduced maximal aerobic capacity, CPET supports the need for further follow-up visits and helps to identify candidates for pulmonary rehabilitation, exer- cise, or weight-reduction programmes. 435,436 CPET may also be helpful in patients with suspected CTEPH and coexisting left heart and/or respiratory disease; in such cases, it can help to establish the main limiting factor and thus set priorities for the treatment strategy. 472 For patients who report as free of dyspnoea or functional limita- tion at 3 \u0002 6-month follow-up after acute PE but have risk factors/pre- disposing conditions for CTEPH ( Table 13 ), further follow-up visits may be scheduled and the patient must be advised to return if symp- toms appear. Alternatively, TTE may be considered to assess the probability of PH ( Figure 8 ). Apart from the recommended screening and diagnostic measures, an integrated model of patient care after PE should be provided, tak- ing into consideration the infrastructure and possibilities offered by each country’s health system. The model should include appropri- ately qualified nurses, interdisciplinary working with physicians in the care of both in-hospital and ambulatory PE patients, standardized treatment protocols adapted to the capacities of each hospital, and bidirectional referral pathways between general practice and the hos- pital. Such models ensure smooth transitions between hospital spe- cialists and practitioners; provide continuity, and easy access to care along with information and education; and respect the patients’ pref- erences, and those of their families and social environment. In this context, nurse-led care models to deliver follow-up have been shown to be effective after acute coronary syndrome, 473 in primary care-based management of chronic diseases, 474 and in community based self-management initiatives. 475 A recently published study investigated the care of 42 patients followed at a pulmonary arterial hypertension (PAH)/CTEPH nurse-led outpatient clinic and showed positive results. 476 During patient follow-up visits, appropriately qualified nurses screen for signs and symptoms indicating VTE recur- rence or complications of treatment, and assess adherence to medi- cation. Nurses work collaboratively with patients using behavioural frameworks and motivational interviewing, to identify and modify associated risk factors (smoking cessation, diet, physical activity, and exercise). In addition, they promote self-management skills such as the use of compression stockings, safe increase in mobility, increased awareness of signs of recurrence, or complications. 11 Non-thrombotic pulmonary embolism This section is included in the Supplementary Data available online on the EHJ and ESC websites (www.escardio.org/guidelines). 12 Key messages The ESC Task Force has selected 10 simple key messages and rules to guide physicians in the diagnosis and management of PE: (1) In patients presenting with haemodynamic instability, perform bed- side TTE as a fast, immediate step to differentiate suspected high- risk PE from other acute life-threatening situations. 10.4 Recommendations for follow-up after acute pulmo- nary embolism Recommendations Class a Level b Routine clinical evaluation c of patients 3 \u0002 6 months after the acute PE episode is recommended. 288,352,353,437 I B An integrated model of patient care after PE (involving hospital specialists, appropriately qualified nurses, and primary care physicians) is recommended to ensure optimal transition from hospital to community care. I C In symptomatic patients with mismatched per- fusion defects persisting on V/Q scan d beyond 3 months after acute PE, referral to a PH/ CTEPH expert centre is recommended, after taking into account the results of echocardiog- raphy, natriuretic peptide levels, and/or CPET. 477 I C Further diagnostic evaluation e should be con- sidered in patients with persistent or new- onset dyspnoea/exercise limitation after PE. IIa C Further diagnostic evaluation e may be consid- ered in asymptomatic patients with risk factors for CTEPH. f 447 \u0002 449,478 IIb C CPET = cardiopulmonary exercise testing; CT = computed tomography; CTEPH = Chronic thromboembolic pulmonary hypertension; PE = pulmonary embolism; PH = pulmonary hypertension; V/Q = ventilation/perfusion (lung scintigraphy). a Class of recommendation. b Level of evidence. c For symptoms suggesting recurrence, bleeding, malignancy, or persistent or new-onset exercise limitation, and to decide on extension of anticoagulant treatment. d Alternatively, dual-energy CT may be used, if appropriate expertise and resour- ces are available on-site. e As proposed in the algorithm shown in Figure 8 . f Risk factors and predisposing conditions for CTEPH are listed in Table 13 . ESC Guidelines 45 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (2) If you suspect acute PE, institute anticoagulation therapy as soon as possible, while the diagnostic workup is ongoing, unless the patient is bleeding or has absolute contraindications to this therapy. (3) Use recommended, validated diagnostic algorithms for PE, includ- ing standardized assessment of (pre-test) clinical probability and D-dimer testing. They help to avoid unnecessary, expensive, and potentially harmful imaging tests and exposure to ionizing radiation. (4) If the CTPA report suggests single subsegmental PE, consider the possibility of a false-positive finding. Discuss the findings again with the radiologist and/or seek a second opinion to avoid misdiag- nosis, and unnecessary, potentially harmful anticoagulation treatment. (5) Confirmation of PE in a patient, without haemodynamic instability, must be followed by further risk assessment involving clinical find- ings, evaluation of the size and/or function of the RV, and labora- tory biomarkers as appropriate. This information will help you to decide on the need for reperfusion treatment or monitoring for patients at elevated risk, or consider the option of early discharge and continuation of anticoagulation on an ambulatory basis for patients at low risk. (6) As soon as you diagnose (or strongly suspect) high-risk PE, select the best reperfusion option (systemic thrombolysis, surgical embolectomy, or catheter-directed treatment) considering the patient’s risk profile, and the resources and expertise available at your hospital. For patients with intermediate-high-risk PE, reperfu- sion is not first-line treatment, but you should prospectively plan the management strategy with your team to have a contingency plan ready if the situation deteriorates. (7) Prefer anticoagulation with a NOAC over the ‘traditional’ LMWH-VKA regimen unless the patient has contraindication(s) to this type of drug. (8) Always remember that, with the exception of acute PE provoked by a strong transient/reversible risk factor, there is a lifelong risk of VTE recurrence after a first episode of PE. Consequently, re- examine the patient after the first 3 - 6 months of anticoagulation, weigh the benefits vs. risks of continuing treatment, and decide on the extension and dose of anticoagulant therapy, also considering the patient’s preference. Remember to recommend regular follow-up examinations, e.g. at yearly intervals. (9) If you suspect PE in a pregnant patient, consider diagnostic path- ways and algorithms including CTPA or V/Q lung scan, which can be used safely during pregnancy. (10) After acute PE, patients should not be lost to follow-up. Apart from checking for possible signs of VTE recurrence, cancer, or bleeding complications of anticoagulation, ask the patient if there is persisting or new-onset dyspnoea or functional limitation. If yes, implement a staged diagnostic workup to exclude CTEPH or chronic thromboembolic disease, and to detect/treat comorbidity or ‘simple’ deconditioning. Follow-up imaging is not routinely rec- ommended in an asymptomatic patient, but it may be considered in patients with risk factors for development of CTEPH. 13 Gaps in the evidence Diagnosis • The optimal method to adjust (based on the patient’s age or in combination with clinical probability) the D-dimer threshold, per- mitting the exclusion of PE while reducing the number of unnecessary imaging tests to a minimum, remains to be determined. • The diagnostic value and clinical significance of isolated subseg- mental contrast-filling defects in the modern CTPA era remain controversial. • No robust data exist to guide the decision on whether to treat incidental PE with anticoagulants compared with a strategy of watchful waiting. • For patients presenting with non-traumatic chest pain, the bene- fits vs. risks of ‘triple rule-out’ (for coronary artery disease, PE, and aortic dissection) CT angiography need further evaluation before such an approach can be routinely recommended. Assessment of pulmonary embolism severity and the risk of early death • The optimal, clinically most relevant combination (and cut-off lev- els) of clinical and biochemical predictors of early PE-related death remain to be determined, particularly with regard to identi- fying possible candidates for reperfusion treatment among patients with intermediate-risk PE. • The need for assessment of the RV status in addition to clinical parameters, to classify a patient with acute symptomatic PE as being at low vs. intermediate risk, needs to be confirmed by fur- ther prospective management (cohort) studies. Treatment in the acute phase • The clinical benefits vs. risks of reduced-dose thrombolysis and catheter-based reperfusion modalities in patients with intermedia- te-high-risk PE should be evaluated in prospective randomized trials. • The place of ECMO in the management of acute high-risk PE awaits support by additional evidence from prospective manage- ment (cohort) studies. • The optimal anticoagulant drug(s) and regimen in patients with renal insufficiency and CrCl <30 mL/min remain unclear. • The criteria for selecting patients for early discharge and outpatient treatment of PE, and particularly the need for assessment of the RV status with imaging methods and/or laboratory markers in addition to calculating a clinical score, need to be further validated in prospective cohort studies. Chronic treatment and prevention of recurrence • The clinical value and the possible therapeutic implications of models or scores assessing the risk of VTE recurrence, and the risk of bleeding under anticoagulation, need to be revisited in the NOAC era. • The effectiveness of extended treatment with a reduced dose, or apixaban or rivaroxaban, should be confirmed in patients with a high risk of recurrent PE. 46 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . • The evidence supporting the efficacy and safety of NOACs for the treatment of PE in patients with cancer needs to be extended by further studies. • In patients with cancer, the anticoagulant regimen and dose after the first 6 months should be clarified and prospectively tested. • The optimal time for discontinuing anticoagulant treatment after an episode of acute PE in patients with cancer is yet to be determined. Pulmonary embolism and pregnancy • Diagnostic algorithms for PE in pregnancy, using modern radio- logical imaging techniques and low radiation doses, need to be prospectively tested in adequately powered cohort studies. • Controversy persists on the optimal LMWH dose and regimen for the treatment of PE during pregnancy. • NOACs are not allowed in pregnancy. However, if exposure to these drugs occurs during pregnancy despite this warning, any possible effects on the foetus should be recorded to provide more precise information on the risks and complications of these drugs, and adapt the instructions to physicians in the future. Long-term sequelae of pulmonary embolism • The optimal follow-up strategy, including the spectrum of diag- nostic tests that may be necessary, in patients with persisting symptoms and functional limitation after acute PE needs to be defined and prospectively validated. • In the absence of persisting symptoms or functional limitation after acute PE, the criteria for identifying patients whose risk of developing CTEPH may be sufficiently high to justify further diag- nostic workup require further elaboration and validation in pro- spective cohort studies. 14 ‘What to do’ and ‘what not to do’ messages from the Guidelines Diagnosis Class a In suspected high-risk PE, perform bedside echocardiography or emergency CTPA (depending on availability and clinical circumstan- ces) for diagnosis. I In suspected high-risk PE, initiate intravenous anticoagulation with UFH without delay, including a weight-adjusted bolus injection. I In suspected PE without haemodynamic instability, use validated diagnostic criteria. I In suspected PE without haemodynamic instability, initiate anticoagulation in case of high or intermediate clinical probability, while diagnostic workup is in progress. I Base the diagnostic strategy on clinical probability, using either clinical judgement or a validated prediction rule. I Measure D-dimers in plasma, preferably with a highly sensitive assay, in outpatients/emergency department patients with low or inter- mediate clinical probability, or who are PE-unlikely. I Reject the diagnosis of PE (without further testing) if CTPA is normal in a patient with low or intermediate clinical probability, or if the patient is PE-unlikely. I Reject the diagnosis of PE (without further testing) if the perfusion lung scan is normal. I Accept the diagnosis of PE if CTPA shows a segmental or more proximal filling defect in a patient with intermediate or high clinical probability. I Accept the diagnosis of VTE if CUS shows a proximal DVT in a patient with clinical suspicion of PE. I Do not measure D-dimers in patients with high clinical probability, as a normal result does not safely exclude PE. III Do not perform CT venography as an adjunct to CTPA. III Do not perform MRA to rule out PE. III Risk assessment Stratify patients with suspected or confirmed PE, based on the presence of haemodynamic instability, to identify those at high risk of early mortality. I In patients without haemodynamic instability, further stratify PE into intermediate- and low-risk categories. I Treatment in the acute phase Administer systemic thrombolytic therapy to patients with high-risk PE. I Surgical pulmonary embolectomy for patients with high-risk PE, in whom recommended thrombolysis is contraindicated or has failed. I If anticoagulation is initiated parenterally in a patient without haemodynamic instability, prefer LMWH or fondaparinux over UFH. I Continued ESC Guidelines 47 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Supplementary data Supplementary Data with additional Web Supplementary Tables complementing the full text, as well as section 11 on non-thrombotic PE, are available on the European Heart Journal website and via the ESC website at www.escardio.org/guidelines. 16 Appendix Author/Task Force Member Affiliations: Cecilia Becattini , Internal and Cardiovascular Medicine, University of Perugia, Perugia, Italy; He ´ctor Bueno , Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; and Cardiology, Hospital Universitario 12 de Octubre & i þ 12 Research Institute, Madrid, Spain; CIBERCV, Madrid, Spain; Geert-Jan Geersing , Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands; Veli- Pekka Harjola , Emergency Medicine, Department of Emergency Medicine and Services, Helsinki University, Helsinki University Hospital, Helsinki, Finland; Menno V. Huisman , Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, Netherlands; Marc Humbert , Service de Pneumologie, Ho ˆpital Bic ^ etre, Assistance Publique-Ho ˆpitaux de Paris, Univ. Paris-Sud, Universite ´ Paris-Saclay, Le Kremlin-Bic ^ etre, France; Catriona Sian Jennings , National Heart and Lung Institute (NHLI), Imperial College London, London, United Kingdom; David Jime ´nez , Respiratory Department, Ram \u0013 on y Cajal Hospital and Alcala University, IRYCIS, Madrid, Spain; Nils Kucher , Angiology, University Hospital, Zurich, Switzerland; Irene Marthe Lang , Cardiology, Medical University of Vienna, Vienna, Austria; Mareike Lankeit , Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charite ´ \u0002 University Medicine Berlin, Berlin, Germany; and Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany; Clinic When oral anticoagulation is initiated in a patient with PE who is eligible for a NOAC (apixaban, dabigatran, edoxaban, or rivaroxa- ban), prefer a NOAC. I As an alternative to a NOAC, administer a VKA, overlapping with parenteral anticoagulation until an INR of 2.5 (range 2.0 \u0002 3.0) has been reached. I Administer rescue thrombolytic therapy to a patient with haemodynamic deterioration on anticoagulation treatment. I Do not use NOACs in patients with severe renal impairment or in those with antiphospholipid antibody syndrome. III Do not routinely administer systemic thrombolysis as primary treatment in patients with intermediate- or low-risk PE. III Do not routinely use inferior vena cava filters. III Chronic treatment and prevention of recurrence Administer therapeutic anticoagulation for > _3 months to all patients with PE. I Discontinue therapeutic oral anticoagulation after 3 months in patients with first PE secondary to a major transient/reversible risk factor. I Continue oral anticoagulant treatment indefinitely in patients presenting with recurrent VTE (at least one previous episode of PE or DVT) that is not related to a major transient or reversible risk factor. I Continue oral anticoagulant treatment with a VKA indefinitely in patients with antiphospholipid antibody syndrome. I In patients who receive extended anticoagulation, reassess drug tolerance and adherence, hepatic and renal function, and the bleeding risk at regular intervals. I PE in pregnancy Perform formal diagnostic assessment with validated methods if PE is suspected during pregnancy or in the post-partum period. I Administer therapeutic, fixed doses of LMWH, based on early pregnancy weight, in the majority of pregnant women without haemo- dynamic instability. I Do not insert a spinal or epidural needle within 24 h since the last LMWH dose. III Do not administer LMWH within 4 h of removal of an epidural catheter. III Do not use NOACs during pregnancy or lactation. III Post-PE care and long-term sequelae Routinely re-evaluate patients 3 \u0002 6 months after acute PE. I Implement an integrated model of care after acute PE, in order to ensure optimal transition from hospital to ambulatory care. I Refer symptomatic patients with mismatched perfusion defects on V/Q lung scan beyond 3 months after acute PE to a pulmonary hypertension/CTEPH expert centre, taking into account the results of echocardiography, natriuretic peptide, and/or cardiopulmonary exercise testing. I CT = computed tomography; CTPA = computed tomographic pulmonary angiography/angiogram; CTEPH = Chronic thromboembolic pulmonary hypertension; CUS = com- pression ultrasonography; DVT = deep vein thrombosis; INR = international normalized ratio; LMWH = low-molecular weight heparin; MRA = magnetic resonance angiogra- phy; NOAC(s) = non-vitamin K antagonist oral anticoagulant(s); PE = pulmonary embolism; UFH = unfractionated heparin; VKA = vitamin K antagonist; V/Q = ventilation/ perfusion (lung scintigraphy); VTE = venous thromboembolism. a Class of recommendation. 48 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . of Cardiology and Pneumology, University Medical Center Go ¨ttingen, Go ¨ttingen, Germany; Roberto Lorusso , Cardio-Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC), Cardiovascular Research Institute Maastricht (CARIM), Maastricht, Netherlands; Lucia Mazzolai , Department of Angiology, CHUV, Lausanne, Switzerland; Nicolas Meneveau , Department of Cardiology, University Hospital Jean Minjoz and EA3920, University of Franche-Comte ´, Besanc ¸on, France; Fionnuala N \u0013 ı \u0013 Ainle , Haematology, Rotunda and Mater University Hospitals, Dublin, University College Dublin, Dublin, Ireland; Paolo Prandoni , Arianna Foundation on Anticoagulation, Bologna, Italy; Piotr Pruszczyk , Department of Internal Medicine and Cardiology, Medical University of Warsaw, Warsaw, Poland; Marc Righini , Division of Angiology and Hemostasis, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland; Adam Torbicki , Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, Warsaw, ECZ-Otwock, Poland; Eric Van Belle , Cardiology, Institut Coeur Poumon CHU de Lille and INSERM U1011 Lille, Lille, France; Jose ´ Luis Zamorano , Cardiology, Hospital Ram \u0013 on y Cajal, Madrid, Spain. ESC Committee for Practice Guidelines (CPG): Stephan Windecker (Chairperson) (Switzerland), Victor Aboyans (France), Colin Baigent (United Kingdom), Jean-Philippe Collet (France), Veronica Dean (France), Victoria Delgado (Netherlands), Donna Fitzsimons (United Kingdom), Chris P. Gale (United Kingdom), Diederick E. Grobbee (Netherlands), Sigrun Halvorsen (Norway), Gerhard Hindricks (Germany), Bernard Iung (France), Peter Ju ¨ni (Canada), Hugo A. Katus (Germany), Ulf Landmesser (Germany), Christophe Leclercq (France), Maddalena Lettino (Italy), Basil S. Lewis (Israel), Bela Merkely (Hungary), Christian Mueller (Switzerland), Steffen E. Petersen (United Kingdom), Anna Sonia Petronio (Italy), Dimitrios J. Richter (Greece), Marco Roffi (Switzerland), Evgeny Shlyakhto (Russian Federation), Iain A. Simpson (United Kingdom), Miguel Sousa-Uva (Portugal), Rhian M. Touyz (United Kingdom). ESC National Cardiac Societies actively involved in the review process of the 2019 ESC Guidelines on the diagnosis and manage- ment of acute pulmonary embolism: Algeria: Algerian Society of Cardiology, Naima Hammoudi; Armenia: Armenian Cardiologists Association, Hamlet Hayrapetyan; Austria: Austrian Society of Cardiology, Julia Mascherbauer; Azerbaijan: Azerbaijan Society of Cardiology, Firdovsi Ibrahimov; Belarus: Belorussian Scientific Society of Cardiologists, Oleg Polonetsky; Belgium: Belgian Society of Cardiology, Patrizio Lancellotti; Bulgaria: Bulgarian Society of Cardiology, Mariya Tokmakova; Croatia: Croatian Cardiac Society, Bosko Skoric; Cyprus: Cyprus Society of Cardiology, Ioannis Michaloliakos; Czech Republic: Czech Society of Cardiology, Martin Hutyra; Denmark: Danish Society of Cardiology, Søren Mellemkjaer; Egypt: Egyptian Society of Cardiology, Mansour Mostafa; Estonia: Estonian Society of Cardiology, Julia Reinmets; Finland: Finnish Cardiac Society, Pertti J € a € askel € ainen; France: French Society of Cardiology, Denis Angoulvant; Germany: German Cardiac Society, Johann Bauersachs; Greece: Hellenic Society of Cardiology, George Giannakoulas; Hungary: Hungarian Society of Cardiology, Endre Zima; Italy: Italian Federation of Cardiology, Carmine Dario Vizza; Kazakhstan: Association of Cardiologists of Kazakhstan, Akhmetzhan Sugraliyev; Kosovo (Republic of): Kosovo Society of Cardiology, Ibadete Bytyc ¸i; Latvia: Latvian Society of Cardiology, Aija Maca; Lithuania: Lithuanian Society of Cardiology, Egle Ereminiene; Luxembourg: Luxembourg Society of Cardiology, Steve Huijnen; Malta: Maltese Cardiac Society, Robert Xuereb; Moldova (Republic of): Moldavian Society of Cardiology, Nadejda Diaconu; Montenegro: Montenegro Society of Cardiology, Nebojsa Bulatovic; Morocco: Moroccan Society of Cardiology, Ilyasse Asfalou; North Macedonia : North Macedonian Society of Cardiology, Marijan Bosevski; Norway: Norwegian Society of Cardiology, Sigrun Halvorsen; Poland: Polish Cardiac Society, Bo _ zena Sobkowicz; Portugal: Portuguese Society of Cardiology, Daniel Ferreira; Romania: Romanian Society of Cardiology, Antoniu Octavian Petris; Russian Federation: Russian Society of Cardiology, Olga Moiseeva; San Marino: San Marino Society of Cardiology, Marco Zavatta; Serbia: Cardiology Society of Serbia, Slobodan Obradovic; Slovakia: Slovak Society of Cardiology, Iveta \u0014 Simkova; Slovenia: Slovenian Society of Cardiology, Peter Radsel; Spain: Spanish Society of Cardiology, Borja Ibanez; Sweden: Swedish Society of Cardiology, Gerhard Wikstro ¨m; Switzerland: Swiss Society of Cardiology, Drahomir Aujesky; Turkey: Turkish Society of Cardiology, Cihangir Kaymaz; Ukraine: Ukrainian Association of Cardiology, Alexander Parkhomenko; United Kingdom of Great Britain and Northern Ireland: British Cardiovascular Society, Joanna Pepke-Zaba. 17 References 1. Mazzolai L, Aboyans V, Ageno W, Agnelli G, Alatri A, Bauersachs R, Brekelmans MPA, Buller HR, Elias A, Farge D, Konstantinides S, Palareti G, Prandoni P, Righini M, Torbicki A, Vlachopoulos C, Brodmann M. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmo- nary circulation and right ventricular function. Eur Heart J 2018; 39 :4208 \u0002 4218. 2. Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, Hylek EM, Kakkar A, Konstantinides SV, McCumber M, Ozaki Y, Wendelboe A, Weitz JI. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol 2014; 34 :2363 \u0002 2371. 3. Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circ Res 2016; 118 :1340 \u0002 1347. 4. Keller K, Hobohm L, Ebner M, Kresoja KP, Munzel T, Konstantinides SV, Lankeit M. Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany. Eur Heart J ;doi: 10.1093/eurheartj/ehz236. Published online ahead of print 18 May 2019. 5. de Miguel-Diez J, Jimenez-Garcia R, Jimenez D, Monreal M, Guijarro R, Otero R, Hernandez-Barrera V, Trujillo-Santos J, Lopez de Andres A, Carrasco-Garrido P. Trends in hospital admissions for pulmonary embolism in Spain from 2002 to 2011. Eur Respir J 2014; 44 :942 \u0002 950. 6. Dentali F, Ageno W, Pomero F, Fenoglio L, Squizzato A, Bonzini M. Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy. Thromb Haemost 2016; 115 :399 \u0002 405. 7. Lehnert P, Lange T, Moller CH, Olsen PS, Carlsen J. Acute pulmonary embolism in a national Danish cohort: increasing incidence and decreasing mortality. Thromb Haemost 2018; 118 :539 \u0002 546. 8. Barco S, Woersching AL, Spyropoulos AC, Piovella F, Mahan CE. European Union-28: an annualised cost-of-illness model for venous thromboembolism. Thromb Haemost 2016; 115 :800 \u0002 808. 9. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E, Samama MM, Spannagl M; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortal- ity. Thromb Haemost 2007; 98 :756 \u0002 764. ESC Guidelines 49 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10. Jimenez D, de Miguel-Diez J, Guijarro R, Trujillo-Santos J, Otero R, Barba R, Muriel A, Meyer G, Yusen RD, Monreal M; RIETE Investigators. Trends in the management and outcomes of acute pulmonary embolism: analysis from the RIETE registry. J Am Coll Cardiol 2016; 67 :162 \u0002 170. 11. Agarwal S, Clark D III, Sud K, Jaber WA, Cho L, Menon V. Gender disparities in outcomes and resource utilization for acute pulmonary embolism hospitaliza- tions in the United States. Am J Cardiol 2015; 116 :1270 \u0002 1276. 12. Roy PM, Meyer G, Vielle B, Le Gall C, Verschuren F, Carpentier F, Leveau P, Furber A; EMDEPU Study Group. Appropriateness of diagnostic management and outcomes of suspected pulmonary embolism. Ann Intern Med 2006; 144 :157 \u0002 164. 13. Jimenez D, Bikdeli B, Barrios D, Morillo R, Nieto R, Guerassimova I, Muriel A, Jara-Palomares L, Moores L, Tapson V, Yusen RD, Monreal M; RIETE Investigators. Management appropriateness and outcomes of patients with acute pulmonary embolism. Eur Respir J 2018; 51 :1800445. 14. Wiener RS, Schwartz LM, Woloshin S. Time trends in pulmonary embolism in the United States: evidence of overdiagnosis. Arch Intern Med 2011; 171 :831 \u0002 837. 15. Shiraev TP, Omari A, Rushworth RL. Trends in pulmonary embolism morbidity and mortality in Australia. Thromb Res 2013; 132 :19 \u0002 25. 16. Tsai J, Grosse SD, Grant AM, Hooper WC, Atrash HK. Trends in in-hospital deaths among hospitalizations with pulmonary embolism. Arch Intern Med 2012; 172 :960 \u0002 961. 17. Yang Y, Liang L, Zhai Z, He H, Xie W, Peng X, Wang C; Investigators for National Cooperative Project for Prevention and Treatment of PTE-DVT. Pulmonary embolism incidence and fatality trends in chinese hospitals from 1997 to 2008: a multicenter registration study. PLoS One 2011; 6 :e26861. 18. Konstantinides SV, Barco S, Lankeit M, Meyer G. Management of pulmonary embolism: an update. J Am Coll Cardiol 2016; 67 :976 \u0002 990. 19. Biss TT, Brandao LR, Kahr WH, Chan AK, Williams S. Clinical features and out- come of pulmonary embolism in children. Br J Haematol 2008; 142 :808 \u0002 818. 20. Andrew M, David M, Adams M, Ali K, Anderson R, Barnard D, Bernstein M, Brisson L, Cairney B, DeSai D. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994; 83 :1251 \u0002 1257. 21. Stein PD, Kayali F, Olson RE. Incidence of venous thromboembolism in infants and children: data from the National Hospital Discharge Survey. J Pediatr 2004; 145 :563 \u0002 565. 22. van Ommen CH, Heijboer H, Buller HR, Hirasing RA, Heijmans HS, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr 2001; 139 :676 \u0002 681. 23. Rogers MA, Levine DA, Blumberg N, Flanders SA, Chopra V, Langa KM. Triggers of hospitalization for venous thromboembolism. Circulation 2012; 125 :2092 \u0002 2099. 24. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107 :I9 \u0002 I16. 25. Ku GH, White RH, Chew HK, Harvey DJ, Zhou H, Wun T. Venous throm- boembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood 2009; 113 :3911 \u0002 3917. 26. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous throm- boembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166 :458 \u0002 464. 27. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer- associated venous thrombosis. Blood 2013; 122 :1712 \u0002 1723. 28. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293 :715 \u0002 722. 29. Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M; RIETE Investigators. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res 2013; 131 :24 \u0002 30. 30. Blanco-Molina A, Rota L, Di Micco P, Brenner B, Trujillo-Santos J, Ruiz-Gamietea A, Monreal M; RIETE Investigators. Venous thromboembolism during pregnancy, postpartum or during contraceptive use. Thromb Haemost 2010; 103 :306 \u0002 311. 31. Blanco-Molina A, Trujillo-Santos J, Tirado R, Canas I, Riera A, Valdes M, Monreal M; RIETE Investigators. Venous thromboembolism in women using hormonal contra- ceptives. Findings from the RIETE Registry. Thromb Haemost 2009; 101 :478 \u0002 482. 32. van Hylckama Vlieg A, Middeldorp S. Hormone therapies and venous throm- boembolism: where are we now? J Thromb Haemost 2011; 9 :257 \u0002 266. 33. Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different pro- gestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011; 343 :d6423. 34. de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014; 3 :CD010813. 35. van Vlijmen EF, Wiewel-Verschueren S, Monster TB, Meijer K. Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a sys- tematic review and meta-analysis. J Thromb Haemost 2016; 14 :1393 \u0002 1403. 36. Tricotel A, Collin C, Zureik M. Impact of the sharp changes in the use of contra- ception in 2013 on the risk of pulmonary embolism in France. J Thromb Haemost 2015; 13 :1576 \u0002 1580. 37. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001; 323 :131 \u0002 134. 38. van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate con- traceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010; 30 :2297 \u0002 2300. 39. Sweetland S, Beral V, Balkwill A, Liu B, Benson VS, Canonico M, Green J, Reeves GK; Million Women Study Collaborators. Venous thromboembolism risk in rela- tion to use of different types of postmenopausal hormone therapy in a large pro- spective study. J Thromb Haemost 2012; 10 :2277 \u0002 2286. 40. Clayton TC, Gaskin M, Meade TW. Recent respiratory infection and risk of venous thromboembolism: case-control study through a general practice data- base. Int J Epidemiol 2011; 40 :819 \u0002 827. 41. Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community set- ting. Lancet 2006; 367 :1075 \u0002 1079. 42. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 :4902 \u0002 4907. 43. Dijk FN, Curtin J, Lord D, Fitzgerald DA. Pulmonary embolism in children. Paediatr Respir Rev 2012; 13 :112 \u0002 122. 44. Piazza G, Goldhaber SZ. Venous thromboembolism and atherothrombosis: an integrated approach. Circulation 2010; 121 :2146 \u0002 2150. 45. Steffen LM, Cushman M, Peacock JM, Heckbert SR, Jacobs DR Jr, Rosamond WD, Folsom AR. Metabolic syndrome and risk of venous thromboembolism: longitudinal investigation of thromboembolism etiology. J Thromb Haemost 2009; 7 :746 \u0002 751. 46. Severinsen MT, Kristensen SR, Johnsen SP, Dethlefsen C, Tjonneland A, Overvad K. Anthropometry, body fat, and venous thromboembolism: a Danish follow-up study. Circulation 2009; 120 :1850 \u0002 1857. 47. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117 :93 \u0002 102. 48. Piazza G, Goldhaber SZ, Lessard DM, Goldberg RJ, Emery C, Spencer FA. Venous thromboembolism in patients with symptomatic atherosclerosis. Thromb Haemost 2011; 106 :1095 \u0002 1102. 49. Montecucco F, Mach F. Should we focus on \"venous vulnerability\" instead of \"pla- que vulnerability\" in symptomatic atherosclerotic patients? Thromb Haemost 2011; 106 :995 \u0002 996. 50. Gresele P, Momi S, Migliacci R. Endothelium, venous thromboembolism and ischaemic cardiovascular events. Thromb Haemost 2010; 103 :56 \u0002 61. 51. Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis - A systematic review of clinical studies. Thromb Haemost 2005; 94 :362 \u0002 365. 52. Wattanakit K, Lutsey PL, Bell EJ, Gornik H, Cushman M, Heckbert SR, Rosamond WD, Folsom AR. Association between cardiovascular disease risk fac- tors and occurrence of venous thromboembolism. A time-dependent analysis. Thromb Haemost 2012; 108 :508 \u0002 515. 53. Enga KF, Braekkan SK, Hansen-Krone IJ, le Cessie S, Rosendaal FR, Hansen JB. Cigarette smoking and the risk of venous thromboembolism: the Tromsø Study. J Thromb Haemost 2012; 10 :2068 \u0002 2074. 54. Sorensen HT, Horvath-Puho E, Lash TL, Christiansen CF, Pesavento R, Pedersen L, Baron JA, Prandoni P. Heart disease may be a risk factor for pulmonary embolism without peripheral deep venous thrombosis. Circulation 2011; 124 :1435 \u0002 1441. 55. Prandoni P, Pesavento R, Sorensen HT, Gennaro N, Dalla Valle F, Minotto I, Perina F, Pengo V, Pagnan A. Prevalence of heart diseases in patients with pulmo- nary embolism with and without peripheral venous thrombosis: findings from a cross-sectional survey. Eur J Intern Med 2009; 20 :470 \u0002 473. 56. Sorensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardio- vascular events: a 20-year cohort study. Lancet 2007; 370 :1773 \u0002 1779. 57. McIntyre KM, Sasahara AA. The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary disease. Am J Cardiol 1971; 28 :288 \u0002 294. 58. Smulders YM. Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: the pivotal role of pulmonary vasoconstriction. Cardiovasc Res 2000; 48 :23 \u0002 33. 59. Lankhaar JW, Westerhof N, Faes TJC, Marques KMJ, Marcus JT, Postmus PE, Vonk-Noordegraaf A. Quantification of right ventricular afterload in patients with and without pulmonary hypertension. Am J Physiol Heart Circ Physiol 2006; 291 :H1731 \u0002 H1737. 60. Marcus JT, Gan CT, Zwanenburg JJ, Boonstra A, Allaart CP, Gotte MJ, Vonk- Noordegraaf A. Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling. J Am Coll Cardiol 2008; 51 :750 \u0002 757. 50 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61. Mauritz GJ, Marcus JT, Westerhof N, Postmus PE, Vonk-Noordegraaf A. Prolonged right ventricular post-systolic isovolumic period in pulmonary arterial hypertension is not a reflection of diastolic dysfunction. Heart 2011; 97 :473 \u0002 478. 62. Begieneman MP, van de Goot FR, van der Bilt IA, Vonk Noordegraaf A, Spreeuwenberg MD, Paulus WJ, van Hinsbergh VW, Visser FC, Niessen HW. Pulmonary embolism causes endomyocarditis in the human heart. Heart 2008; 94 :450 \u0002 456. 63. Lankeit M, Jime ´nez D, Kostrubiec M, Dellas C, Hasenfuss G, Pruszczyk P, Konstantinides S. Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation 2011; 124 :2716 \u0002 2724. 64. Lankeit M, Kempf T, Dellas C, Cuny M, Tapken H, Peter T, Olschewski M, Konstantinides S, Wollert KC. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med 2008; 177 :1018 \u0002 1025. 65. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk NA, Zamorano JL, Zompatori M. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35 :3033 \u0002 3073. 66. Burrowes KS, Clark AR, Tawhai MH. Blood flow redistribution and ventilation- perfusion mismatch during embolic pulmonary arterial occlusion. Pulm Circ 2011; 1 :365 \u0002 376. 67. Konstantinides S, Geibel A, Kasper W, Olschewski M, Blumel L, Just H. Patent foramen ovale is an important predictor of adverse outcome in patients with major pulmonary embolism. Circulation 1998; 97 :1946 \u0002 1951. 68. Harjola VP, Mebazaa A, Celutkiene J, Bettex D, Bueno H, Chioncel O, Crespo- Leiro MG, Falk V, Filippatos G, Gibbs S, Leite-Moreira A, Lassus J, Masip J, Mueller C, Mullens W, Naeije R, Nordegraaf AV, Parissis J, Riley JP, Ristic A, Rosano G, Rudiger A, Ruschitzka F, Seferovic P, Sztrymf B, Vieillard-Baron A, Yilmaz MB, Konstantinides S. Contemporary management of acute right ventricu- lar failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur J Heart Fail 2016; 18 :226 \u0002 241. 69. Mebazaa A, Tolppanen H, Mueller C, Lassus J, DiSomma S, Baksyte G, Cecconi M, Choi DJ, Cohen Solal A, Christ M, Masip J, Arrigo M, Nouira S, Ojji D, Peacock F, Richards M, Sato N, Sliwa K, Spinar J, Thiele H, Yilmaz MB, Januzzi J. Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance. Intensive Care Med 2016; 42 :147 \u0002 163. 70. Thiele H, Ohman EM, Desch S, Eitel I, de Waha S. Management of cardiogenic shock. Eur Heart J 2015; 36 :1223 \u0002 1230. 71. Righini M, Robert-Ebadi H, Le Gal G. Diagnosis of acute pulmonary embolism. J Thromb Haemost 2017; 15 :1251 \u0002 1261. 72. Dronkers CEA, van der Hulle T, Le Gal G, Kyrle PA, Huisman MV, Cannegieter SC, Klok FA; Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease. Towards a tailored diagnostic standard for future diagnostic studies in pulmonary embolism: communication from the SSC of the ISTH. J Thromb Haemost 2017; 15 :1040 \u0002 1043. 73. Pollack CV, Schreiber D, Goldhaber SZ, Slattery D, Fanikos J, O’Neil BJ, Thompson JR, Hiestand B, Briese BA, Pendleton RC, Miller CD, Kline JA. Clinical characteristics, management, and outcomes of patients diagnosed with acute pul- monary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J Am Coll Cardiol 2011; 57 :700 \u0002 706. 74. Miniati M, Prediletto R, Formichi B, Marini C, Di Ricco G, Tonelli L, Allescia G, Pistolesi M. Accuracy of clinical assessment in the diagnosis of pulmonary embo- lism. Am J Respir Crit Care Med 1999; 159 :864 \u0002 871. 75. Wells PS, Ginsberg JS, Anderson DR, Kearon C, Gent M, Turpie AG, Bormanis J, Weitz J, Chamberlain M, Bowie D, Barnes D, Hirsh J. Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med 1998; 129 :997 \u0002 1005. 76. Barco S, Ende-Verhaar YM, Becattini C, Jimenez D, Lankeit M, Huisman MV, Konstantinides SV, Klok FA. Differential impact of syncope on the prognosis of patients with acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J 2018; 39 :4186 \u0002 4195. 77. Prandoni P, Lensing AW, Prins MH, Ciammaichella M, Perlati M, Mumoli N, Bucherini E, Visona A, Bova C, Imberti D, Campostrini S, Barbar S; PESIT Investigators. Prevalence of pulmonary embolism among patients hospitalized for syncope. N Engl J Med 2016; 375 :1524 \u0002 1531. 78. Stein PD, Henry JW. Clinical characteristics of patients with acute pulmonary embo- lism stratified according to their presenting syndromes. Chest 1997; 112 :974 \u0002 979. 79. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107 :I4 \u0002 I8. 80. Rodger MA, Carrier M, Jones GN, Rasuli P, Raymond F, Djunaedi H, Wells PS. Diagnostic value of arterial blood gas measurement in suspected pulmonary embolism. Am J Respir Crit Care Med 2000; 162 :2105 \u0002 2108. 81. Stein PD, Goldhaber SZ, Henry JW, Miller AC. Arterial blood gas analysis in the assessment of suspected acute pulmonary embolism. Chest 1996; 109 :78 \u0002 81. 82. Elliott CG, Goldhaber SZ, Visani L, DeRosa M. Chest radiographs in acute pul- monary embolism. Results from the International Cooperative Pulmonary Embolism Registry. Chest 2000; 118 :33 \u0002 38. 83. Shopp JD, Stewart LK, Emmett TW, Kline JA. Findings from 12-lead electrocar- diography that predict circulatory shock from pulmonary embolism: systematic review and meta-analysis. Acad Emerg Med 2015; 22 :1127 \u0002 1137. 84. Sanders S, Doust J, Glasziou P. A systematic review of studies comparing diag- nostic clinical prediction rules with clinical judgment. PLoS One 2015; 10 :e0128233. 85. Penaloza A, Verschuren F, Meyer G, Quentin-Georget S, Soulie C, Thys F, Roy PM. Comparison of the unstructured clinician gestalt, the wells score, and the revised Geneva score to estimate pretest probability for suspected pulmonary embolism. Ann Emerg Med 2013; 62 :117 \u0002 124 e2. 86. Wells PS, Anderson DR, Rodger M, Ginsberg JS, Kearon C, Gent M, Turpie AG, Bormanis J, Weitz J, Chamberlain M, Bowie D, Barnes D, Hirsh J. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000; 83 :416 \u0002 420. 87. Klok FA, Mos IC, Nijkeuter M, Righini M, Perrier A, Le Gal G, Huisman MV. Simplification of the revised Geneva score for assessing clinical probability of pul- monary embolism. Arch Intern Med 2008; 168 :2131 \u0002 2136. 88. Gibson NS, Sohne M, Kruip MJHA, Tick LW, Gerdes VE, Bossuyt PM, Wells PS, Buller HR; Christopher Study Investigators. Further validation and simplification of the Wells clinical decision rule in pulmonary embolism. Thromb Haemost 2008; 99 :229 \u0002 234. 89. Douma RA, Mos IC, Erkens PM, Nizet TA, Durian MF, Hovens MM, van Houten AA, Hofstee HM, Klok FA, ten Cate H, Ullmann EF, Bu ¨ller HR, Kamphuisen PW, Huisman MV; Prometheus Study Group. Performance of 4 clinical decision rules in the diagnostic management of acute pulmonary embolism: a prospective cohort study. Ann Intern Med 2011; 154 :709 \u0002 718. 90. Douma RA, Gibson NS, Gerdes VE, Buller HR, Wells PS, Perrier A, Le Gal G. Validity and clinical utility of the simplified Wells rule for assessing clinical proba- bility for the exclusion of pulmonary embolism. Thromb Haemost 2009; 101 :197 \u0002 200. 91. Le Gal G, Righini M, Roy PM, Sanchez O, Aujesky D, Bounameaux H, Perrier A. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med 2006; 144 :165 \u0002 171. 92. Ceriani E, Combescure C, Le Gal G, Nendaz M, Perneger T, Bounameaux H, Perrier A, Righini M. Clinical prediction rules for pulmonary embolism: a system- atic review and meta-analysis. J Thromb Haemost 2010; 8 :957 \u0002 970. 93. Kline JA, Mitchell AM, Kabrhel C, Richman PB, Courtney DM. Clinical criteria to prevent unnecessary diagnostic testing in emergency department patients with suspected pulmonary embolism. J Thromb Haemost 2004; 2 :1247 \u0002 1255. 94. Penaloza A, Soulie C, Moumneh T, Delmez Q, Ghuysen A, El Kouri D, Brice C, Marjanovic NS, Bouget J, Moustafa F, Trinh-Duc A, Le Gall C, Imsaad L, Chretien JM, Gable B, Girard P, Sanchez O, Schmidt J, Le Gal G, Meyer G, Delvau N, Roy PM. Pulmonary embolism rule-out criteria (PERC) rule in European patients with low implicit clinical probability (PERCEPIC): a multicentre, prospective, observa- tional study. Lancet Haematol 2017; 4 :e615 \u0002 e621. 95. Freund Y, Cachanado M, Aubry A, Orsini C, Raynal PA, Feral-Pierssens AL, Charpentier S, Dumas F, Baarir N, Truchot J, Desmettre T, Tazarourte K, Beaune S, Leleu A, Khellaf M, Wargon M, Bloom B, Rousseau A, Simon T, Riou B, Group PI. Effect of the pulmonary embolism rule-out criteria on subsequent thromboembolic events among low-risk emergency department patients: the PROPER randomized clinical trial. JAMA 2018; 319 :559 \u0002 566. 96. Righini M, Le Gal G, De Lucia S, Roy PM, Meyer G, Aujesky D, Bounameaux H, Perrier A. Clinical usefulness of D-dimer testing in cancer patients with sus- pected pulmonary embolism. Thromb Haemost 2006; 95 :715 \u0002 719. 97. Di Nisio M, Sohne M, Kamphuisen PW, Buller HR. D-dimer test in cancer patients with suspected acute pulmonary embolism. J Thromb Haemost 2005; 3 :1239 \u0002 1242. 98. Miron MJ, Perrier A, Bounameaux H, de Moerloose P, Slosman DO, Didier D, Junod A. Contribution of noninvasive evaluation to the diagnosis of pulmonary embolism in hospitalized patients. Eur Respir J 1999; 13 :1365 \u0002 1370. 99. Chabloz P, Reber G, Boehlen F, Hohlfeld P, de Moerloose P. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br J Haematol 2001; 115 :150 \u0002 152. 100. Francalanci I, Comeglio P, Liotta AA, Cellai AP, Fedi S, Parretti E, Mello G, Prisco D, Abbate R. D-dimer concentrations during normal pregnancy, as meas- ured by ELISA. Thromb Res 1995; 78 :399 \u0002 405. ESC Guidelines 51 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101. Perrier A, Roy PM, Sanchez O, Le Gal G, Meyer G, Gourdier AL, Furber A, Revel MP, Howarth N, Davido A, Bounameaux H. Multidetector-row com- puted tomography in suspected pulmonary embolism. N Engl J Med 2005; 352 :1760 \u0002 1768. 102. Perrier A, Roy PM, Aujesky D, Chagnon I, Howarth N, Gourdier AL, Leftheriotis G, Barghouth G, Cornuz J, Hayoz D, Bounameaux H. Diagnosing pulmonary embolism in outpatients with clinical assessment, D-dimer measure- ment, venous ultrasound, and helical computed tomography: a multicenter management study. Am J Med 2004; 116 :291 \u0002 299. 103. Wells PS, Anderson DR, Rodger M, Stiell I, Dreyer JF, Barnes D, Forgie M, Kovacs G, Ward J, Kovacs MJ. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and D-dimer. Ann Intern Med 2001; 135 :98 \u0002 107. 104. Carrier M, Righini M, Djurabi RK, Huisman MV, Perrier A, Wells PS, Rodger M, Wuillemin WA, Le Gal G. VIDAS D-dimer in combination with clinical pre-test probability to rule out pulmonary embolism. A systematic review of manage- ment outcome studies. Thromb Haemost 2009; 101 :886 \u0002 892. 105. Righini M, Goehring C, Bounameaux H, Perrier A. Effects of age on the per- formance of common diagnostic tests for pulmonary embolism. Am J Med 2000; 109 :357 \u0002 361. 106. Righini M, Van Es J, Den Exter PL, Roy PM, Verschuren F, Ghuysen A, Rutschmann OT, Sanchez O, Jaffrelot M, Trinh-Duc A, Le Gall C, Moustafa F, Principe A, Van Houten AA, Ten Wolde M, Douma RA, Hazelaar G, Erkens PM, Van Kralingen KW, Grootenboers MJ, Durian MF, Cheung YW, Meyer G, Bounameaux H, Huisman MV, Kamphuisen PW, Le Gal G. Age-adjusted D- dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA 2014; 311 :1117 \u0002 1124. 107. van der Hulle T, Cheung WY, Kooij S, Beenen LFM, van Bemmel T, van Es J, Faber LM, Hazelaar GM, Heringhaus C, Hofstee H, Hovens MMC, Kaasjager KAH, van Klink RCJ, Kruip M, Loeffen RF, Mairuhu ATA, Middeldorp S, Nijkeuter M, van der Pol LM, Schol-Gelok S, Ten Wolde M, Klok FA, Huisman MV, Years Study Group. Simplified diagnostic management of suspected pulmo- nary embolism (the YEARS study): a prospective, multicentre, cohort study. Lancet 2017; 390 :289 \u0002 297. 108. Howick J, Cals JW, Jones C, Price CP, Pluddemann A, Heneghan C, Berger MY, Buntinx F, Hickner J, Pace W, Badrick T, Van den Bruel A, Laurence C, van Weert HC, van Severen E, Parrella A, Thompson M. Current and future use of point-of-care tests in primary care: an international survey in Australia, Belgium, The Netherlands, the UK and the USA. BMJ Open 2014; 4 :e005611. 109. Kingma AEC, van Stel HF, Oudega R, Moons KGM, Geersing GJ. Multi-faceted implementation strategy to increase use of a clinical guideline for the diagnosis of deep venous thrombosis in primary care. Fam Pract 2017; 34 :446 \u0002 451. 110. Geersing GJ, Janssen KJ, Oudega R, Bax L, Hoes AW, Reitsma JB, Moons KG. Excluding venous thromboembolism using point of care D-dimer tests in outpa- tients: a diagnostic meta-analysis. BMJ 2009; 339 :b2990. 111. Geersing GJ, Erkens PM, Lucassen WA, Buller HR, Cate HT, Hoes AW, Moons KG, Prins MH, Oudega R, van Weert HC, Stoffers HE. Safe exclusion of pulmo- nary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study. BMJ 2012; 345 :e6564. 112. Patel S, Kazerooni EA, Cascade PN. Pulmonary embolism: optimization of small pulmonary artery visualization at multi-detector row CT. Radiology 2003; 227 :455 \u0002 460. 113. Ghaye B, Szapiro D, Mastora I, Delannoy V, Duhamel A, Remy J, Remy-Jardin M. Peripheral pulmonary arteries: how far in the lung does multi-detector row spiral CT allow analysis? Radiology 2001; 219 :629 \u0002 636. 114. Carrier M, Righini M, Wells PS, Perrier A, Anderson DR, Rodger MA, Pleasance S, Le Gal G. Subsegmental pulmonary embolism diagnosed by computed tomogra- phy: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies. J Thromb Haemost 2010; 8 :1716 \u0002 1722. 115. Stein PD, Fowler SE, Goodman LR, Gottschalk A, Hales CA, Hull RD, Leeper KV Jr, Popovich J Jr, Quinn DA, Sos TA, Sostman HD, Tapson VF, Wakefield TW, Weg JG, Woodard PK; PIOPED II Investigators. Multidetector computed tomog- raphy for acute pulmonary embolism. N Engl J Med 2006; 354 :2317 \u0002 2327. 116. Reid JH, Coche EE, Inoue T, Kim EE, Dondi M, Watanabe N, Mariani G; International Atomic Energy Agency Consultants’ Group. Is the lung scan alive and well? Facts and controversies in defining the role of lung scintigraphy for the diagnosis of pulmonary embolism in the era of MDCT. Eur J Nucl Med Mol Imaging 2009; 36 :505 \u0002 521. 117. Waxman AD, Bajc M, Brown M, Fahey FH, Freeman LM, Haramati LB, Julien P, Le Gal G, Neilly B, Rabin J, Soudry G, Tapson V, Torbati S, Kauffman J, Ahuja S, Donohoe K. Appropriate use criteria for ventilation-perfusion imaging in pul- monary embolism: summary and excerpts. J Nucl Med 2017; 58 :13N \u0002 15N. 118. Sostman HD, Coleman RE, DeLong DM, Newman GE, Paine S. Evaluation of revised criteria for ventilation-perfusion scintigraphy in patients with suspected pulmonary embolism. Radiology 1994; 193 :103 \u0002 107. 119. Gottschalk A, Sostman HD, Coleman RE, Juni JE, Thrall J, McKusick KA, Froelich JW, Alavi A. Ventilation-perfusion scintigraphy in the PIOPED study. Part II. Evaluation of the scintigraphic criteria and interpretations. J Nucl Med 1993; 34 :1119 \u0002 1126. 120. Glaser JE, Chamarthy M, Haramati LB, Esses D, Freeman LM. Successful and safe implementation of a trinary interpretation and reporting strategy for V/Q lung scintigraphy. J Nucl Med 2011; 52 :1508 \u0002 1512. 121. Bajc M, Olsson B, Palmer J, Jonson B. Ventilation/perfusion SPECT for diagnos- tics of pulmonary embolism in clinical practice. J Intern Med 2008; 264 :379 \u0002 387. 122. Anderson DR, Kahn SR, Rodger MA, Kovacs MJ, Morris T, Hirsch A, Lang E, Stiell I, Kovacs G, Dreyer J, Dennie C, Cartier Y, Barnes D, Burton E, Pleasance S, Skedgel C, O’Rouke K, Wells PS. Computed tomographic pulmonary angiog- raphy vs ventilation-perfusion lung scanning in patients with suspected pulmo- nary embolism: a randomized controlled trial. JAMA 2007; 298 :2743 \u0002 2753. 123. Sostman HD, Stein PD, Gottschalk A, Matta F, Hull R, Goodman L. Acute pul- monary embolism: sensitivity and specificity of ventilation-perfusion scintigraphy in PIOPED II study. Radiology 2008; 246 :941 \u0002 946. 124. Roy PM, Colombet I, Durieux P, Chatellier G, Sors H, Meyer G. Systematic review and meta-analysis of strategies for the diagnosis of suspected pulmonary embolism. BMJ 2005; 331 :259. 125. van Es J, Douma RA, Hezemans RE, Penaloza A, Motte S, Erkens PG, Durian MF, van Eck-Smit BL, Kamphuisen PW. Accuracy of X-ray with perfusion scan in young patients with suspected pulmonary embolism. Thromb Res 2015; 136 :221 \u0002 224. 126. Gutte H, Mortensen J, Jensen CV, Johnbeck CB, von der Recke P, Petersen CL, Kjaergaard J, Kristoffersen US, Kjaer A. Detection of pulmonary embolism with combined ventilation-perfusion SPECT and low-dose CT: head-to-head comparison with multidetector CT angiography. J Nucl Med 2009; 50 :1987 \u0002 1992. 127. Reinartz P, Wildberger JE, Schaefer W, Nowak B, Mahnken AH, Buell U. Tomographic imaging in the diagnosis of pulmonary embolism: a comparison between V/Q lung scintigraphy in SPECT technique and multislice spiral CT. J Nucl Med 2004; 45 :1501 \u0002 1508. 128. Collart JP, Roelants V, Vanpee D, Lacrosse M, Trigaux JP, Delaunois L, Gillet JB, De CP, Vander BT. Is a lung perfusion scan obtained by using single photon emission computed tomography able to improve the radionuclide diagnosis of pulmonary embolism? Nucl Med Commun 2002; 23 :1107 \u0002 1113. 129. Kumar N, Xie K, Mar W, Anderson TM, Carney B, Mehta N, Machado R, Blend MJ, Lu Y. Software-based hybrid perfusion SPECT/CT provides diagnostic accu- racy when other pulmonary embolism imaging is indeterminate. Nucl Med Mol Imaging 2015; 49 :303 \u0002 311. 130. Ling IT, Naqvi HA, Siew TK, Loh NK, Ryan GF. SPECT ventilation perfusion scanning with the addition of low-dose CT for the investigation of suspected pulmonary embolism. Intern Med J 2012; 42 :1257 \u0002 1261. 131. Le Duc-Pennec A, Le Roux PY, Cornily JC, Jaffrelot M, Delluc A, de Saint- Martin L, Guillo P, Le Gal G, Salaun PY, Leroyer C. Diagnostic accuracy of single-photon emission tomography ventilation/perfusion lung scan in the diag- nosis of pulmonary embolism. Chest 2012; 141 :381 \u0002 387. 132. Simanek M, Koranda P. The benefit of personalized hybrid SPECT/CT pulmo- nary imaging. Am J Nucl Med Mol Imaging 2016; 6 :215 \u0002 222. 133. Qanadli SD, Hajjam ME, Mesurolle B, Barre O, Bruckert F, Joseph T, Mignon F, Vieillard-Baron A, Dubourg O, Lacombe P. Pulmonary embolism detection: prospective evaluation of dual-section helical CT versus selective pulmonary arteriography in 157 patients. Radiology 2000; 217 :447 \u0002 455. 134. Investigators P. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diag- nosis (PIOPED). JAMA 1990; 263 :2753 \u0002 2759. 135. Stein PD, Henry JW, Gottschalk A. Reassessment of pulmonary angiography for the diagnosis of pulmonary embolism: relation of interpreter agreement to the order of the involved pulmonary arterial branch. Radiology 1999; 210 :689 \u0002 691. 136. Diffin DC, Leyendecker JR, Johnson SP, Zucker RJ, Grebe PJ. Effect of anatomic distribution of pulmonary emboli on interobserver agreement in the interpreta- tion of pulmonary angiography. AJR Am J Roentgenol 1998; 171 :1085 \u0002 1089. 137. Stein PD, Athanasoulis C, Alavi A, Greenspan RH, Hales CA, Saltzman HA, Vreim CE, Terrin ML, Weg JG. Complications and validity of pulmonary angiog- raphy in acute pulmonary embolism. Circulation 1992; 85 :462 \u0002 468. 138. Engelberger RP, Kucher N. Catheter-based reperfusion treatment of pulmonary embolism. Circulation 2011; 124 :2139 \u0002 2144. 139. Revel MP, Sanchez O, Couchon S, Planquette B, Hernigou A, Niarra R, Meyer G, Chatellier G. Diagnostic accuracy of magnetic resonance imaging for an acute pulmonary embolism: results of the ‘IRM-EP’ study. J Thromb Haemost 2012; 10 :743 \u0002 750. 140. Stein PD, Chenevert TL, Fowler SE, Goodman LR, Gottschalk A, Hales CA, Hull RD, Jablonski KA, Leeper KV Jr, Naidich DP, Sak DJ, Sostman HD, Tapson VF, Weg JG, Woodard PK; PIOPED III (Prospective Investigation of Pulmonary Embolism Diagnosis II) Investigators. Gadolinium-enhanced magnetic resonance 52 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . angiography for pulmonary embolism: a multicenter prospective study (PIOPED III). Ann Intern Med 2010; 152 :434 \u0002 443, W142 \u0002 W143. 141. Leung AN, Bull TM, Jaeschke R, Lockwood CJ, Boiselle PM, Hurwitz LM, James AH, McCullough LB, Menda Y, Paidas MJ, Royal HD, Tapson VF, Winer-Muram HT, Chervenak FA, Cody DD, McNitt-Gray MF, Stave CD, Tuttle BD. An offi- cial American Thoracic Society/Society of Thoracic Radiology clinical practice guideline: evaluation of suspected pulmonary embolism in pregnancy. Am J Respir Crit Care Med 2011; 184 :1200 \u0002 1208. 142. Grifoni S, Olivotto I, Cecchini P, Pieralli F, Camaiti A, Santoro G, Conti A, Agnelli G, Berni G. Short-term clinical outcome of patients with acute pulmo- nary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 2000; 101 :2817 \u0002 2822. 143. Torbicki A, Kurzyna M, Ciurzynski M, Pruszczyk P, Pacho R, Kuch-Wocial A, Szulc M. Proximal pulmonary emboli modify right ventricular ejection pattern. Eur Respir J 1999; 13 :616 \u0002 621. 144. Bova C, Greco F, Misuraca G, Serafini O, Crocco F, Greco A, Noto A. Diagnostic utility of echocardiography in patients with suspected pulmonary embolism. Am J Emerg Med 2003; 21 :180 \u0002 183. 145. Kurnicka K, Lichodziejewska B, Goliszek S, Dzikowska-Diduch O, Zdonczyk O, Kozlowska M, Kostrubiec M, Ciurzynski M, Palczewski P, Grudzka K, Krupa M, Koc M, Pruszczyk P. Echocardiographic pattern of acute pulmonary embolism: analysis of 511 consecutive patients. J Am Soc Echocardiogr 2016; 29 :907 \u0002 913. 146. Kurzyna M, Torbicki A, Pruszczyk P, Burakowska B, Fijalkowska A, Kober J, Oniszh K, Kuca P, Tomkowski W, Burakowski J, Wawrzy \u0013 nska L. Disturbed right ventricular ejection pattern as a new Doppler echocardiographic sign of acute pulmonary embolism. Am J Cardiol 2002; 90 :507 \u0002 511. 147. Casazza F, Bongarzoni A, Capozi A, Agostoni O. Regional right ventricular dys- function in acute pulmonary embolism and right ventricular infarction. Eur J Echocardiogr 2005; 6 :11 \u0002 4. 148. Pruszczyk P, Goliszek S, Lichodziejewska B, Kostrubiec M, Ciurzy \u0013 nski M, Kurnicka K, Dzikowska-Diduch O, Palczewski P, Wyzgal A. Prognostic value of echocardiography in normotensive patients with acute pulmonary embolism. JACC Cardiovasc Imaging 2014; 7 :553 \u0002 560. 149. Lobo JL, Holley A, Tapson V, Moores L, Oribe M, Barr \u0013 on M, Otero R, Nauffal D, Valle R, Monreal M, Yusen RD, Jime ´nez D; PROTECT and RIETE Investigators. Prognostic significance of tricuspid annular displacement in nor- motensive patients with acute symptomatic pulmonary embolism. J Thromb Haemost 2014; 12 :1020 \u0002 1027. 150. Platz E, Hassanein AH, Shah A, Goldhaber SZ, Solomon SD. Regional right ven- tricular strain pattern in patients with acute pulmonary embolism. Echocardiography 2012; 29 :464 \u0002 470. 151. Sugiura E, Dohi K, Onishi K, Takamura T, Tsuji A, Ota S, Yamada N, Nakamura M, Nobori T, Ito M. Reversible right ventricular regional non-uniformity quanti- fied by speckle-tracking strain imaging in patients with acute pulmonary throm- boembolism. J Am Soc Echocardiogr 2009; 22 :1353 \u0002 1359. 152. Dresden S, Mitchell P, Rahimi L, Leo M, Rubin-Smith J, Bibi S, White L, Langlois B, Sullivan A, Carmody K. Right ventricular dilatation on bedside echocardiogra- phy performed by emergency physicians aids in the diagnosis of pulmonary embolism. Ann Emerg Med 2014; 63 :16 \u0002 24. 153. Casazza F, Becattini C, Guglielmelli E, Floriani I, Morrone V, Caponi C, Pizzorno L, Masotti L, Bongarzoni A, Pignataro L. Prognostic significance of free-floating right heart thromboemboli in acute pulmonary embolism: results from the Italian Pulmonary Embolism Registry. Thromb Haemost 2014; 111 :53 \u0002 57. 154. Mansencal N, Attias D, Caille V, Desperramons J, Guiader J, El Hajjam M, Lacombe P, Abi Nasr I, Jardin F, Vieillard-Baron A, Dubourg O. Computed tomography for the detection of free-floating thrombi in the right heart in acute pulmonary embolism. Eur Radiol 2011; 21 :240 \u0002 245. 155. Torbicki A, Galie ´ N, Covezzoli A, Rossi E, De Rosa M, Goldhaber SZ; ICOPER Study Group. Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. J Am Coll Cardiol 2003; 41 :2245 \u0002 2251. 156. Casazza F, Bongarzoni A, Centonze F, Morpurgo M. Prevalence and prognostic significance of right-sided cardiac mobile thrombi in acute massive pulmonary embolism. Am J Cardiol 1997; 79 :1433 \u0002 1435. 157. Ko \u0013 c M, Kostrubiec M, Elikowski W, Meneveau N, Lankeit M, Grifoni S, Kuch- Wocial A, Petris A, Zaborska B, Stefanovi \u0013 c BS, Hugues T, Torbicki A, Konstantinides S, Pruszczyk P, RiHTER Investigators. Outcome of patients with right heart thrombi: the Right Heart Thrombi European Registry. Eur Respir J 2016; 47 :869 \u0002 875. 158. Barrios D, Rosa-Salazar V, Morillo R, Nieto R, Fernandez S, Zamorano JL, Monreal M, Torbicki A, Yusen RD, Jimenez D. Prognostic significance of right heart thrombi in patients with acute symptomatic pulmonary embolism: system- atic review and meta-analysis. Chest 2017; 151 :409 \u0002 416. 159. Barrios D, Rosa-Salazar V, Jime ´nez D, Morillo R, Muriel A, Del Toro J, L \u0013 opez- Jime ´nez L, Farge-Bancel D, Yusen R, Monreal M; RIETE investigators. Right heart thrombi in pulmonary embolism. Eur Respir J 2016; 48 :1377 \u0002 1385. 160. Guerin L, Couturaud F, Parent F, Revel MP, Gillaizeau F, Planquette B, Pontal D, Guegan M, Simonneau G, Meyer G, Sanchez O. Prevalence of chronic throm- boembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Haemost 2014; 112 :598 \u0002 605. 161. Hull RD, Hirsh J, Carter CJ, Jay RM, Dodd PE, Ockelford PA, Coates G, Gill GJ, Turpie AG, Doyle DJ, Buller HR, Raskob GE. Pulmonary angiography, ventila- tion lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med 1983; 98 :891 \u0002 899. 162. Perrier A, Bounameaux H. Ultrasonography of leg veins in patients suspected of having pulmonary embolism. Ann Intern Med 1998; 128 :243 \u0002 243. 163. Kearon C, Ginsberg JS, Hirsh J. The role of venous ultrasonography in the diag- nosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med 1998; 129 :1044 \u0002 1049. 164. Righini M, Le Gal G, Aujesky D, Roy PM, Sanchez O, Verschuren F, Rutschmann O, Nonent M, Cornuz J, Thys F, Le Manach CP, Revel MP, Poletti PA, Meyer G, Mottier D, Perneger T, Bounameaux H, Perrier A. Diagnosis of pulmonary embolism by multidetector CT alone or combined with venous ultrasonography of the leg: a randomised non-inferiority trial. Lancet 2008; 371 :1343 \u0002 13452. 165. Le Gal G, Righini M, Sanchez O, Roy PM, Baba-Ahmed M, Perriers A, Bounameaux H. A positive compression ultrasonography of the lower limb veins is highly predictive of pulmonary embolism on computed tomography in suspected patients. Thromb Haemost 2006; 95 :963 \u0002 966. 166. Da Costa Rodrigues J, Alzuphar S, Combescure C, Le Gal G, Perrier A. Diagnostic characteristics of lower limb venous compression ultrasonography in suspected pulmonary embolism: a meta-analysis. J Thromb Haemost 2016; 14 :1765 \u0002 1772. 167. Nazerian P, Volpicelli G, Gigli C, Lamorte A, Grifoni S, Vanni S. Diagnostic accu- racy of focused cardiac and venous ultrasound examinations in patients with shock and suspected pulmonary embolism. Intern Emerg Med 2018; 13 :567 \u0002 574. 168. Rademaker J, Griesshaber V, Hidajat N, Oestmann JW, Felix R. Combined CT pulmonary angiography and venography for diagnosis of pulmonary embolism and deep vein thrombosis: radiation dose. J Thorac Imaging 2001; 16 :297 \u0002 299. 169. Kucher N, Luder CM, Dornhofer T, Windecker S, Meier B, Hess OM. Novel management strategy for patients with suspected pulmonary embolism. Eur Heart J 2003; 24 :366 \u0002 376. 170. Lucassen W, Geersing GJ, Erkens PM, Reitsma JB, Moons KG, Buller H, van Weert HC. Clinical decision rules for excluding pulmonary embolism: a meta- analysis. Ann Intern Med 2011; 155 :448 \u0002 460. 171. van Belle A, Buller HR, Huisman MV, Huisman PM, Kaasjager K, Kamphuisen PW, Kramer MH, Kruip MJ, Kwakkel-van Erp JM, Leebeek FW, Nijkeuter M, Prins MH, Sohne M, Tick LW. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA 2006; 295 :172 \u0002 179. 172. Musset D, Parent F, Meyer G, Maı ˆtre S, Girard P, Leroyer C, Revel MP, Carette MF, Laurent M, Charbonnier B, Laurent F, Mal H, Nonent M, Lancar R, Grenier P, Simonneau G; Evaluation du Scanner Spirale ´ dans l’Embolie Pulmonaire study group. Diagnostic strategy for patients with suspected pulmonary embolism: a prospective multicentre outcome study. Lancet 2002; 360 :1914 \u0002 1920. 173. Kruip MJHA, Slob MJ, Schijen JHEM, van der Heul C, Bu ¨ller HR. Use of a clinical decision rule in combination with D-dimer concentration in diagnostic workup of patients with suspected pulmonary embolism - A prospective management study. Arch Intern Med 2002; 162 :1631 \u0002 1635. 174. Perrier A, Desmarais S, Miron MJ, de Moerloose P, Lepage R, Slosman D, Didier D, Unger PF, Patenaude JV, Bounameaux H. Non-invasive diagnosis of venous thromboembolism in outpatients. Lancet 1999; 353 :190 \u0002 195. 175. Di Nisio M, Squizzato A, Rutjes AWS, Buller HR, Zwinderman AH, Bossuyt PMM. Diagnostic accuracy of D-dimer test for exclusion of venous throm- boembolism: a systematic review. J Thromb Haemost 2007; 5 :296 \u0002 304. 176. Stein PD, Hull RD, Patel KC, Olson RE, Ghali WA, Brant R, Biel RK, Bharadia V, Kalra NK. D-dimer for the exclusion of acute venous thrombosis and pulmo- nary embolism: a systematic review. Ann Intern Med 2004; 140 :589 \u0002 602. 177. Righini M, Le Gal G, Aujesky D, Roy PM, Sanchez O, Verschuren F, Kossovsky M, Bressollette L, Meyer G, Perrier A, Bounameaux H. Complete venous ultra- sound in outpatients with suspected pulmonary embolism. J Thromb Haemost 2009; 7 :406 \u0002 412. 178. Aujesky D, Roy PM, Verschuren F, Righini M, Osterwalder J, Egloff M, Renaud B, Verhamme P, Stone RA, Legall C, Sanchez O, Pugh NA, N’Gako A, Cornuz J, Hugli O, Beer HJ, Perrier A, Fine MJ, Yealy DM. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open- label, randomised, non-inferiority trial. Lancet 2011; 378 :41 \u0002 48. 179. Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, Bluhmki E, Bouvaist H, Brenner B, Couturaud F, Dellas C, Empen K, Franca A, Galie N, Geibel A, Goldhaber SZ, Jimenez D, Kozak M, Kupatt C, Kucher N, Lang IM, Lankeit M, Meneveau N, Pacouret G, Palazzini M, Petris A, Pruszczyk P, Rugolotto M, Salvi A, Schellong S, Sebbane M, Sobkowicz B, Stefanovic BS, ESC Guidelines 53 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Thiele H, Torbicki A, Verschuren F, Konstantinides SV; PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014; 370 :1402 \u0002 1411. 180. Coutance G, Cauderlier E, Ehtisham J, Hamon M, Hamon M. The prognostic value of markers of right ventricular dysfunction in pulmonary embolism: a meta-analysis. Crit Care 2011; 15 :R103. 181. Sanchez O, Trinquart L, Colombet I, Durieux P, Huisman MV, Chatellier G, Meyer G. Prognostic value of right ventricular dysfunction in patients with hae- modynamically stable pulmonary embolism: a systematic review. Eur Heart J 2008; 29 :1569 \u0002 1577. 182. Doyen D, Castellani M, Moceri P, Chiche O, Lazdunski R, Bertora D, Cerboni P, Chaussade C, Ferrari E. Patent foramen ovale and stroke in intermediate-risk pulmonary embolism. Chest 2014; 146 :967 \u0002 973. 183. Goliszek S, Wisniewska M, Kurnicka K, Lichodziejewska B, Ciurzynski M, Kostrubiec M, Golebiowski M, Babiuch M, Paczynska M, Koc M, Palczewski P, Wyzgal A, Pruszczyk P. Patent foramen ovale increases the risk of acute ische- mic stroke in patients with acute pulmonary embolism leading to right ventricu- lar dysfunction. Thromb Res 2014; 134 :1052 \u0002 1056. 184. Becattini C, Agnelli G, Vedovati MC, Pruszczyk P, Casazza F, Grifoni S, Salvi A, Bianchi M, Douma R, Konstantinides S, Lankeit M, Duranti M. Multidetector computed tomography for acute pulmonary embolism: diagnosis and risk strati- fication in a single test. Eur Heart J 2011; 32 :1657 \u0002 1663. 185. Meinel FG, Nance JW Jr, Schoepf UJ, Hoffmann VS, Thierfelder KM, Costello P, Goldhaber SZ, Bamberg F. Predictive value of computed tomography in acute pulmonary embolism: systematic review and meta-analysis. Am J Med 2015; 128 :747 \u0002 759.e2. 186. Cote ´ B, Jimenez D, Planquette B, Roche A, Marey J, Pastre J, Meyer G, Sanchez O. Prognostic value of right ventricular dilatation in patients with low-risk pul- monary embolism. Eur Respir J 2017; 50 :1701611. 187. George E, Kumamaru KK, Ghosh N, Gonzalez Quesada C, Wake N, Bedayat A, Dunne RM, Saboo SS, Khandelwal A, Hunsaker AR, Rybicki FJ, Gerhard- Herman M. Computed tomography and echocardiography in patients with acute pulmonary embolism: part 2: prognostic value. J Thorac Imaging 2014; 29 :W7 \u0002 W12. 188. Etesamifard N, Shirani S, Jenab Y, Lotfi-Tokaldany M, Pourjafari M, Jalali A. Role of clinical and pulmonary computed tomography angiographic parameters in the prediction of short- and long-term mortality in patients with pulmonary embolism. Intern Emerg Med 2016; 11 :405 \u0002 413. 189. Aviram G, Soikher E, Bendet A, Shmueli H, Ziv-Baran T, Amitai Y, Friedensohn L, Berliner S, Meilik A, Topilsky Y. Prediction of mortality in pulmonary embo- lism based on left atrial volume measured on CT pulmonary angiography. Chest 2016; 149 :667 \u0002 675. 190. Aviram G, Sirota-Cohen C, Steinvil A, Keren G, Banai S, Sosna J, Berliner S, Rogowski O. Automated volumetric analysis of four cardiac chambers in pul- monary embolism: a novel technology for fast risk stratification. Thromb Haemost 2012; 108 :384 \u0002 393. 191. Kang DK, Thilo C, Schoepf UJ, Barraza JM Jr, Nance JW Jr, Bastarrika G, Abro JA, Ravenel JG, Costello P, Goldhaber SZ. CT signs of right ventricular dysfunc- tion: prognostic role in acute pulmonary embolism. JACC Cardiovasc Imaging 2011; 4 :841 \u0002 849. 192. Bach AG, Nansalmaa B, Kranz J, Taute BM, Wienke A, Schramm D, Surov A. CT pulmonary angiography findings that predict 30-day mortality in patients with acute pulmonary embolism. Eur J Radiol 2015; 84 :332 \u0002 337. 193. Aviram G, Cohen D, Steinvil A, Shmueli H, Keren G, Banai S, Berliner S, Rogowski O. Significance of reflux of contrast medium into the inferior vena cava on computerized tomographic pulmonary angiogram. Am J Cardiol 2012; 109 :432 \u0002 437. 194. Bajaj A, Saleeb M, Rathor P, Sehgal V, Kabak B, Hosur S. Prognostic value of troponins in acute nonmassive pulmonary embolism: a meta-analysis. Heart Lung 2015; 44 :327 \u0002 334. 195. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pul- monary embolism: a meta-analysis. Circulation 2007; 116 :427 \u0002 433. 196. Kaeberich A, Seeber V, Jimenez D, Kostrubiec M, Dellas C, Hasenfuss G, Giannitsis E, Pruszczyk P, Konstantinides S, Lankeit M. Age-adjusted high- sensitivity troponin T cut-off value for risk stratification of pulmonary embolism. Eur Respir J 2015; 45 :1323 \u0002 1331. 197. Lankeit M, Friesen D, Aschoff J, Dellas C, Hasenfuss G, Katus H, Konstantinides S, Giannitsis E. Highly sensitive troponin T assay in normotensive patients with acute pulmonary embolism. Eur Heart J 2010; 31 :1836 \u0002 1844. 198. Boscheri A, Wunderlich C, Langer M, Schoen S, Wiedemann B, Stolte D, Elmer G, Barthel P, Strasser RH. Correlation of heart-type fatty acid-binding protein with mortality and echocardiographic data in patients with pulmonary embolism at intermediate risk. Am Heart J 2010; 160 :294 \u0002 300. 199. Puls M, Dellas C, Lankeit M, Olschewski M, Binder L, Geibel A, Reiner C, Schafer K, Hasenfuss G, Konstantinides S. Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. Eur Heart J 2007; 28 :224 \u0002 229. 200. Dellas C, Puls M, Lankeit M, Schafer K, Cuny M, Berner M, Hasenfuss G, Konstantinides S. Elevated heart-type fatty acid-binding protein levels on admis- sion predict an adverse outcome in normotensive patients with acute pulmo- nary embolism. J Am Coll Cardiol 2010; 55 :2150 \u0002 2157. 201. Dellas C, Lobo JL, Rivas A, Ballaz A, Portillo AK, Nieto R, Del Rey JM, Zamorano JL, Lankeit M, Jimenez D. Risk stratification of acute pulmonary embolism based on clinical parameters, H-FABP and multidetector CT. Int J Cardiol 2018; 265 :223 \u0002 228. 202. Bajaj A, Rathor P, Sehgal V, Shetty A, Kabak B, Hosur S. Risk stratification in acute pulmonary embolism with heart-type fatty acid-binding protein: a meta- analysis. J Crit Care 2015; 30 :1151.e1 \u0002 7. 203. Henzler T, Roeger S, Meyer M, Schoepf UJ, Nance JW Jr, Haghi D, Kaminski WE, Neumaier M, Schoenberg SO, Fink C. Pulmonary embolism: CT signs and cardiac biomarkers for predicting right ventricular dysfunction. Eur Respir J 2012; 39 :919 \u0002 926. 204. Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the pre- diction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med 2008; 178 :425 \u0002 430. 205. Kucher N, Goldhaber SZ. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation 2003; 108 :2191 \u0002 2194. 206. Agterof MJ, Schutgens RE, Snijder RJ, Epping G, Peltenburg HG, Posthuma EF, Hardeman JA, van der GR, Koster T, Prins MH, Biesma DH. Out of hospital treatment of acute pulmonary embolism in patients with a low NT-proBNP level. J Thromb Haemost 2010; 8 :1235 \u0002 1241. 207. Lankeit M, Jimenez D, Kostrubiec M, Dellas C, Kuhnert K, Hasenfuss G, Pruszczyk P, Konstantinides S. Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism. Eur Respir J 2014; 43 :1669 \u0002 1677. 208. Vanni S, Viviani G, Baioni M, Pepe G, Nazerian P, Socci F, Bartolucci M, Bartolini M, Grifoni S. Prognostic value of plasma lactate levels among patients with acute pulmonary embolism: the thrombo-embolism lactate outcome study. Ann Emerg Med 2013; 61 :330 \u0002 338. 209. Vanni S, Jimenez D, Nazerian P, Morello F, Parisi M, Daghini E, Pratesi M, Lopez R, Bedate P, Lobo JL, Jara-Palomares L, Portillo AK, Grifoni S. Short-term clini- cal outcome of normotensive patients with acute PE and high plasma lactate. Thorax 2015; 70 :333 \u0002 338. 210. Vanni S, Nazerian P, Bova C, Bondi E, Morello F, Pepe G, Paladini B, Liedl G, Cangioli E, Grifoni S, Jimenez D. Comparison of clinical scores for identification of patients with pulmonary embolism at intermediate-high risk of adverse clini- cal outcome: the prognostic role of plasma lactate. Intern Emerg Med 2017; 12 :657 \u0002 665. 211. Kostrubiec M, Plywaczewska M, Jime ´nez D, Lankeit M, Ciurzynski M, Konstantinides S, Pruszczyk P. The prognostic value of renal function in acute pulmonary embolism- a multi-centre cohort study. Thromb Haemost 2019; 119 :140 \u0002 148. 212. Kostrubiec M, Labyk A, Pedowska-Wloszek J, Dzikowska-Diduch O, Wojciechowski A, Garlinska M, Ciurzynski M, Pruszczyk P. Neutrophil gelatinase-associated lipocalin, cystatin C and eGFR indicate acute kidney injury and predict prognosis of patients with acute pulmonary embolism. Heart 2012; 98 :1221 \u0002 1228. 213. Zhou XY, Chen HL, Ni SS. Hyponatremia and short-term prognosis of patients with acute pulmonary embolism: a meta-analysis. Int J Cardiol 2017; 227 :251 \u0002 256. 214. Vuilleumier N, Simona A, Mean M, Limacher A, Lescuyer P, Gerstel E, Bounameaux H, Aujesky D, Righini M. Comparison of cardiac and non-cardiac biomarkers for risk stratification in elderly patients with non-massive pulmonary embolism. PLoS One 2016; 11 :e0155973. 215. Wyzgal A, Koc M, Pacho S, Bielecki M, Wawrzyniak R, Kostrubiec M, Ciurzynski M, Kurnicka K, Goliszek S, Paczynska M, Palczewski P, Pruszczyk P. Plasma copeptin for short term risk stratification in acute pulmonary embolism. J Thromb Thrombolysis 2016; 41 :563 \u0002 568. 216. Hellenkamp K, Schwung J, Rossmann H, Kaeberich A, Wachter R, Hasenfuss G, Konstantinides S, Lankeit M. Risk stratification of normotensive pulmonary embolism: prognostic impact of copeptin. Eur Respir J 2015; 46 :1701 \u0002 1710. 217. Hellenkamp K, Pruszczyk P, Jimenez D, Wyzgal A, Barrios D, Ciurzynski M, Morillo R, Hobohm L, Keller K, Kurnicka K, Kostrubiec M, Wachter R, Hasenfuss G, Konstantinides S, Lankeit M. Prognostic impact of copeptin in pulmonary embolism: a multicentre validation study. Eur Respir J 2018; 51 :1702037. 218. Jimenez D, Lobo JL, Fernandez-Golfin C, Portillo AK, Nieto R, Lankeit M, Konstantinides S, Prandoni P, Muriel A, Yusen RD; PROTECT Investigators. Effectiveness of prognosticating pulmonary embolism using the ESC algorithm and the Bova score. Thromb Haemost 2016; 115 :827 \u0002 834. 219. Hobohm L, Hellenkamp K, Hasenfuss G, Munzel T, Konstantinides S, Lankeit M. Comparison of risk assessment strategies for not-high-risk pulmonary embo- lism. Eur Respir J 2016; 47 :1170 \u0002 1178. 54 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 220. Fernandez C, Bova C, Sanchez O, Prandoni P, Lankeit M, Konstantinides S, Vanni S, Fernandez-Golfin C, Yusen RD, Jimenez D. Validation of a model for identification of patients at intermediate to high risk for complications associ- ated with acute symptomatic pulmonary embolism. Chest 2015; 148 :211 \u0002 218. 221. Bova C, Sanchez O, Prandoni P, Lankeit M, Konstantinides S, Vanni S, Jimenez D. Identification of intermediate-risk patients with acute symptomatic pulmo- nary embolism. Eur Respir J 2014; 44 :694 \u0002 703. 222. Dellas C, Tschepe M, Seeber V, Zwiener I, Kuhnert K, Schafer K, Hasenfuss G, Konstantinides S, Lankeit M. A novel H-FABP assay and a fast prognostic score for risk assessment of normotensive pulmonary embolism. Thromb Haemost 2014; 111 :996 \u0002 1003. 223. Lankeit M, Friesen D, Schafer K, Hasenfuss G, Konstantinides S, Dellas C. A sim- ple score for rapid risk assessment of non-high-risk pulmonary embolism. Clin Res Cardiol 2013; 102 :73 \u0002 80. 224. Committee TPS. Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evi- dence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Am Heart J 2012; 163 :33 \u0002 38. 225. Donze J, Le Gal G, Fine MJ, Roy PM, Sanchez O, Verschuren F, Cornuz J, Meyer G, Perrier A, Righini M, Aujesky D. Prospective validation of the Pulmonary Embolism Severity Index. A clinical prognostic model for pulmonary embolism. Thromb Haemost 2008; 100 :943 \u0002 948. 226. Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J, Roy PM, Fine MJ. Derivation and validation of a prognostic model for pulmonary embo- lism. Am J Respir Crit Care Med 2005; 172 :1041 \u0002 1046. 227. Elias A, Mallett S, Daoud-Elias M, Poggi JN, Clarke M. Prognostic models in acute pulmonary embolism: a systematic review and meta-analysis. BMJ Open 2016; 6 :e010324. 228. Kohn CG, Mearns ES, Parker MW, Hernandez AV, Coleman CI. Prognostic accuracy of clinical prediction rules for early post-pulmonary embolism all- cause mortality: a bivariate meta-analysis. Chest 2015; 147 :1043 \u0002 1062. 229. Jime ´nez D, Aujesky D, Moores L, G \u0013 omez V, Lobo JL, Uresandi F, Otero R, Monreal M, Muriel A, Yusen RD; RIETE Investigators. Simplification of the pul- monary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010; 170 :1383 \u0002 1389. 230. Righini M, Roy PM, Meyer G, Verschuren F, Aujesky D, Le Gal G. The Simplified Pulmonary Embolism Severity Index (PESI): validation of a clinical prognostic model for pulmonary embolism. J Thromb Haemost 2011; 9 :2115 \u0002 2117. 231. Sam A, Sanchez D, Gomez V, Wagner C, Kopecna D, Zamarro C, Moores L, Aujesky D, Yusen R, Jimenez Castro D. The shock index and the simplified PESI for identification of low-risk patients with acute pulmonary embolism. Eur Respir J 2011; 37 :762 \u0002 766. 232. Jime ´nez D, Aujesky D, D \u0013 ıaz G, Monreal M, Otero R, Mart \u0013 ı D, Marin E, Aracil E, Sueiro A, Yusen RD; RIETE Investigators. Prognostic significance of deep vein thrombosis in patients presenting with acute symptomatic pulmonary embo- lism. Am J Respir Crit Care Med 2010; 181 :983 \u0002 991. 233. Becattini C, Cohen AT, Agnelli G, Howard L, Castejon B, Trujillo-Santos J, Monreal M, Perrier A, Yusen RD, Jime ´nez D. Risk stratification of patients with acute symptomatic pulmonary embolism based on presence or absence of lower extremity DVT: systematic review and Meta-analysis. Chest 2016; 149 :192 \u0002 200. 234. Barco S, Mahmoudpour SH, Planquette B, Sanchez O, Konstantinides SV, Meyer G. Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review and meta-analysis. Eur Heart J 2019; 40 :902 \u0002 910. 235. Becattini C, Agnelli G, Lankeit M, Masotti L, Pruszczyk P, Casazza F, Vanni S, Nitti C, Kamphuisen P, Vedovati MC, De Natale MG, Konstantinides S. Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. Eur Respir J 2016; 48 :780 \u0002 786. 236. Messika J, Goutorbe P, Hajage D, Ricard JD. Severe pulmonary embolism managed with high-flow nasal cannula oxygen therapy. Eur J Emerg Med 2017; 24 :230 \u0002 232. 237. Lacroix G, Pons F, D’Aranda E, Legodec J, Romanat PE, Goutorbe P. High-flow oxygen, a therapeutic bridge while awaiting thrombolysis in pulmonary embo- lism? Am J Emerg Med 2013; 31 :463.e1 \u0002 2. 238. Mercat A, Diehl JL, Meyer G, Teboul JL, Sors H. Hemodynamic effects of fluid loading in acute massive pulmonary embolism. Crit Care Med 1999; 27 :540 \u0002 544. 239. Green EM, Givertz MM. Management of acute right ventricular failure in the intensive care unit. Curr Heart Fail Rep 2012; 9 :228 \u0002 235. 240. Ghignone M, Girling L, Prewitt RM. Volume expansion versus norepinephrine in treatment of a low cardiac output complicating an acute increase in right ventricular afterload in dogs. Anesthesiology 1984; 60 :132 \u0002 135. 241. Manier G, Castaing Y. Influence of cardiac output on oxygen exchange in acute pulmonary embolism. Am Rev Respir Dis 1992; 145 :130 \u0002 136. 242. Kerbaul F, Gariboldi V, Giorgi R, Mekkaoui C, Guieu R, Fesler P, Gouin F, Brimioulle S, Collart F. Effects of levosimendan on acute pulmonary embolism- induced right ventricular failure. Crit Care Med 2007; 35 :1948 \u0002 1954. 243. Capellier G, Jacques T, Balvay P, Blasco G, Belle E, Barale F. Inhaled nitric oxide in patients with pulmonary embolism. Intensive Care Med 1997; 23 :1089 \u0002 1092. 244. Szold O, Khoury W, Biderman P, Klausner JM, Halpern P, Weinbroum AA. Inhaled nitric oxide improves pulmonary functions following massive pulmonary embolism: a report of four patients and review of the literature. Lung 2006; 184 :1 \u0002 5. 245. Summerfield DT, Desai H, Levitov A, Grooms DA, Marik PE. Inhaled nitric oxide as salvage therapy in massive pulmonary embolism: a case series. Respir Care 2012; 57 :444 \u0002 448. 246. Bhat T, Neuman A, Tantary M, Bhat H, Glass D, Mannino W, Akhtar M, Bhat A, Teli S, Lafferty J. Inhaled nitric oxide in acute pulmonary embolism: a systematic review. Rev Cardiovasc Med 2015; 16 :1 \u0002 8. 247. Corsi F, Lebreton G, Brechot N, Hekimian G, Nieszkowska A, Trouillet JL, Luyt CE, Leprince P, Chastre J, Combes A, Schmidt M. Life-threatening massive pul- monary embolism rescued by venoarterial-extracorporeal membrane oxygena- tion. Crit Care 2017; 21 :76. 248. Weinberg A, Tapson VF, Ramzy D. Massive pulmonary embolism: extracorpor- eal membrane oxygenation and surgical pulmonary embolectomy. Semin Respir Crit Care Med 2017; 38 :66 \u0002 72. 249. Dolmatova EV, Moazzami K, Cocke TP, Elmann E, Vaidya P, Ng AF, Satya K, Narayan RL. Extracorporeal membrane oxygenation in massive pulmonary embolism. Heart Lung 2017; 46 :106 \u0002 109. 250. Swol J, Buchwald D, Strauch J, Schildhauer TA. Extracorporeal life support (ECLS) for cardiopulmonary resuscitation (CPR) with pulmonary embolism in surgical patients - a case series. Perfusion 2016; 31 :54 \u0002 59. 251. Yusuff HO, Zochios V, Vuylsteke A. Extracorporeal membrane oxygenation in acute massive pulmonary embolism: a systematic review. Perfusion 2015; 30 :611 \u0002 616. 252. Meneveau N, Guillon B, Planquette B, Piton G, Kimmoun A, Gaide-Chevronnay L, Aissaoui N, Neuschwander A, Zogheib E, Dupont H, Pili-Floury S, Ecarnot F, Schiele F, Deye N, de Prost N, Favory R, Girard P, Cristinar M, Ferre A, Meyer G, Capellier G, Sanchez O. Outcomes after extracorporeal membrane oxygen- ation for the treatment of high-risk pulmonary embolism: a multicentre series of 52 cases. Eur Heart J 2018; 39 :4196 \u0002 4204. 253. Shokr M, Rashed A, Mostafa A, Mohamad T, Schreiber T, Elder M, Kaki A. Impella RP support and catheter-directed thrombolysis to treat right ventricular failure caused by pulmonary embolism in 2 patients. Tex Heart Inst J 2018; 45 :182 \u0002 185. 254. Kumar Bhatia N, Dickert NW, Samady H, Babaliaros V. The use of hemody- namic support in massive pulmonary embolism. Catheter Cardiovasc Interv 2017; 90 :516 \u0002 520. 255. Perkins GD, Olasveengen TM, Maconochie I, Soar J, Wyllie J, Greif R, Lockey A, Semeraro F, Van de Voorde P, Lott C, Monsieurs KG, Nolan JP; European Resuscitation Council. European Resuscitation Council Guidelines for Resuscitation: 2017 update. Resuscitation 2018; 123 :43 \u0002 50. 256. Soar J, Nolan JP, Bo ¨ttiger BW, Perkins GD, Lott C, Carli P, Pellis T, Sandroni C, Skrifvars MB, Smith GB, Sunde K, Deakin CD; Adult advanced life support section Collaborators. European Resuscitation Council Guidelines for Resuscitation 2015: Section 3. Adult advanced life support. Resuscitation 2015; 95 :100 \u0002 147. 257. Truhl \u0013 a \u0014 r A, Deakin CD, Soar J, Khalifa GE, Alfonzo A, Bierens JJ, Brattebø G, Brugger H, Dunning J, Hunyadi-Anti \u0014 cevi \u0013 c S, Koster RW, Lockey DJ, Lott C, Paal P, Perkins GD, Sandroni C, Thies KC, Zideman DA, Nolan JP; Cardiac arrest in special circumstances section Collaborators. European Resuscitation Council Guidelines for Resuscitation 2015: Section 4. Cardiac arrest in special circum- stances. Resuscitation 2015; 95 :148 \u0002 201. 258. Aso S, Matsui H, Fushimi K, Yasunaga H. In-hospital mortality and successful weaning from venoarterial extracorporeal membrane oxygenation: analysis of 5,263 patients using a national inpatient database in Japan. Crit Care 2016; 20 :80. 259. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbu ¨chel H; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antago- nist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39 :1330 \u0002 1393. 260. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 :799 \u0002 808. 261. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 :1287 \u0002 1297. ESC Guidelines 55 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 262. Cossette B, Pelletier ME, Carrier N, Turgeon M, Leclair C, Charron P, Echenberg D, Fayad T, Farand P. Evaluation of bleeding risk in patients exposed to therapeu- tic unfractionated or low-molecular-weight heparin: a cohort study in the context of a quality improvement initiative. Ann Pharmacother 2010; 44 :994 \u0002 1002. 263. Erkens PM, Prins MH. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2010; 9 :CD001100. 264. Stein PD, Hull RD, Matta F, Yaekoub AY, Liang J. Incidence of thrombocytope- nia in hospitalized patients with venous thromboembolism. Am J Med 2009; 122 :919 \u0002 930. 265. Prandoni P, Siragusa S, Girolami B, Fabris F; BELZONI Investigators Group. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 2005; 106 :3049 \u0002 3054. 266. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based hep- arin dosing nomogram compared with a \"standard care\" nomogram. A random- ized controlled trial. Ann Intern Med 1993; 119 :874 \u0002 881. 267. van Es N, Coppens M, Schulman S, Middeldorp S, Bu ¨ller HR. Direct oral antico- agulants compared with vitamin K antagonists for acute venous thromboembo- lism: evidence from phase 3 trials. Blood 2014; 124 :1968 \u0002 1975. 268. van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2014; 12 :320 \u0002 328. 269. Witt DM, Clark NP, Kaatz S, Schnurr T, Ansell JE. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis 2016; 41 :187 \u0002 205. 270. Carlquist JF, Anderson JL. Using pharmacogenetics in real time to guide warfarin initiation: a clinician update. Circulation 2011; 124 :2554 \u0002 2559. 271. Epstein RS, Moyer TP, Aubert RE, DJ OK, Xia F, Verbrugge RR, Gage BF, Teagarden JR. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 2010; 55 :2804 \u0002 2812. 272. Kheiri B, Abdalla A, Haykal T, Osman M, Ahmed S, Hassan M, Bachuwa G. Meta-analysis of genotype-guided versus standard dosing of vitamin K antago- nists. Am J Cardiol 2018; 121 :879 \u0002 887. 273. Mearns ES, White CM, Kohn CG, Hawthorne J, Song JS, Meng J, Schein JR, Raut MK, Coleman CI. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J 2014; 12 :14. 274. Garcia DA, Witt DM, Hylek E, Wittkowsky AK, Nutescu EA, Jacobson A, Moll S, Merli GJ, Crowther M, Earl L, Becker RC, Oertel L, Jaffer A, Ansell JE; Anticoagulation Forum. Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother 2008; 42 :979 \u0002 988. 275. Sharma P, Scotland G, Cruickshank M, Tassie E, Fraser C, Burton C, Croal B, Ramsay CR, Brazzelli M. Is self-monitoring an effective option for people receiv- ing long-term vitamin K antagonist therapy? A systematic review and economic evaluation. BMJ Open 2015; 5 :e007758. 276. Goldhaber SZ, Come PC, Lee RT, Braunwald E, Parker JA, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, Taveira da Silva AM, Mogtader A, McDonough TJ. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993; 341 :507 \u0002 511. 277. Dalla-Volta S, Palla A, Santolicandro A, Giuntini C, Pengo V, Visioli O, Zonzin P, Zanuttini D, Barbaresi F, Agnelli G, Morpurgo M, Marini MG, Visani L. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pul- monary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol 1992; 20 :520 \u0002 526. 278. Kline JA, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, Rondina MT, Diercks DB, Klinger JR, Hernandez J. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost 2014; 12 :459 \u0002 468. 279. Becattini C, Agnelli G, Salvi A, Grifoni S, Pancaldi LG, Enea I, Balsemin F, Campanini M, Ghirarduzzi A, Casazza F. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res 2010; 125 :e82 \u0002 e86. 280. Daniels LB, Parker JA, Patel SR, Grodstein F, Goldhaber SZ. Relation of dura- tion of symptoms with response to thrombolytic therapy in pulmonary embo- lism. Am J Cardiol 1997; 80 :184 \u0002 188. 281. Meneveau N, Seronde MF, Blonde MC, Legalery P, Didier-Petit K, Briand F, Caulfield F, Schiele F, Bernard Y, Bassand JP. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest 2006; 129 :1043 \u0002 1050. 282. Marti C, John G, Konstantinides S, Combescure C, Sanchez O, Lankeit M, Meyer G, Perrier A. Systemic thrombolytic therapy for acute pulmonary embo- lism: a systematic review and meta-analysis. Eur Heart J 2015; 36 :605 \u0002 614. 283. Chatterjee S, Chakraborty A, Weinberg I, Kadakia M, Wilensky RL, Sardar P, Kumbhani DJ, Mukherjee D, Jaff MR, Giri J. Thrombolysis for pulmonary embo- lism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA 2014; 311 :2414 \u0002 2421. 284. Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M; MOPETT Investigators. Moderate pulmonary embolism treated with thrombolysis (from the \"MOPETT\" Trial). Am J Cardiol 2013; 111 :273 \u0002 277. 285. Wang C, Zhai Z, Yang Y, Wu Q, Cheng Z, Liang L, Dai H, Huang K, Lu W, Zhang Z, Cheng X, Shen YH. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary throm- boembolism: a randomized, multicenter, controlled trial. Chest 2010; 137 :254 \u0002 262. 286. Tebbe U, Graf A, Kamke W, Zahn R, Forycki F, Kratzsch G, Berg G. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J 1999; 138 :39 \u0002 44. 287. Tebbe U, Bramlage P, Graf A, Lechleitner P, Bode C, Riess FC, Clemens N, Al Rawi Y, Konstantinides S, Goldhaber SZ. Desmoteplase in acute massive pul- monary thromboembolism. Thromb Haemost 2009; 101 :557 \u0002 562. 288. Konstantinides SV, Vicaut E, Danays T, Becattini C, Bertoletti L, Beyer- Westendorf J, Bouvaist H, Couturaud F, Dellas C, Duerschmied D, Empen K, Ferrari E, Galie N, Jimenez D, Kostrubiec M, Kozak M, Kupatt C, Lang IM, Lankeit M, Meneveau N, Palazzini M, Pruszczyk P, Rugolotto M, Salvi A, Sanchez O, Schellong S, Sobkowicz B, Meyer G. Impact of thrombolytic therapy on the long-term outcome of intermediate-risk pulmonary embolism. J Am Coll Cardiol 2017; 69 :1536 \u0002 1544. 289. Galie ` N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hyperten- sion: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37 :67 \u0002 119. 290. Tafur AJ, Shamoun FE, Patel SI, Tafur D, Donna F, Murad MH. Catheter- directed treatment of pulmonary embolism: a systematic review and meta- analysis of modern literature. Clin Appl Thromb Hemost 2017; 23 :821 \u0002 829. 291. Kaymaz C, Akbal OY, Tanboga IH, Hakgor A, Yilmaz F, Ozturk S, Poci N, Turkday S, Ozdemir N, Konstantinides S. Ultrasound-assisted catheter-directed thrombolysis in high-risk and intermediate-high-risk pulmonary embolism: a meta-analysis. Curr Vasc Pharmacol 2018; 16 :179 \u0002 189. 292. Bajaj NS, Kalra R, Arora P, Ather S, Guichard JL, Lancaster WJ, Patel N, Raman F, Arora G, Al Solaiman F, Clark DT III, Dell’Italia LJ, Leesar MA, Davies JE, McGiffin DC, Ahmed MI. Catheter-directed treatment for acute pulmonary embolism: systematic review and single-arm meta-analyses. Int J Cardiol 2016; 225 :128 \u0002 139. 293. Kucher N, Boekstegers P, Muller OJ, Kupatt C, Beyer-Westendorf J, Heitzer T, Tebbe U, Horstkotte J, Muller R, Blessing E, Greif M, Lange P, Hoffmann RT, Werth S, Barmeyer A, Hartel D, Grunwald H, Empen K, Baumgartner I. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 2014; 129 :479 \u0002 486. 294. Piazza G, Hohlfelder B, Jaff MR, Ouriel K, Engelhardt TC, Sterling KM, Jones NJ, Gurley JC, Bhatheja R, Kennedy RJ, Goswami N, Natarajan K, Rundback J, Sadiq IR, Liu SK, Bhalla N, Raja ML, Weinstock BS, Cynamon J, Elmasri FF, Garcia MJ, Kumar M, Ayerdi J, Soukas P, Kuo W, Liu PY, Goldhaber SZ. A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low- dose fibrinolysis for acute massive and submassive pulmonary embolism: the SEATTLE II study. JACC Cardiovasc Interv 2015; 8 :1382 \u0002 1392. 295. Tapson VF, Sterling K, Jones N, Elder M, Tripathy U, Brower J, Maholic RL, Ross CB, Natarajan K, Fong P, Greenspon L, Tamaddon H, Piracha AR, Engelhardt T, Katopodis J, Marques V, Sharp ASP, Piazza G, Goldhaber SZ. A randomized trial of the optimum duration of acoustic pulse thrombolysis pro- cedure in acute intermediate-risk pulmonary embolism: the OPTALYSE PE trial. JACC Cardiovasc Interv 2018; 11 :1401 \u0002 1410. 296. Kuo WT, Banerjee A, Kim PS, DeMarco FJ Jr, Levy JR, Facchini FR, Unver K, Bertini MJ, Sista AK, Hall MJ, Rosenberg JK, De Gregorio MA. Pulmonary Embolism Response to Fragmentation, Embolectomy, and Catheter Thrombolysis (PERFECT): initial results from a prospective multicenter Registry. Chest 2015; 148 :667 \u0002 673. 297. Lee T, Itagaki S, Chiang YP, Egorova NN, Adams DH, Chikwe J. Survival and recurrence after acute pulmonary embolism treated with pulmonary embolec- tomy or thrombolysis in New York State, 1999 to 2013. J Thorac Cardiovasc Surg 2018; 155 :1084 \u0002 1090.e12. 298. Wu MY, Liu YC, Tseng YH, Chang YS, Lin PJ, Wu TI. Pulmonary embolectomy in high-risk acute pulmonary embolism: the effectiveness of a comprehensive 56 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . therapeutic algorithm including extracorporeal life support. Resuscitation 2013; 84 :1365 \u0002 1370. 299. Keeling WB, Sundt T, Leacche M, Okita Y, Binongo J, Lasajanak Y, Aklog L, Lattouf OM. Outcomes after surgical pulmonary embolectomy for acute pul- monary embolus: a multi-institutional study. Ann Thorac Surg 2016; 102 :1498 \u0002 1502. 300. Pasrija C, Kronfli A, Rouse M, Raithel M, Bittle GJ, Pousatis S, Ghoreishi M, Gammie JS, Griffith BP, Sanchez PG, Kon ZN. Outcomes after surgical pulmo- nary embolectomy for acute submassive and massive pulmonary embolism: a single-center experience. J Thorac Cardiovasc Surg 2018; 155 :1095 \u0002 1106.e2. 301. Dudzinski DM, Piazza G. Multidisciplinary pulmonary embolism response teams. Circulation 2016; 133 :98 \u0002 103. 302. Mismetti P, Laporte S, Pellerin O, Ennezat PV, Couturaud F, Elias A, Falvo N, Meneveau N, Quere I, Roy PM, Sanchez O, Schmidt J, Seinturier C, Sevestre MA, Beregi JP, Tardy B, Lacroix P, Presles E, Leizorovicz A, Decousus H, Barral FG, Meyer G; PREPIC2 Study Group. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmo- nary embolism: a randomized clinical trial. JAMA 2015; 313 :1627 \u0002 1635. 303. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d’Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005; 112 :416 \u0002 422. 304. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simonneau G. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d’Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998; 338 :409 \u0002 415. 305. Bikdeli B, Chatterjee S, Desai NR, Kirtane AJ, Desai MM, Bracken MB, Spencer FA, Monreal M, Goldhaber SZ, Krumholz HM. Inferior vena cava filters to pre- vent pulmonary embolism: systematic review and meta-analysis. J Am Coll Cardiol 2017; 70 :1587 \u0002 1597. 306. Jia Z, Wu A, Tam M, Spain J, McKinney JM, Wang W. Caval penetration by infe- rior vena cava filters: a systematic literature review of clinical significance and management. Circulation 2015; 132 :944 \u0002 952. 307. Durack JC, Westphalen AC, Kekulawela S, Bhanu SB, Avrin DE, Gordon RL, Kerlan RK. Perforation of the IVC: rule rather than exception after longer indwelling times for the Gunther Tulip and Celect retrievable filters. Cardiovasc Intervent Radiol 2012; 35 :299 \u0002 308. 308. Angel LF, Tapson V, Galgon RE, Restrepo MI, Kaufman J. Systematic review of the use of retrievable inferior vena cava filters. J Vasc Interv Radiol 2011; 22 :1522 \u0002 1530.e3. 309. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombo- sis: a randomized trial. Ann Intern Med 2004; 140 :867 \u0002 873. 310. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, vdB-S, AECariou, R Leeuwenkamp, O Lensing AW. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349 :1695 \u0002 1702. 311. Robertson L, Jones LE. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev 2017; 2 :CD001100. 312. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le MF, Peter N, Kearon C. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129 :764 \u0002 772. 313. Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous throm- boembolism. N Engl J Med 2013; 369 :1406 \u0002 1415. 314. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 :2342 \u0002 2352. 315. Brandjes DP, Heijboer H, Buller HR, de RM, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327 :1485 \u0002 1489. 316. Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS, Hirsh J, Martin GJ, Green D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322 :1260 \u0002 1264. 317. Zondag W, Mos IC, Creemers-Schild D, Hoogerbrugge AD, Dekkers OM, Dolsma J, Eijsvogel M, Faber LM, Hofstee HM, Hovens MM, Jonkers GJ, van Kralingen KW, Kruip MJ, Vlasveld T, DE Vreede MJ, Huisman MV; Hestia Study Investigators. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost 2011; 9 :1500 \u0002 1507. 318. den Exter PL, Zondag W, Klok FA, Brouwer RE, Dolsma J, Eijsvogel M, Faber LM, van GM, Grootenboers MJ, Heller-Baan R, Hovens MM, Jonkers GJ, van Kralingen KW, Melissant CF, Peltenburg H, Post JP, Van De Ree MA, Vlasveld T, DE Vreede MJ, Huisman MV; Vesta Study Investigators.Efficacy and safety of outpatient treatment based on the Hestia clinical decision rule with or without NT-proBNP testing in patients with acute pulmonary embolism: a randomized clinical trial. Am J Respir Crit Care Med 2016; 194 :998 \u0002 1006. 319. Barco S, Schmidtmann I, Ageno W, Bauersachs RM, Becattini C, Bernardi E, Beyer-Westendorf J, Bonacchini L, Brachmann J, Christ M, Czihal M, Duerschmied D, Empen K, Espinola-Klein C, Ficker J, Fonseca C, Genth-Zotz S, Jimenez D, Harjola VP, Held M, Iogna Prat L, Lange TJ, Manolis A, Meyer A, Mustonen P, Rauch-Kroehner U, Ruiz-Artacho P, Schellong S, Schwaiblmair M, Stahrenberg R, Westerweel PE, Wild PS, Konstantinides SV, Lankeit M; HoT-PE Investigators. Early discharge and home treatment of patients with low-risk pul- monary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. Eur Heart J ;doi: 10.1093/eurheartj/ehz367. Published online ahead of print 23 May 2019. 320. Kline JA, Webb WB, Jones AE, Hernandez-Nino J. Impact of a rapid rule-out protocol for pulmonary embolism on the rate of screening, missed cases, and pulmonary vascular imaging in an urban US emergency department. Ann Emerg Med 2004; 44 :490 \u0002 502. 321. Pierre-Justin G, Pierard LA. Management of mobile right heart thrombi: a pro- spective series. Int J Cardiol 2005; 99 :381 \u0002 388. 322. Ferrari E, Benhamou M, Berthier F, Baudouy M. Mobile thrombi of the right heart in pulmonary embolism: delayed disappearance after thrombolytic treat- ment. Chest 2005; 127 :1051 \u0002 1053. 323. Righini M, Aujesky D, Roy PM, Cornuz J, de Moerloose P, Bounameaux H, Perrier A. Clinical usefulness of D-dimer depending on clinical probability and cutoff value in outpatients with suspected pulmonary embolism. Arch Intern Med 2004; 164 :2483 \u0002 2487. 324. Brenner DJ, Hall EJ. Computed tomography–an increasing source of radiation exposure. N Engl J Med 2007; 357 :2277 \u0002 2284. 325. Perrier A, Miron MJ, Desmarais S, de MP, Slosman D, Didier D, Unger PF, Junod A, Patenaude JV, Bounameaux H. Using clinical evaluation and lung scan to rule out suspected pulmonary embolism: is it a valid option in patients with normal results of lower-limb venous compression ultrasonography? Arch Intern Med 2000; 160 :512 \u0002 516. 326. Stein PD, Sostman HD, Dalen JE, Bailey DL, Bajc M, Goldhaber SZ, Goodman LR, Gottschalk A, Hull RD, Matta F, Pistolesi M, Tapson VF, Weg JG, Wells PS, Woodard PK; Consensus Group. Controversies in diagnosis of pulmonary embolism. Clin Appl Thromb Hemost 2011; 17 :140 \u0002 149. 327. Roy PM, Moumneh T, Penaloza A, Sanchez O. Outpatient management of pul- monary embolism. Thromb Res 2017; 155 :92 \u0002 100. 328. Otero R, Uresandi F, Jimenez D, Cabezudo MA, Oribe M, Nauffal D, Conget F, Rodriguez C, Cayuela A. Home treatment in pulmonary embolism. Thromb Res 2010; 126 :e1 \u0002 e5. 329. Torbicki A. Assessing the severity of acute pulmonary embolism: back to the future? Eur Heart J 2019; 40 :911 \u0002 913. 330. Couturaud F, Sanchez O, Pernod G, Mismetti P, Jego P, Duhamel E, Provost K, dit Sollier CB, Presles E, Castellant P, Parent F, Salaun PY, Bressollette L, Nonent M, Lorillon P, Girard P, Lacut K, Gue ´gan M, Bosson JL, Laporte S, Leroyer C, De ´cousus H, Meyer G, Mottier D; PADIS-PE Investigators. Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE randomized clinical trial. JAMA 2015; 314 :31 \u0002 40. 331. Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, Imberti D, Poggio R, Ageno W, Pogliani E, Porro F, Zonzin P. Extended oral anticoagulant ther- apy after a first episode of pulmonary embolism. Ann Intern Med 2003; 139 :19 \u0002 25. 332. Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost 2002; 88 :407 \u0002 414. 333. Carrier M, Le GG, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010; 152 :578 \u0002 589. 334. Douketis JD, Gu CS, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med 2007; 147 :766 \u0002 774. 335. Campbell IA, Bentley DP, Prescott RJ, Routledge PA, Shetty HG, Williamson IJ. Anticoagulation for three versus six months in patients with deep vein throm- bosis or pulmonary embolism, or both: randomised trial. BMJ 2007; 334 :674. 336. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999 ; 340 :901 \u0002 907; Erratum N Engl J Med 1999;341:298]. 337. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H. A comparison of six weeks with six ESC Guidelines 57 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . months of oral anticoagulant therapy after a first episode of venous throm- boembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995; 332 :1661 \u0002 1665. 338. Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle PA; Subcommittees on Control of Anticoagulation, and Predictive and Diagnostic Variables in Thrombotic Disease. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost 2016; 14 :1480 \u0002 1483. 339. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved interna- tional normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18 :3078 \u0002 3083. 340. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: pro- spective cohort study. Lancet 2003; 362 :523 \u0002 526. 341. Iorio A, Kearon C, Filippucci E, Marcucci M, Macura A, Pengo V, Siragusa S, Palareti G. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 2010; 170 :1710 \u0002 1716. 342. Devreese KMJ, Ortel TL, Pengo V, de Laat B’ Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. Laboratory criteria for antiphos- pholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16 :809 \u0002 813. 343. Rodger MA, Le Gal G, Anderson DR, Schmidt J, Pernod G, Kahn SR, Righini M, Mismetti P, Kearon C, Meyer G, Elias A, Ramsay T, Ortel TL, Huisman MV, Kovacs MJ; REVERSE II Study Investigators. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ 2017; 356 :j1065. 344. Ensor J, Riley RD, Moore D, Snell KI, Bayliss S, Fitzmaurice D. Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post- treatment of first unprovoked VTE. BMJ Open 2016; 6 :e011190. 345. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139 :893 \u0002 900. 346. Kakkos SK, Kirkilesis GI, Tsolakis IA. Editor’s Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. Eur J Vasc Endovasc Surg 2014; 48 :565 \u0002 575. 347. Boutitie F, Pinede L, Schulman S, Agnelli G, Raskob G, Julian J, Hirsh J, Kearon C. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ 2011; 342 :d3036. 348. Helmert S, Marten S, Mizera H, Reitter A, Sahin K, Tittl L, Beyer-Westendorf J. Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry. J Thromb Thrombolysis 2017; 44 :169 \u0002 178. 349. Beyer-Westendorf J, Forster K, Pannach S, Ebertz F, Gelbricht V, Thieme C, Michalski F, Kohler C, Werth S, Sahin K, Tittl L, Hansel U, Weiss N. Rates, man- agement, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014; 124 :955 \u0002 962. 350. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ. Extended use of dabiga- tran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368 :709 \u0002 718. 351. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 :2499 \u0002 2510. 352. Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376 :1211 \u0002 1222. 353. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; AMPLIFY-EXT Investigators. Apixaban for extended treat- ment of venous thromboembolism. N Engl J Med 2013; 368 :699 \u0002 708. 354. Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, Barcellona D, Gerosa M, Banzato A. Rivaroxaban vs warfarin in high-risk patients with antiphospholi- pid syndrome. Blood 2018; 132 :1365 \u0002 1371. 355. Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, Gibbs H, Hague W, Xavier D, Diaz R, Kirby A, Simes J. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367 :1979 \u0002 1987. 356. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, Bianchi M, Moia M, Ageno W, Vandelli MR, Grandone E, Prandoni P. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366 :1959 \u0002 1967. 357. Andreozzi GM, Bignamini AA, Dav \u0012 ı G, Palareti G, Matuska J, Holy M, Pawlaczyk- Gabriel K, D \u0014 zupina A, Sokurenko GY, Didenko YP, Andrei LD, Lessiani G, Vison \u0012 a A; SURVET Study Investigators. Sulodexide for the prevention of recurrent venous thromboembolism: the Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) study: a multicenter, randomized, double-blind, placebo-controlled trial. Circulation 2015; 132 :1891 \u0002 1897. 358. Schulman S, Granqvist S, Holmstro ¨ m M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, L € arfars G, Leijd B, Linder O, Loogna E. The duration of oral anticoagulant therapy after a second episode of venous thromboembo- lism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997; 336 :393 \u0002 398. 359. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous throm- boembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998; 104 :332 \u0002 338. 360. Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA. Tinzaparin vs warfarin for treatment of acute venous throm- boembolism in patients with active cancer: a randomized clinical trial. JAMA 2015; 314 :677 \u0002 686. 361. Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J. Secondary pre- vention of venous thromboembolic events in patients with active cancer: enox- aparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006; 12 :389 \u0002 396. 362. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. Low-molecular-weight heparin versus a cou- marin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 :146 \u0002 153. 363. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembo- lism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162 :1729 \u0002 1735. 364. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G. Long-term low-molecular-weight heparin ver- sus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119 :1062 \u0002 1072. 365. Posch F, Konigsbrugge O, Zielinski C, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res 2015; 136 :582 \u0002 589. 366. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Bu ¨ller HR; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous throm- boembolism. N Engl J Med 2018; 378 :615 \u0002 624. 367. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M. Comparison of an oral factor Xa inhib- itor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 :2017 \u0002 2023. 368. Louzada ML, Carrier M, Lazo-Langner A, Dao V, Kovacs MJ, Ramsay TO, Rodger MA, Zhang J, Lee AY, Meyer G, Wells PS. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 2012; 126 :448 \u0002 454. 369. Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T, Asensio-Cruz M, Blasco- Esquivias I, Marin-Barrera L, de la Borbolla-Artacho MR, Praena-Fernandez JM, Montero-Romero E, Navarro-Herrero S, Serrano-Gotarredona MP, S \u0013 anchez- D \u0013 ıaz JM, Palacios C, Otero R. Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study. Thromb Res 2017; 157 :90 \u0002 96. 370. Francis CW, Kessler CM, Goldhaber SZ, Kovacs MJ, Monreal M, Huisman MV, Bergqvist D, Turpie AG, Ortel TL, Spyropoulos AC, Pabinger I, Kakkar AK. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN study. J Thromb Haemost 2015; 13 : 1028 \u0002 1035. 371. van Es N, Le Gal G, Otten HM, Robin P, Piccioli A, Lecumberri R, Jara- Palomares L, Religa P, Rieu V, Rondina M, Beckers MM, Prandoni P, Salaun PY, Di Nisio M, Bossuyt PM, Buller HR, Carrier M. Screening for occult cancer in patients with unprovoked venous thromboembolism: a systematic review and meta-analysis of individual patient data. Ann Intern Med 2017; 167 :410 \u0002 417. 372. Carrier M, Lazo-Langner A, Shivakumar S, Tagalakis V, Zarychanski R, Solymoss S, Routhier N, Douketis J, Danovitch K, Lee AY, Le GG, Wells PS, Corsi DJ, 58 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ramsay T, Coyle D, Chagnon I, Kassam Z, Tao H, Rodger MA. Screening for occult cancer in unprovoked venous thromboembolism. N Engl J Med 2015; 373 :697 \u0002 704. 373. Robin P, Le Roux PY, Planquette B, Accassat S, Roy PM, Couturaud F, Ghazzar N, Prevot-Bitot N, Couturier O, Delluc A, Sanchez O, Tardy B, Le Gal G, Salaun PY; NVTEP study group. Limited screening with versus without (18)F-fluorodeoxyglu- cose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncol 2016; 17 :193 \u0002 199. 374. Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, Pabinger I, Solymoss S, Douketis J, Kakkar A. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2016; 17 :e452 \u0002 e466. 375. Mandal \u0012 a M, Falanga A, Roila F; .ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22 :vi85 \u0002 vi92. 376. den Exter PL, Hooijer J, Dekkers OM, Huisman MV. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol 2011; 29 :2405 \u0002 2409. 377. Dentali F, Ageno W, Becattini C, Galli L, Gianni M, Riva N, Imberti D, Squizzato A, Venco A, Agnelli G. Prevalence and clinical history of incidental, asympto- matic pulmonary embolism: a meta-analysis. Thromb Res 2010; 125 :518 \u0002 522. 378. Napolitano M, Saccullo G, Malato A, Sprini D, Ageno W, Imberti D, Mascheroni D, Bucherini E, Gallucci P, D’Alessio A, Prantera T, Spadaro P, Rotondo S, Di Micco P, Oriana V, Urbano O, Recchia F, Ghirarduzzi A, Lo Coco L, Mancuso S, Casuccio A, Rini GB, Siragusa S. Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein throm- bosis: the Cancer-DACUS Study. J Clin Oncol 2014; 32 :3607 \u0002 3612. 379. Berg CJ, Callaghan WM, Syverson C, Henderson Z. Pregnancy-related mortality in the United States, 1998 to 2005. Obstet Gynecol 2010; 116 :1302 \u0002 1309. 380. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ III. Trends in the incidence of venous thromboembolism during pregnancy or post- partum: a 30-year population-based study. Ann Intern Med 2005; 143 :697 \u0002 706. 381. Sultan AA, West J, Tata LJ, Fleming KM, Nelson-Piercy C, Grainge MJ. Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study. Br J Haematol 2012; 156 :366 \u0002 373. 382. Henriksson P, Westerlund E, Wallen H, Brandt L, Hovatta O, Ekbom A. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study. BMJ 2013; 346 :e8632. 383. Sultan AA, West J, Grainge MJ, Riley RD, Tata LJ, Stephansson O, Fleming KM, Nelson-Piercy C, Ludvigsson JF. Development and validation of risk prediction model for venous thromboembolism in postpartum women: multinational cohort study. BMJ 2016; 355 :i6253. 384. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstro ¨ m-Lundqvist C, C \u0013 ıfkov \u0013 a R, De Bonis M, Iung B, Johnson MR, Kintscher U, Kranke P, Lang IM, Morais J, Pieper PG, Presbitero P, Price S, Rosano GMC, Seeland U, Simoncini T, Swan L, Warnes CA; ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018; 39 :3165 \u0002 3241. 385. Sheen JJ, Haramati LB, Natenzon A, Ma H, Tropper P, Bader AS, Freeman LM, Bernstein PS, Moadel RM. Performance of low-dose perfusion scintigraphy and CT pulmonary angiography for pulmonary embolism in pregnancy. Chest 2018; 153 :152 \u0002 160. 386. van Mens TE, Scheres LJ, de Jong PG, Leeflang MM, Nijkeuter M, Middeldorp S. Imaging for the exclusion of pulmonary embolism in pregnancy. Cochrane Database Syst Rev 2017; 1 :CD011053. 387. Hamilton EJ, Green AQ, Cook JA, Nash H. Investigating for pulmonary embo- lism in pregnancy: Five year retrospective review of referrals to the acute medi- cal unit of a large teaching hospital. Acute Med 2016; 15 :58 \u0002 62. 388. Righini M, Robert-Ebadi H, Elias A, Sanchez O, Le Moigne E, Schmidt J, Le Gall C, Cornuz J, Aujesky D, Roy PM, Chauleur C, Rutschmann OT, Poletti PA, Le Gal G; CT-PE-Pregnancy Group. Diagnosis of pulmonary embolism during preg- nancy: a multicenter prospective management outcome study. Ann Intern Med 2018; 169 :766 \u0002 773. 389. Murphy N, Broadhurst DI, Khashan AS, Gilligan O, Kenny LC, O’Donoghue K. Gestation-specific D-dimer reference ranges: a cross-sectional study. BJOG 2015; 122 :395 \u0002 400. 390. Ercan S, Ozkan S, Yucel N, Orcun A. Establishing reference intervals for D- dimer to trimesters. J Matern Fetal Neonatal Med 2015; 28 :983 \u0002 987. 391. van der Pol LM, Tromeur C, Bistervels IM, Ni Ainle F, van Bemmel T, Bertoletti L, Couturaud F, van Dooren YPA, Elias A, Faber LM, Hofstee HMA, van der Hulle T, Kruip M, Maignan M, Mairuhu ATA, Middeldorp S, Nijkeuter M, Roy PM, Sanchez O, Schmidt J, Ten Wolde M, Klok FA, Huisman MV; Artemis Study Investigators. Pregnancy-adapted YEARS algorithm for diagnosis of suspected pulmonary embolism. N Engl J Med 2019; 380 :1139 \u0002 1149. 392. Mitchell DP, Rowan M, Loughman E, Ridge CA, MacMahon PJ. Contrast moni- toring techniques in CT pulmonary angiography: an important and underappre- ciated contributor to breast dose. Eur J Radiol 2017; 86 :184 \u0002 189. 393. Shahir K, McCrea JM, Lozano LA, Goodman LR. Reduced z-axis technique for CT pulmonary angiography in pregnancy–validation for practical use and dose reduction. Emerg Radiol 2015; 22 :651 \u0002 656. 394. Perisinakis K, Seimenis I, Tzedakis A, Damilakis J. Perfusion scintigraphy versus 256-slice CT angiography in pregnant patients suspected of pulmonary embo- lism: comparison of radiation risks. J Nucl Med 2014; 55 :1273 \u0002 1280. 395. Astani SA, Davis LC, Harkness BA, Supanich MP, Dalal I. Detection of pulmo- nary embolism during pregnancy: comparing radiation doses of CTPA and pul- monary scintigraphy. Nucl Med Commun 2014; 35 :704 \u0002 711. 396. Chunilal SD, Bates SM. Venous thromboembolism in pregnancy: diagnosis, man- agement and prevention. Thromb Haemost 2009; 101 :428 \u0002 438. 397. Bajc M, Neilly JB, Miniati M, Schuemichen C, Meignan M, Jonson B; EANM Committee. EANM guidelines for ventilation/perfusion scintigraphy : Part 1. Pulmonary imaging with ventilation/perfusion single photon emission tomogra- phy. Eur J Nucl Med Mol Imaging 2009; 36 :1356 \u0002 1370. 398. Nijkeuter M, Geleijns J, De Roos A, Meinders AE, Huisman MV. Diagnosing pul- monary embolism in pregnancy: rationalizing fetal radiation exposure in radio- logical procedures. J Thromb Haemost 2004; 2 :1857 \u0002 1858. 399. Tromeur C, van der Pol LM, Klok FA, Couturaud F, Huisman MV. Pitfalls in the diagnostic management of pulmonary embolism in pregnancy. Thromb Res 2017; 151 :S86 \u0002 S91. 400. Ginsberg JS, Hirsh J, Rainbow AJ, Coates G. Risks to the fetus of radiologic pro- cedures used in the diagnosis of maternal venous thromboembolic disease. Thromb Haemost 1989; 61 :189 \u0002 196. 401. Schembri GP, Miller AE, Smart R. Radiation dosimetry and safety issues in the investigation of pulmonary embolism. Semin Nucl Med 2010; 40 :442 \u0002 454. 402. Ramsay R, Byrd L, Tower C, James J, Prescott M, Thachil J. The problem of pul- monary embolism diagnosis in pregnancy. Br J Haematol 2015; 170 :727 \u0002 728. 403. Bourjeily G, Khalil H, Raker C, Martin S, Auger P, Chalhoub M, Larson L, Miller M. Outcomes of negative multidetector computed tomography with pulmonary angiography in pregnant women suspected of pulmonary embolism. Lung 2012; 190 :105 \u0002 111. 404. Chan WS, Ray JG, Murray S, Coady GE, Coates G, Ginsberg JS. Suspected pulmo- nary embolism in pregnancy: clinical presentation, results of lung scanning, and sub- sequent maternal and pediatric outcomes. Arch Intern Med 2002; 162 :1170 \u0002 1175. 405. Siegel Y, Kuker R, Banks J, Danton G. CT pulmonary angiogram quality compar- ison between early and later pregnancy. Emerg Radiol 2017; 24 :635 \u0002 640. 406. Armstrong L, Gleeson F, Mackillop L, Mutch S, Beale A. Survey of UK imaging practice for the investigation of pulmonary embolism in pregnancy. Clin Radiol 2017; 72 :696 \u0002 701. 407. Bajc M, Olsson B, Gottsater A, Hindorf C, Jogi J. V/P SPECT as a diagnostic tool for pregnant women with suspected pulmonary embolism. Eur J Nucl Med Mol Imaging 2015; 42 :1325 \u0002 1330. 408. Romualdi E, Dentali F, Rancan E, Squizzato A, Steidl L, Middeldorp S, Ageno W. Anticoagulant therapy for venous thromboembolism during pregnancy: a sys- tematic review and a meta-analysis of the literature. J Thromb Haemost 2013; 11 :270 \u0002 281. 409. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 :e691S \u0002 e736S. 410. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thrombopro- phylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106 :401 \u0002 407. 411. Ni Ainle F, Wong A, Appleby N, Byrne B, Regan C, Hassan T, Milner M, Sullivan AO, White B, O’Donnell J. Efficacy and safety of once daily low molec- ular weight heparin (tinzaparin sodium) in high risk pregnancy. Blood Coagul Fibrinolysis 2008; 19 :689 \u0002 692. 412. Baglin T, Barrowcliffe TW, Cohen A, Greaves M; British Committee for Standards in Haematology. Guidelines on the use and monitoring of heparin. Br J Haematol 2006; 133 :19 \u0002 34. 413. Harenberg J. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes. J Thromb Haemost 2004; 2 :547 \u0002 550. 414. Greer I, Hunt BJ. Low molecular weight heparin in pregnancy: current issues. Br J Haematol 2005; 128 :593 \u0002 601. 415. Galambosi P, Hiilesmaa V, Ulander VM, Laitinen L, Tiitinen A, Kaaja R. Prolonged low-molecular-weight heparin use during pregnancy and subsequent bone mineral density. Thromb Res 2016; 143 :122 \u0002 126. 416. Dempfle CE. Minor transplacental passage of fondaparinux in vivo. N Engl J Med 2004; 350 :1914 \u0002 1915. 417. Cohen H, Arachchillage DR, Middeldorp S, Beyer-Westendorf J, Abdul-Kadir R. Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14 :1673 \u0002 1676. ESC Guidelines 59 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 418. Leffert L, Butwick A, Carvalho B, Arendt K, Bates SM, Friedman A, Horlocker T, Houle T, Landau R, Taskforce SV. The Society for Obstetric Anesthesia and Perinatology Consensus Statement on the anesthetic management of pregnant and postpartum women receiving thromboprophylaxis or higher dose anticoa- gulants. Anesth Analg 2018; 126 :928 \u0002 944. 419. Leffert LR, Dubois HM, Butwick AJ, Carvalho B, Houle TT, Landau R. Neuraxial anesthesia in obstetric patients receiving thromboprophylaxis with unfractio- nated or low-molecular-weight heparin: a systematic review of spinal epidural hematoma. Anesth Analg 2017; 125 :223 \u0002 231. 420. Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM; European Soceity of Anaesthesiology. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol 2010; 27 :999 \u0002 1015. 421. Martillotti G, Boehlen F, Robert-Ebadi H, Jastrow N, Righini M, Blondon M. Treatment options for severe pulmonary embolism during pregnancy and the postpartum period: a systematic review. J Thromb Haemost 2017; 15 :1942 \u0002 1950. 422. Fitzpatrick KE, Tuffnell D, Kurinczuk JJ, Knight M. Incidence, risk factors, man- agement and outcomes of amniotic-fluid embolism: a population-based cohort and nested case-control study. BJOG 2016; 123 :100 \u0002 109. 423. Society for Maternal-Fetal Medicine; Pacheco LD, Saade G, Hankins GD, Clark SL. Amniotic fluid embolism: diagnosis and management. Am J Obstet Gynecol 2016; 215 :B16 \u0002 B24. 424. Clark SL, Romero R, Dildy GA, Callaghan WM, Smiley RM, Bracey AW, Hankins GD, D’Alton ME, Foley M, Pacheco LD, Vadhera RB, Herlihy JP, Berkowitz RL, Belfort MA. Proposed diagnostic criteria for the case definition of amniotic fluid embolism in research studies. Am J Obstet Gynecol 2016; 215 :408 \u0002 412. 425. Fong A, Chau CT, Pan D, Ogunyemi DA. Amniotic fluid embolism: antepartum, intrapartum and demographic factors. J Matern Fetal Neonatal Med 2015; 28 :793 \u0002 798. 426. McDonnell N, Knight M, Peek MJ, Ellwood D, Homer CS, McLintock C, Vaughan G, Pollock W, Li Z, Javid N, Sullivan E; the Australasian Maternity Outcomes Surveillance System (AMOSS). Amniotic fluid embolism: an Australian-New Zealand population-based study. BMC Pregnancy Childbirth 2015; 15 :352. 427. den Exter PL, Van EJ, Kroft LJ, Erkens PM, Douma RA, Mos IC, Jonkers G, Hovens MM, Durian MF, ten CH, Beenen LF, Kamphuisen PW, Huisman MV. Thromboembolic resolution assessed by CT pulmonary angiography after treat- ment for acute pulmonary embolism. Thromb Haemost 2015; 114 :26 \u0002 34. 428. Klok FA, van der Hulle T, den Exter PL, Lankeit M, Huisman MV, Konstantinides S. The post-PE syndrome: a new concept for chronic complica- tions of pulmonary embolism. Blood Rev 2014; 28 :221 \u0002 226. 429. Klok FA, van Kralingen KW, van Dijk AP, Heyning FH, Vliegen HW, Huisman MV. Prevalence and potential determinants of exertional dyspnea after acute pulmonary embolism. Respir Med 2010; 104 :1744 \u0002 1749. 430. Kline JA, Steuerwald MT, Marchick MR, Hernandez-Nino J, Rose GA. Prospective evaluation of right ventricular function and functional status 6 months after acute submassive pulmonary embolism: frequency of persistent or subsequent elevation in estimated pulmonary artery pressure. Chest 2009; 136 :1202 \u0002 1210. 431. Becattini C, Agnelli G, Pesavento R, Silingardi M, Poggio R, Taliani MR, Ageno W. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest 2006; 130 :172 \u0002 175. 432. Sanchez O, Helley D, Couchon S, Roux A, Delaval A, Trinquart L, Collignon MA, Fischer AM, Meyer G. Perfusion defects after pulmonary embolism: risk factors and clinical significance. J Thromb Haemost 2010; 8 :1248 \u0002 1255. 433. Stevinson BG, Hernandez-Nino J, Rose G, Kline JA. Echocardiographic and func- tional cardiopulmonary problems 6 months after first-time pulmonary embo- lism in previously healthy patients. Eur Heart J 2007; 28 :2517 \u0002 2524. 434. Meneveau N, Ider O, Seronde MF, Chopard R, Davani S, Bernard Y, Schiele F. Long-term prognostic value of residual pulmonary vascular obstruction at dis- charge in patients with intermediate- to high-risk pulmonary embolism. Eur Heart J 2013; 34 :693 \u0002 701. 435. Kahn SR, Hirsch AM, Akaberi A, Hernandez P, Anderson DR, Wells PS, Rodger MA, Solymoss S, Kovacs MJ, Rudski L, Shimony A, Dennie C, Rush C, Geerts WH, Aaron SD, Granton JT. Functional and exercise limitations after a first epi- sode of pulmonary embolism: results of the ELOPE prospective cohort study. Chest 2017; 151 :1058 \u0002 1068. 436. Kahn SR, Akaberi A, Granton JT, Anderson DR, Wells PS, Rodger MA, Solymoss S, Kovacs MJ, Rudski L, Shimony A, Dennie C, Rush C, Hernandez P, Aaron SD, Hirsch AM. Quality of life, dyspnea, and functional exercise capacity following a first episode of pulmonary embolism: results of the ELOPE cohort study. Am J Med 2017; 130 :990.e9 \u0002 990.e21. 437. Albaghdadi MS, Dudzinski DM, Giordano N, Kabrhel C, Ghoshhajra B, Jaff MR, Weinberg I, Baggish A. Cardiopulmonary exercise testing in patients following massive and submassive pulmonary embolism. J Am Heart Assoc 2018; 7 :e006841. 438. Konstantinides SV, Barco S, Rosenkranz S, Lankeit M, Held M, Gerhardt F, Bruch L, Ewert R, Faehling M, Freise J, Ghofrani HA, Grunig E, Halank M, Heydenreich N, Hoeper MM, Leuchte HH, Mayer E, Meyer FJ, Neurohr C, Opitz C, Pinto A, Seyfarth HJ, Wachter R, Zapf B, Wilkens H, Binder H, Wild PS. Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study. J Thromb Thrombolysis 2016; 42 :600 \u0002 609. 439. Simonneau G, Hoeper MM. Evaluation of the incidence of rare diseases: difficul- ties and uncertainties, the example of chronic thromboembolic pulmonary hypertension. Eur Respir J 2017; 49 :1602522. 440. Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, Delcroix M, Pruszczyk P, Mairuhu AT, Huisman MV, Klok FA. Incidence of chronic throm- boembolic pulmonary hypertension after acute pulmonary embolism: a con- temporary view of the published literature. Eur Respir J 2017; 49 :1601792. 441. Coquoz N, Weilenmann D, Stolz D, Popov V, Azzola A, Fellrath JM, Stricker H, Pagnamenta A, Ott S, Ulrich S, Gyorik S, Pasquier J, Aubert JD. Multicentre observational screening survey for the detection of CTEPH following pulmo- nary embolism. Eur Respir J 2018; 51 :1702505. 442. Kramm T, Wilkens H, Fuge J, Schafers HJ, Guth S, Wiedenroth CB, Weingard B, Huscher D, Pittrow D, Cebotari S, Hoeper MM, Mayer E, Olsson KM. Incidence and characteristics of chronic thromboembolic pulmonary hyperten- sion in Germany. Clin Res Cardiol 2018; 107 :548 \u0002 553. 443. Dorfmuller P, Gunther S, Ghigna MR, Thomas de Montpreville V, Boulate D, Paul JF, Jais X, Decante B, Simonneau G, Dartevelle P, Humbert M, Fadel E, Mercier O. Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. Eur Respir J 2014; 44 :1275 \u0002 1288. 444. Azarian R, Wartski M, Collignon MA, Parent F, Herve P, Sors H, Simonneau G. Lung perfusion scans and hemodynamics in acute and chronic pulmonary embo- lism. J Nucl Med 1997; 38 :980 \u0002 983. 445. Lewczuk J, Piszko P, Jagas J, Porada A, Wojciak S, Sobkowicz B, Wrabec K. Prognostic factors in medically treated patients with chronic pulmonary embo- lism. Chest 2001; 119 :818 \u0002 823. 446. Riedel M, Stanek V, Widimsky J, Prerovsky I. Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemody- namic and respiratory data. Chest 1982; 81 :151 \u0002 158. 447. Pepke-Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D, Treacy C, D’Armini AM, Morsolini M, Snijder R, Bresser P, Torbicki A, Kristensen B, Lewczuk J, Simkova I, Barbera JA, de Perrot M, Hoeper MM, Gaine S, Speich R, Gomez-Sanchez MA, Kovacs G, Hamid AM, Jais X, Simonneau G. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an interna- tional prospective registry. Circulation 2011; 124 :1973 \u0002 1981. 448. Lang IM, Simonneau G, Pepke-Zaba JW, Mayer E, Ambroz D, Blanco I, Torbicki A, Mellemkjaer S, Yaici A, Delcroix M. Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. A case- control study. Thromb Haemost 2013; 110 :83 \u0002 91. 449. Bonderman D, Wilkens H, Wakounig S, Schafers HJ, Jansa P, Lindner J, Simkova I, Martischnig AM, Dudczak J, Sadushi R, Skoro-Sajer N, Klepetko W, Lang IM. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 2009; 33 :325 \u0002 331. 450. Klok FA, Dzikowska-Diduch O, Kostrubiec M, Vliegen HW, Pruszczyk P, Hasenfuss G, Huisman MV, Konstantinides S, Lankeit M. Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. J Thromb Haemost 2016; 14 :121 \u0002 128. 451. Klok FA, Surie S, Kempf T, Eikenboom J, van Straalen JP, van Kralingen KW, van Dijk AP, Vliegen HW, Bresser P, Wollert KC, Huisman MV. A simple non-invasive diag- nostic algorithm for ruling out chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Thromb Res 2011; 128 :21 \u0002 26. 452. Klok FA, Tesche C, Rappold L, Dellas C, Hasenfuss G, Huisman MV, Konstantinides S, Lankeit M. External validation of a simple non-invasive algo- rithm to rule out chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Thromb Res 2015; 135 :796 \u0002 801. 453. Pepke-Zaba J, Jansa P, Kim NH, Naeije R, Simonneau G. Chronic thromboem- bolic pulmonary hypertension: role of medical therapy. Eur Respir J 2013; 41 :985 \u0002 990. 454. Taboada D, Pepke-Zaba J, Jenkins DP, Berman M, Treacy CM, Cannon JE, Toshner M, Dunning JJ, Ng C, Tsui SS, Sheares KK. Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease. Eur Respir J 2014; 44 :1635 \u0002 1645. 455. Tunariu N, Gibbs SJ, Win Z, Gin-Sing W, Graham A, Gishen P, Al-Nahhas A. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007; 48 :680 \u0002 684. 456. Fang W, Ni XH, He JG, Liu ZH, Xiong CM, He ZX. Value of radionuclide lung scintigraphy in the diagnosis and quantitative analysis of chronic thromboem- bolic pulmonary hypertension [article in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi 2008; 36 :7 \u0002 10. 457. Ley S, Ley-Zaporozhan J, Pitton MB, Schneider J, Wirth GM, Mayer E, Duber C, Kreitner KF. Diagnostic performance of state-of-the-art imaging techniques for 60 ESC Guidelines Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . morphological assessment of vascular abnormalities in patients with chronic thromboembolic pulmonary hypertension (CTEPH). Eur Radiol 2012; 22 :607 \u0002 616. 458. Fukuda T, Ogo T, Nakanishi N, Ueda J, Sanda Y, Morita Y, Sugiyama M, Fukui S, Tsuji A, Naito H. Evaluation of organized thrombus in distal pulmonary arteries in patients with chronic thromboembolic pulmonary hypertension using cone- beam computed tomography. Jpn J Radiol 2016; 34 :423 \u0002 431. 459. Shure D, Gregoratos G, Moser KM. Fiberoptic angioscopy: role in the diagnosis of chronic pulmonary arterial obstruction. Ann Intern Med 1985; 103 : 844 \u0002 850. 460. Vuylsteke A, Sharples L, Charman G, Kneeshaw J, Tsui S, Dunning J, Wheaton E, Klein A, Arrowsmith J, Hall R, Jenkins D. Circulatory arrest versus cerebral perfusion during pulmonary endarterectomy surgery (PEACOG): a randomised controlled trial. Lancet 2011; 378 :1379 \u0002 1387. 461. Jenkins D, Madani M, Fadel E, D’Armini AM, Mayer E. Pulmonary endarterec- tomy in the management of chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2017; 26 :160111. 462. Mayer E, Jenkins D, Lindner J, D’Armini A, Kloek J, Meyns B, Ilkjaer LB, Klepetko W, Delcroix M, Lang I, Pepke-Zaba J, Simonneau G, Dartevelle P. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg 2011; 141 :702 \u0002 710. 463. Madani MM, Auger WR, Pretorius V, Sakakibara N, Kerr KM, Kim NH, Fedullo PF, Jamieson SW. Pulmonary endarterectomy: recent changes in a single institu- tion’s experience of more than 2,700 patients. Ann Thorac Surg 2012; 94 :97 \u0002 103; discussion 103. 464. Jenkins D, Mayer E, Screaton N, Madani M. State-of-the-art chronic throm- boembolic pulmonary hypertension diagnosis and management. Eur Respir Rev 2012; 21 :32 \u0002 39. 465. Delcroix M, Lang I, Pepke-Zaba J, Jansa P, D’Armini AM, Snijder R, Bresser P, Torbicki A, Mellemkjaer S, Lewczuk J, Simkova I, Barbera JA, de Perrot M, Hoeper MM, Gaine S, Speich R, Gomez-Sanchez MA, Kovacs G, Jais X, Ambroz D, Treacy C, Morsolini M, Jenkins D, Lindner J, Dartevelle P, Mayer E, Simonneau G. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. Circulation 2016; 133 :859 \u0002 871. 466. Cannon JE, Su L, Kiely DG, Page K, Toshner M, Swietlik E, Treacy C, Ponnaberanam A, Condliffe R, Sheares K, Taboada D, Dunning J, Tsui S, Ng C, Gopalan D, Screaton N, Elliot C, Gibbs S, Howard L, Corris P, Lordan J, Johnson M, Peacock A, MacKenzie-Ross R, Schreiber B, Coghlan G, Dimopoulos K, Wort SJ, Gaine S, Moledina S, Jenkins DP, Pepke-Zaba J. Dynamic risk stratification of patient long-term outcome after pulmonary endarterectomy: results from the United Kingdom National Cohort. Circulation 2016; 133 :1761 \u0002 1771. 467. Ogawa A, Satoh T, Fukuda T, Sugimura K, Fukumoto Y, Emoto N, Yamada N, Yao A, Ando M, Ogino H, Tanabe N, Tsujino I, Hanaoka M, Minatoya K, Ito H, Matsubara H. Balloon pulmonary angioplasty for chronic thromboembolic pul- monary hypertension: results of a multicenter registry. Circ Cardiovasc Qual Outcomes 2017; 10 :e004029. 468. Collaud S, Brenot P, Mercier O, Fadel E. Rescue balloon pulmonary angioplasty for early failure of pulmonary endarterectomy: the earlier the better? Int J Cardiol 2016; 222 :39 \u0002 40. 469. Ghofrani HA, D’Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C. Riociguat for the treatment of chronic thromboembolic pulmonary hyper- tension. N Engl J Med 2013; 369 :319 \u0002 329. 470. Ghofrani HA, Simonneau G, D’Armini AM, Fedullo P, Howard LS, Jais X, Jenkins DP, Jing ZC, Madani MM, Martin N, Mayer E, Papadakis K, Richard D, Kim NH; MERIT study investigators. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med 2017; 5 :785 \u0002 794. 471. Jais X, D’Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ. Bosentan for treatment of inoperable chronic thromboembolic pul- monary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo- controlled trial. J Am Coll Cardiol 2008; 52 :2127 \u0002 2134. 472. van Kan C, van der Plas MN, Reesink HJ, van Steenwijk RP, Kloek JJ, Tepaske R, Bonta PI, Bresser P. Hemodynamic and ventilatory responses during exercise in chronic thromboembolic disease. J Thorac Cardiovasc Surg 2016; 152 :763 \u0002 771. 473. Al-Mallah MH, Farah I, Al-Madani W, Bdeir B, Al Habib S, Bigelow ML, Murad MH, Ferwana M. The impact of nurse-led clinics on the mortality and morbidity of patients with cardiovascular diseases: a systematic review and meta-analysis. J Cardiovasc Nurs 2016; 31 :89 \u0002 95. 474. Mart \u0013 ınez-Gonz \u0013 alez NA, Tandjung R, Djalali S, Huber-Geismann F, Markun S, Rosemann T. Effects of physician-nurse substitution on clinical parameters: a systematic review and meta-analysis. PLoS One 2014; 9 :e89181. 475. Massimi A, De Vito C, Brufola I, Corsaro A, Marzuillo C, Migliara G, Rega ML, Ricciardi W, Villari P, Damiani G. Are community-based nurse-led self- management support interventions effective in chronic patients? Results of a systematic review and meta-analysis. PLoS One 2017; 12 :e0173617. 476. Ivarsson B, Radegran G, Hesselstrand R, Kjellstrom B. Coping, social support and information in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: a 2-year retrospective cohort study. SAGE Open Med 2018; 6 :2050312117749159. 477. Kim NH, Delcroix M, Jenkins DP, Channick R, Dartevelle P, Jansa P, Lang I, Madani MM, Ogino H, Pengo V, Mayer E. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2013; 62 :D92 \u0002 D99. 478. Barco S, Russo M, Vicaut E, Becattini C, Bertoletti L, Beyer-Westendorf J, Bouvaist H, Couturaud F, Danays T, Dellas C, Duerschmied D, Empen K, Ferrari E, Galie N, Jimenez D, Klok FA, Kostrubiec M, Kozak M, Kupatt C, Lang IM, Lankeit M, Meneveau N, Palazzini M, Pruszczyk P, Rugolotto M, Salvi A, Sanchez O, Schellong S, Sobkowicz B, Meyer G, Konstantinides SV. Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Clin Res Cardiol ;doi: 10.1007/s00392- 018-1405-1. Published online ahead of print 18 December 2018. ESC Guidelines 61 Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz405/5556136 by guest on 02 September 2019"
  ],
  "processed_at": "2026-01-30T14:42:21.275Z"
}